The Effects Of Beetroot Juice Supplementation On The Oxygen Cost Of Breathing In Obese Males by Fletcher, Dalton & NC DOCKS at Appalachian State University
 
 
 
 
 
 
 
 
THE EFFECTS OF BEETROOT JUICE SUPPLEMENTATION ON THE OXYGEN COST 
OF BREATHING IN OBESE MALES 
 
 
 
 
 
 
 
A Thesis  
by 
DALTON FLETCHER 
 
 
 
 
 
 
Submitted to the Graduate School 
 at Appalachian State University 
in partial fulfillment of the requirements for the degree of 
MASTER OF SCIENCE  
 
 
 
 
 
 
 
 
 
August 2019 
Department of Health and Exercise Science 
 
 
 
 
  
 
 
 
THE EFFECTS OF BEETROOT JUICE SUPPLEMENTATION ON THE OXYGEN COST 
OF BREATHING IN OBESE MALES 
 
 
 
 
 
A Thesis  
by 
DALTON FLETCHER 
August 2019 
 
 
 
 
 
APPROVED BY:  
  
 
        
Jonathon L. Stickford, Ph.D. 
Chairperson, Thesis Committee 
 
 
        
Abigail S.L. Stickford, Ph.D. 
Member, Thesis Committee 
 
 
        
R. Andrew Shanely, Ph.D. 
Member, Thesis Committee 
 
 
        
Kelly J. Cole, Ph.D. 
Chairperson, Department of Health and Exercise Science  
 
 
        
Mike McKenzie, Ph.D. 
Dean, Cratis D. Williams School of Graduate Studies 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright by Dalton Fletcher 2019 
All Rights Reserved 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
 
 
 
 
 
 
Abstract 
 
THE EFFECTS OF BEETROOT JUICE SUPPLEMENTATION ON THE OXYGEN COST 
OF BREATHING IN OBESE MALES 
 
Dalton Fletcher 
B.S., Appalachian State University 
M.S., Appalachian State University  
 
 
Chairperson:  Jonathon L. Stickford, Ph.D. 
 
 
 Introduction: Obese adults exhibit increased oxygen (O2) cost of breathing, 
whole body O2 utilization (V̇O2), and ratings of perceived breathlessness when 
compared with normal weight adults. Beetroot juice supplementation (BRJ) has been 
reported to reduce whole body V̇O2 at a given work rate. Purpose: The purpose of 
this study was to measure the O2 cost of breathing during a eucapnic voluntary 
hyperventilation test, and whole body V̇O2 and ratings of perceived breathlessness 
during constant work rate cycling in obese males following BRJ supplementation. 
Methods: Six (n=6) obese males performed spirometry measures and a V̇O2peak test 
on a cycle ergometer during the initial visit. During the remaining two subsequent 
visits, subjects mimicked the ventilation and breathing pattern corresponding to 50%, 
70%, and 90% VȮ2peak, to measure the O2 cost of breathing. After a passive 
recovery period, subjects cycled at a moderate intensity for 6 minutes.  Subjects 
supplemented with either the placebo or BRJ for ten days in a double-blind, 
randomized, cross-over design. A 10-day washout period separated the two  
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supplementation periods. Data was compared between supplements using paired t-
tests. Significance was set at α = 0.05. Results: The O2 cost of breathing was 2.32 ± 
1.39 mL O2/L during BRJ conditions and 2.78 ± 0.78 mL O2/L during placebo 
conditions (t(3)=0.808, p = 0.478). VT was reduced during moderate intensity cycling 
during BRJ conditions when compared to placebo conditions, but no other 
physiological or perceptual measures were improved. Conclusion: These findings 
suggest that BRJ does not lower the O2 cost of breathing during eucapnic voluntary 
hyperventilation, nor does BRJ lower V̇O2 during moderate intensity cycling in 
young obese males. 
Key Words: hyperventilation, moderate intensity exercise, spirometry, breathlessness 
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Chapter 1 
Introduction 
Background 
Obesity is a growing epidemic that is causing a national crisis not only on health 
outcomes but also on economics and sociocultural aspects. Obesity is defined as having a 
body mass index (BMI) ≥ 30 kg∙m-2. The Centers for Disease Control and Prevention 
reported that in 2016 the prevalence of obesity among American adults was 39.8%, which 
equates to 93.3 million people (1). In 2008, the medical costs of obesity reportedly totaled 
$147 billion; furthermore, obese individuals spend over $1,400 more per person per year on 
healthcare costs compared with normal weight individuals (2).   
The World Health Organization reported that obesity was the fifth leading risk factor 
of death in the world (3). Further, three of the top four risk factors are associated with 
obesity:  hypertension, hyperglycemia, and sedentary behavior. Obesity is associated with 
increased prevalence of type II diabetes, heart disease, stroke, certain types of cancers, and 
several other preventable chronic diseases.  The increased body mass in obesity typically 
results from years of caloric excess combined with the lack of adequate physical activity. 
Additionally, obesity can lead to social and psychological issues. A meta-analysis by 
Luppino (4) concluded that obese adults had a higher prevalence of clinical depression than 
normal weight adults and that depression was predictive of developing obesity.   
Obesity presents challenges to the respiratory and cardiovascular systems at rest and 
during exercise. It is well-established that additional fat deposits on the chest wall and within 
the abdomen affect pulmonary function. Specifically, functional residual capacity (FRC) and 
expiratory reserve volume (ERV) are reduced, while common spirometric indices largely are 
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maintained similar to that of normal weight individuals (5). These changes are the 
manifestation of a decrease in compliance of the respiratory system (6). Due to the 
compliance curve of the chest wall in obesity being shifted to the right, the respiratory 
compliance curve is shifted to the right, with a less intense slope, making one have to 
generate greater pressure differentials in order to obtain the desired change in lung volume. 
These noted effects continue to be evident even during exercise. The result of ERV being 
diminished compared to normal weight individuals causes the operating lung volume during 
quiet breathing to be similar to be closer residual (RV) (Figure 1) (7). Thus, end-expiratory 
lung volume (EELV) is decreased, which requires greater respiratory pressure generation, 
and tidal volume (VT) becomes positioned closer to the lower nonlinear and less compliant 
end of the pulmonary system’s sigmoid-shaped pressure-volume relation (8).  
As a result of the additional stress placed on the respiratory and cardiovascular 
systems, exercise capacity during submaximal and peak intensities is reduced (9, 10).  
Furthermore, many obese individuals experience dyspnea during exercise. Sjostrom (11) 
reported that 80% of obese men felt shortness of breath after walking up two flights of stairs, 
while only 16% of normal weight males felt shortness of breath. It is estimated that 
approximately one third of obese adults experience dyspnea during exercise (12). Thus, the 
prevalence of dyspnea during exercise represents a serious clinical concern to many obese 
adults. The underlying mechanism of exertional dyspnea in obese adults is poorly understood 
but it is not believed to be entirely due to alterations in pulmonary function or to the 
additional  metabolic stress placed on the cardiopulmonary system during exercise. 
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Figure 1:  The alterations in lung volumes caused by obesity (13). 
The O2 cost of breathing represents the amount of O2 consumed by the respiratory 
muscles (V̇O2RM) during the ventilatory cycle. The V̇O2RM is a reflection of the total work 
accomplished by the respiratory muscles. Typically, only 1-2% of whole body V̇O2 at rest is 
attributed to V̇O2RM (14) but this value will increase exponentially as ventilation meets the 
metabolic demands of exercise. The V̇O2RM can increase to around 10% of whole body V̇O2 
during intensive exercise in healthy untrained individuals (15, 16) and can approach 15% of 
maximal aerobic capacity (V̇O2max) in highly trained aerobic athletes (16). Yet, obese 
individuals display a greater V̇O2RM when compared to normal weight individuals at rest (17) 
and during exercise (18), in part, because the respiratory muscles must complete more work 
due to the aforementioned greater ventilatory demand and reduced compliance. Therefore, 
the increased V̇O2RM in obese individuals is attributed to the increased amount of fat within 
the thorax.   
The increased V̇O2RM in obesity may have important clinical considerations. It was 
suggested that exertional dyspnea might originate from increased O2 demand of the 
respiratory muscles along with their decreases in pulmonary compliance and increases in 
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airway resistance. Increases in airway resistance can be attributed to breathing at lower lung 
volumes (5). Babb (19) observed that otherwise-healthy obese adults who experience 
exertional dyspnea have a V̇O2RM that is 38%-70% more than obese adults who do not 
experience exertional dyspnea.  Furthermore, V̇O2RM was positively associated with ratings 
of perceived breathlessness (RPB), suggesting that the amount of work performed by the 
respiratory muscles plays an important role in the sensation of respiratory discomfort during 
exercise. In contrast, weight loss has the ability to decrease V̇O2RM in obese adults (20); an 
8% reduction in body mass reduced V̇O2RM by 16%. Further, the effect of weight loss on 
V̇O2RM accounted for 46% of the decrease in whole body V̇O2 when cycling at a moderate 
intensity. These findings suggest that a decrease in V̇O2RM may improve exercise tolerance 
via a reduction in whole body V̇O2 at relative workloads.   
Beetroot juice (BRJ) supplementation has been reported to affect resting blood 
pressure, muscle blood flow, vascular function, and muscle fiber contractile characteristics 
(21, 22, 23). The marked physiological alterations are largely attributed to nitrate (NO3-) via 
nitric oxide synthase dependent and independent pathways (24).  Importantly, BRJ also has 
been reported to decrease whole body V̇O2 during low- (21) and moderate-intensity exercise 
in young men who are recreationally trained or athletes (22, 23, 25, 26). Furthermore, BRJ 
can increase exercise duration and the total amount of work completed during an exhaustive 
exercise bout in healthy young men who are recreationally active or athletes (21, 22). The 
decreased energy utilization at a given workload indicates that BRJ improves skeletal muscle 
efficiency. Thus, BRJ appears to have ergogenic properties that may benefit exercise 
performance in obese individuals. An improvement in the metabolic efficiency of the 
respiratory muscles would lower the O2 cost of breathing.   
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The potential use of BRJ to improve the metabolic efficiency of skeletal muscles, and 
specifically the respiratory muscles, may have important implications during exercise in 
obese adults. Exercise tolerance could be increased in obese men due to the decreased 
metabolic demands of the respiratory muscles, allowing for more O2 to be delivered to active 
skeletal muscles. The majority of studies to date have utilized normal weight adults, though 
some studies also have examined the effects of BRJ in patients with COPD and heart failure. 
However, these diseased populations have other dysfunctions, including skeletal muscle 
dysfunctions. We are interested in examining the effects of chronic BRJ in obese males who 
are otherwise healthy. To the author’s knowledge, only one investigation has examined BRJ 
and its effects on V̇O2 in obese subjects and they were adolescents (27). Following 
supplementation, V̇O2 at moderate exercise intensities was unchanged, but exercise tolerance 
was increased. However, the adolescents received a dosage of 5 mmol of nitrate per day, 
which is below that used in the investigations noting reductions in submaximal exercise V̇O2 
of normal weight individuals (6.2 – 26 mmol∙day-1); (21, 23, 25, 28). Thus, it is possible that 
the dosage was insufficient to observe an effect on V̇O2 during moderate intensity exercise in 
the obese adolescents (27). Therefore, the effect of BRJ on V̇O2RM and ratings of perceived 
breathlessness (RPB) during eucapnic voluntary hyperventilation and whole body VȮ2 and 
RPB during moderate intensity cycling in otherwise healthy obese males warrants 
investigation. 
 
Summary 
Obesity is an epidemic to health, economics, and sociocultural aspects within 
America.  Obesity leads to exercise intolerance, an increased V̇O2RM, and increases in RPB; 
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all of which may contribute to sedentary behavior in those individuals who are already obese. 
BRJ is an ergogenic aid that has been shown to improve skeletal muscle efficiency. BRJ may 
reduce V̇O2RM and dyspnea during exercise in obese individuals.   
 
Statement of the purpose 
The purpose of this study was to measure V̇O2RM during eucapnic voluntary 
hyperventilation following BRJ supplementation in obese male adults.  Additionally, a 
secondary aim was to assess whole body V̇O2 and RPB during constant work rate cycling and 
examine the association between potential changes in RPB and V̇O2RM following beetroot 
juice supplementation.  
 
Hypotheses 
The following hypotheses were tested: 
Hypothesis 1:  V̇O2RM will be decreased at levels of ventilation corresponding to 
50%, 70%, and 90% of V̇O2peak during the eucapnic voluntary hyperventilation test following 
BRJ supplementation when compared with following placebo supplementation.   
Hypothesis 2:  RPB will be decreased at levels of ventilation corresponding to 50%, 
70%, and 90% of V̇O2peak during the eucapnic voluntary hyperventilation test following BRJ 
supplementation when compared with following placebo supplementation. 
Hypothesis 3:  Whole body V̇O2 will be decreased during constant work rate cycling 
following BRJ supplementation when compared with following placebo supplementation.   
7 
 
Hypothesis 4:  Ratings of perceived breathlessness will be decreased during constant 
work rate cycling following beetroot juice supplementation when compared with following 
placebo supplementation. 
Hypothesis 5:  The changes in V̇O2RM and RPB will be significantly correlated.  
 
 
Significance of the Study 
This study will explore the possible benefits of BRJ on V̇O2, V̇O2RM, and RPB.  
Obesity is associated with a greater V̇O2RM and higher ratings of dyspnea, which make 
exercise seem harder and discourages many obese individuals from exercising.  This study 
could be beneficial to obese people who do not exercise due to increased dyspnea due to an 
increased V̇O2RM.  BRJ could be a possible ergogenic aid to make exercise seem easier and 
therefore increase physical activity.  Increased physical activity could lead to weight 
reduction and a lower risk of developing chronic diseases.   
 
Delimitations  
 The study was delimited to: 
1. Males between the ages of 18 and 40 years. 
2. All subjects were obese and otherwise healthy. 
3. Visit 1 and visit 2 occurred on the tenth day of the supplementation 
periods. 
4. There was at least a 10-day wash out period between supplementation 
periods.   
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5. Subjects drank either BRJ or the placebo in 70 mL shots; one in the 
morning and one in the evening. 
6. Subjects were told to eat similarly during the two-supplementation 
protocols. 
7. Subjects were told to refrain from using mouthwash from the 
completion of visit 1 until they complete visit 3. 
8. Subjects were required to stay seated on the cycle ergometer during 
the V̇O2peak test and the two subsequent constant intensity bouts and to 
maintain a cadence of between 60 and 80 revolutions per minute. 
9. Gas analyzers were used to measure fractional gas concentrations of 
oxygen and carbon dioxide. 
10. Inspiratory and expiratory airflow rates were measured with 
pneumotachs.   
11. Posture during the eucapnic voluntary hyperventilation test was the 
same as during the initial V̇O2peak test on the cycle ergometer.   
 
Limitations 
 Interpretation of the results should consider the following limitations:   
1. All of the subjects were from the same terrestrial area. 
2. Due to the fact that all testing was indoors in a laboratory setting, the 
results may not be representative in the field. 
3. The results can only be able to be applied to obese men who are 
recreationally active and otherwise healthy. 
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4. Subjects were discouraged from eating foods high in nitrates, but the 
foods will not be prohibited. 
5. V̇O2peak testing required the subject to be motivated, so some subjects 
may not have reached a true VO2peak. 
6. Subjects consumed BRJ and the placebo while away from the lab, so it 
can only be inferred that they took the assigned dosages. 
7. The influence of blood pH, temperature, and lactate on spirometry 
measures was unknown.   
8. The work of breathing was not be directly measured.  
9. Ventilatory mechanics are different between exercise and voluntary 
hyperventilation at rest.   
10. Oral nitrate and nitrite concentrations were not measured. 
 
Assumptions  
 Interpretations of the results will have to apply the following assumptions: 
1. The group that was tested is representative of their respected 
population (obese men, aged 18-40, recreationally active, otherwise 
healthy). 
2. Subjects were motivated to perform spirometry measures and a 
V̇O2peak test.   
3. The subjects consumed the required dosages at the times required. 
4. The tubing and mouthpiece required for the V̇O2peak did not affect 
ventilation. 
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5. Any change in V̇O2RM, RPB, or V̇O2 was due to BRJ only. 
6. It was assumed that subjects did not partake in strenuous exercise for 
24 hours and caffeine/alcohol consumption for 12 hours prior to the 3 
visits. 
7. The 20-minute break between eucapnic voluntary hyperventilation and 
the constant intensity exercise test was enough time for V̇O2 to return 
to baseline values.  
8. Any changes in whole body V̇O2 during eucapnic voluntary 
hyperventilation were attributed to the increased metabolic efficiency 
of the respiratory muscles.   
 
Definition of Terms 
Body Mass Index (BMI) – a person’s weight in kilograms divided by the square of 
height in meters (28). 
Carbon dioxide production (V̇CO2) – the volume of carbon dioxide produced per 
minute (29). 
Cost of breathing (V̇O2RM) – the oxygen consumed by the respiratory muscles, is an 
index for the energy required for ventilation (14). 
Dyspnea – difficult or labored breathing. 
Eucapnic voluntary hyperventilation – a test designed to mimic the effect that 
prolonged exercise has on the airway (30). 
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Forced expiratory volume in one second (FEV1) – The maximum volume of air that 
can be forced out in the first second of expiration from a maximal inspiration, 
an important measure of pulmonary function (31). 
Forced mid-expiratory flow (FEF25-75%) –The average expiratory flow over the 
middle half, from 25 to 75%, of the FVC (31). 
Forced vital capacity (FVC) – The volume of air expelled by a forced maximal 
expiration to residual volume from a maximal inspiration (31). 
Frequency of breathing (fB) – The breathing rate in breaths per minute. 
Functional residual capacity (FRC) – The volume of air left in the lungs following a 
normal expiration.  Algebraically, the sum of ERV and RV (31). 
Gas exchange threshold (GET) – has been used as an index of anaerobic threshold 
because it can be measured noninvasively.  GET is estimated from a 
breakpoint in breath by breath values of carbon dioxide and oxygen uptake 
obtained during a progressive exercise test (32).  
Maximal aerobic capacity (V̇O2max) – The maximal ability of an individual to take up, 
transport, and deliver oxygen to the working muscles (33). 
Maximal ventilation (V̇Emax) –  The highest minute ventilation achieved during 
exhaustive exercise (34). 
Maximum voluntary ventilation (MVV) – The maximum volume of air that can be 
breathed over a specified period of time, typically 12 s (31). 
Oxygen consumption (V̇O2) - The volume of oxygen consumed per minute (29). 
Peak expiratory flow rate (PEFR) – The maximum flow rate achieved during a forced 
maximal expiration (31). 
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Peak inspiratory flow rate (PIFR) – The peak inspiratory flow rate achieved during a 
maximal inspiration (31). 
Rating of Perceived Breathlessness (RPB) – a scale that allows individuals to 
subjectively rate their level of dyspnea during exercise or exercise testing 
(35). 
Rating of Perceived Exertion (RPE) – a scale that allows individuals to subjectively 
rate their level of exertion during exercise or exercise testing (35). 
Residual volume (RV) – The volume of air within the lungs at the end of a maximal 
expiration (31). 
Tidal volume (VT) – The volume of air moved in and out of the lungs during each 
breath (29). 
Total lung capacity (TLC) – The total volume of air within the lungs following a 
maximal inspiration (31). 
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Chapter 2 
Review of Literature 
Introduction 
 Beetroot juice (BRJ) has been shown in recent years to have beneficial physiological 
effects on both moderate and severe intensity exercise (21, 22, 23, 25, 36); however, the 
majority of research has been conducted on young, normal weight males who are 
recreationally active or athletes. There has been a lack of research on populations of obese 
males. V̇O2RM is the amount of oxygen that the respiratory muscles consume and is an 
indication of the amount of energy required for ventilation. Obese individuals have an 
increased V̇O2RM due to the increased adipose tissue surrounding the thorax, which requires 
the muscles of the respiratory system to work harder (37, 38, 39). BRJ has demonstrated the 
ability to lower O2 kinetics during moderate intensity exercise in non-obese subjects (26, 40).  
 What is Beetroot Juice? 
 BRJ is juice extracted directly from the roots of beet plants. It is a nutrient dense 
drink that can contain up to 25 carbohydrates per cup, and is an abundant source of folate, 
potassium, Vitamin C, fiber, antioxidants, and most importantly nitrate. Nitrate (NO3-) is the 
substance within BRJ that is responsible for the beneficial physiological effects during 
exercise. NO3- is reduced to Nitrite (NO2-) and then to Nitric Oxide (NO).  
 The inorganic anions, Nitrate and Nitrite, were once viewed as the end products of 
Nitric Oxide metabolism and unwanted byproducts from food consumption, but they are now 
understood as storage pools for Nitric Oxide and complement the L-arginine/NO synthase 
dependent pathway (41). Plants contain Nitrate Reductase Enzymes that reduce NO3- to  
NO2-; however, humans do not produce this enzyme. When NO3- is orally consumed, as with 
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BRJ, it is concentrated in the saliva and reacts with oral commensal bacteria that reduce it to 
NO2- (42). NO2- is then swallowed and absorbed into the gut for further reduction to NO. To 
a lesser extent, NO3- can also be reduced to NO2- in the liver by xanthine oxidoreductase. 
Hypoxic conditions and during times in which oral commensal bacterial are low are the only 
occasions in which xanthine oxidoreductase would be utilized (43).  
 Once NO2- is in the gut, it represents the largest storage pool of NO in the body. NO2- 
is reduced to NO through several means, but most notably through deoxyhemoglobin and 
deoxymyoglobin (42). Deoxyhemoglobin reacts with NO2- to form metheglobin (a molecule 
that cannot bind to oxygen) and NO: Hb(Fe2+) + NO2- + H+  Hb(Fe3+) + NO + OH-. The 
nitrite reductase activity of deoxyhemoglobin takes place under hypoxic conditions (44, 45). 
Red blood cells (RBCs) experience increased deoxygenation as they pass through the 
microcirculation of hypoxic tissue, which would be the case in exercising skeletal muscle, 
and as a result of this, the RBCs increase the amount of NO that they are producing and 
releasing to increase blood flow (46). In this way, RBCs are not only acting as oxygen 
transporters, but also as localized oxygen sensors that mediate local blood flow. This 
mechanism takes occurs in four major steps: 1) NO2- is transported across the membrane of 
the RBC, 2) NO2- reacts with deoxyhemoglobin to form NO, 3) NO leaves the RBC and 
enters the hypoxic tissue, 4) lastly NO induces localized vasodilation (46).  
 Deoxymyoglobin is another potent nitrite reductase, which hypoxic conditions 
regulate, especially when oxygen concentration within the myoglobin falls below p50. The 
NO produced from deoxymyoglobin has profound effects on the mitochondria in hypoxic 
conditions. NO binds to cytochrome c oxidase to inhibit respiration in the mitochondria. This 
inhibition is more potent as oxygen concentrations decrease and is thought to limit hypoxic 
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tissue damage through the extension of tissue oxygen gradients, most notably in cardiac 
tissue (47).  
 Nitric Oxide is a potent vasodilator, and as explained earlier, it is produced from the 
precursor molecule, nitrate, which is found in abundance in BRJ. Exercising signals NO 
through shear stress, which is the parallel friction at the surface of the endothelium caused by 
an increase in blood flow (i.e. exercise). Shear stress signals endothelial nitric oxide synthase 
to convert L-arginine into L-citrulline and NO. NO then diffuses across the cell membrane of 
smooth muscle, which causes guanylate cyclase to convert guanosine triphosphate into cyclic 
guanosine monophosphate. Cyclic guanosine monophosphate activates Protein Kinase G to 
lower cellular calcium concentrations to increase vasodilation in the arteries. NO 
bioavailability is limited in individuals who do not exercise, and reduced by aging (48). 
These decrements can be avoided by lifelong physical activity (Nyberg 2012). Consuming 
nitrate rich BRJ can cause increased bioavailability of NO without the need for shear stress 
or endothelial nitric oxide synthase. BRJ’s vasodilatory properties were evidenced in studies 
conducted by Bailey (22) and Lansley (23); healthy young men were able to reduce their 
systolic blood pressure after BRJ supplementation by 8 mmHg and 4% respectively.  
 Physiological Benefits during Exercise 
 BRJ has been a hot bed for research in recent years, with several studies yielding 
results that show positive physiological benefits during moderate and severe intensity 
exercise, in particular, VO2. In a study by Whitfield (25), 13 recreationally active males 
supplemented 26 mmol·day-1 for 5 days before cycling at 50% and 70% of their VȮ2peak. 
While there were no changes between BRJ and placebo supplementation at light intensity 
(50%), subjects were able to decrease their VȮ2 by 100 mL during moderate intensity (70%). 
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Similarly, in another study when recreationally active men consumed 5.5 mmol·day-1 per day 
for 5 days, they were able to reduce their VȮ2 amplitude by 19% during moderate intensity 
cycling (21). Tan (26) showed similar reductions in VȮ2 during 120 minutes of moderate 
intensity cycling in recreationally trained males. Breese (49) showed that 8 mmol·day-1 for 6 
days could reduce phase II VO2 kinetics in recreationally active males. However, not all 
studies have shown VȮ2 deductions during moderate intensity exercise; Thompson (50) had 
16 recreationally trained males supplement on 5 mmol·day-1 1.5 hours before cycling at 50% 
and 70% of VȮ2peak, and there were no significant changes in VȮ2 when compared to 
placebo. Betteridge (51) also failed to produce VȮ2 reductions at 65% of VȮ2peak. The 
previous two studies mentioned were acute supplementation studies, while the four before 
that were chronic supplementations.   
 Another common experiment type within BRJ research is severe exercise time until 
exhaustion tests. Time until exhaustion following BRJ supplementation has been shown to 
increase by 16% (50) and 22% (49) while cycling. While the total time exercising increased 
significantly, VȮ2 remained the same as placebo supplementation, indicating that power 
output was increased at no metabolic cost. Similarly, another study showed time until 
exhaustion to increase by 90 seconds, while exhibiting a slower slow VO2 component.  
 Time trial experiments are another means to show to positive effects of BRJ. If one 
can decrease their time trial time, while maintaining the same VȮ2, this would indicate an 
increased power output at no metabolic cost. Club level cyclists were able to improve their 
time trials at 4 km and 16 km by 2.8% and 2.7% respectively after supplementing 6.2 
mmol·day-1 2.5 hours before exercise (51). These decreases in time were present with no 
changes in VȮ2. MacLeod (52) found no significant differences while having trained cyclists 
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perform a 10 km time trial after they had supplemented on 6 mmol·day-1 2 hours before 
exercise.  
 Mode of Action 
 The mode of action behind the increased metabolic efficiency exhibited through BRJ 
supplementation is still not fully understood; however, several theories among experts in the 
field exist. The fist theory is that the reductions in VȮ2 stem from mitochondrial biogenesis 
or an increased functioning among mitochondrial parameters. Two particular studies, which 
have yielded VȮ2 reductions during exercise, took muscle biopsies from their subjects and no 
mitochondrial indices were improved (23, 25). This would suggest that mitochondrial 
enhancement is not the mechanism of action. In contrast, Vaughan (53) found increases in 
mitochondrial transcription factor A and glucose transporter 4, which would indicate an 
increase in mitochondrial biogenesis. However, this study used cultured cells in vitro.  
 Another common theory among researchers is that BRJ supplementation increases 
muscle contractile functioning. Most of the research within this theory has been conducted on 
animal models, so human experimentation is needed for interpretations that are more concise. 
A study by Hernandez (54) was the first to show that NO3- supplementation in rats had 
different effects among different muscle fibers. Type II muscle fibers contained significantly 
more myoplasmic free calcium (Ca2+) than control rats when electrically stimulated between 
20 and 150 Hz. At 100 Hz the rate of force development was also 35% greater in the NO3- 
group. The concentrations of the Ca2+ handling protein calsequestrin 1 and the 
dihydropyridine receptor were also increased. Calsequestrin 1 is responsible for buffering 
Ca2+ back into the sarcoplasmic reticulum and increased concentrations would allow a 
muscle to contract more frequently (55). None of these effects were observed in Type I 
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muscle fibers. BRJ supplementation in rats has also been shown to increase vascular 
conductance and muscle blood flow during moderate intensity exercise in Type II muscle 
fibers (56), suggesting increased oxygen delivery capabilities and increased efficiency in 
Type II muscle fibers. This may explain the observed benefits of BRJ supplementation at 
severe intensity exercise, as Type II muscle fibers are recruited more at that intensity.  
 Type II muscle fibers have higher concentrations of Phosphocreatine (PCr) which is 
an essential fuel source during high intensity exercise. Depletion of PCr is associated with 
fatigue and decreased performance. Bailey (57) analyzed the effects of BRJ supplementation 
on light and severe intensity knee extension exercise. The degree of PCr degradation during 
both intensities was reduced accompanied by reductions in estimated ATP utilization during 
both intensities as well. This would suggest that decreases in VȮ2 stem from decreased 
energy needs of skeletal muscle.  
 Dosage 
 Supplementation can be broken down into two categories: acute and chronic. Acute 
supplementation is consumed hours before an exercise bout, while chronic supplementation 
is consumed for multiple days before an exercise bout. In general, acute supplementations 
require higher concentrations of NO3- in order to yield positive metabolic results. Acute 
supplementation had been able to yield positive metabolic results at 10.9 mmol·day-1 (50), 
11.2 mmol·day-1 (58), and 8 mmol·day-1 (51). Chronic supplementation studies tend to have 
subjects consume BRJ for 6-10 days (21, 22, 23, 25, 49). The mmol per day range from 5.5 
mmol per day (21) to 26 mmol·day-1 (25).  
  
 
19 
 
Oxygen Cost of Breathing  
 V̇O2RM is defined as the oxygen consumed by the respiratory muscles and is an index 
for the energy required for ventilation. Muscles that assist in ventilation during exercise 
include the diaphragm, external and internal intercostals, sternocleidomastoid, rectus 
abdominis, external and internal obliques, and several other smaller muscles. V̇O2RM is 
quantified in mL of O2 per L of ventilation (mL O2/L). V̇O2RM increases as minute ventilation 
increases which is associated with exercise or unobstructed hyperventilation and has a 
curvilinear slope (16, 60, 61). The work of breathing can be understood as a reflection of the 
work of the respiratory system, and can be quantified by multiplying the change in volume 
during a breath and the pressure required to generate that volume change (14). Since energy 
consumption is a reflection of the amount of work done, an increased work of breathing 
yields an increased V̇O2RM. One can interpret this as the metabolic efficiency of the 
respiratory muscles. 
 V̇O2RM at rest is extremely low, representing only 1-2% of whole body VȮ2 (P14). 
However, as exercise intensities increase, V̇O2RM will increase exponentially. It can increase 
to around 10% of whole body VȮ2 during intense exercise in healthy untrained adults (15, 
16), and can reach 15% in highly trained athletes (16). During intense exercise or during 
higher levels of voluntary hyperventilation, expiration is no longer passive, so expiratory 
muscles must be recruited in order to reach the necessary ventilation. Cherniak (62) reported 
V̇O2RM in normal weight men to be between 0.45 and 1.87 mL O2/L. The work of breathing 
and thus the O2 required for the respiratory muscles yields different energy requirements 
during exercise and hyperventilation when the ventilation rate is controlled. Coast (61) 
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reported that at higher ventilation rates, the work required to breath during hyperventilation is 
around 25% higher than in exercise. 
 Most normative data in the research is based on the values of normal weight men. 
Sex, weight, and disease can alter the work of breathing and the V̇O2RM. Women’s V̇O2RM is 
larger than that of males, and it represents a larger portion of their whole body VȮ2 (63, 64). 
The additional visceral fat that surrounds the thorax in obese individuals also leads to 
increases in the V̇O2RM (62, 65). Increased airway resistance leads to an increased V̇O2RM in 
individuals with chronic obstructive pulmonary disease (66, 67).  
Outcomes 
 There will be three main outcomes investigated in young, obese males: the V̇O2RM, 
VȮ2, and ratings of perceived breathlessness. There has been a lack of research analyzing the 
effects of BRJ on obese individuals. Currently there is no research analyzing the relationship 
between V̇O2RM and BRJ supplementation. Obese people have been shown to have a higher 
V̇O2RM, and BRJ supplementation could possibly be a means of lowing it.  
 O2 Cost of Breathing 
 Increased fat tissue surrounding the respiratory muscles requires the muscles to work 
harder to breathe, as is the case in obese individuals. Cherniak (62) reported that V̇O2RM was 
almost 3 times higher in obese individuals when compared to normal weight individuals: 
3.45 mL O2/L vs. 1.2 mL O2/L. Sharp (65) reported that the work of breathing in obese 
individuals was 1.3 times greater than normal weight individuals, with some subjects having 
values close to double that of normal weight subjects. Their respiratory compliance was also 
remarkable lower. Obese individuals tend to breathe at a less steep pulmonary compliance 
curve, meaning that greater pressures are required to generate volume changes. As mentioned 
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earlier, if either pressure or volume differentials are increased, work increases. Kress (17) 
reported that morbidly obese individuals who were put on mechanical ventilators were able 
to reduce their V̇O2RM by 16%, while normal weight individuals were only able to decrease 
by 1%. The 15% difference can be attributed to the increased visceral fat surrounding the 
thorax. An 8% weight loss in obese females has been shown to decrease to V̇O2RM by 16%. 
 There are currently no studies analyzing the effects of BRJ supplementation on 
V̇O2RM in any population. NO3- can make skeletal muscle more efficient during exercise, so it 
can be predicted that it will yield similar results in the respiratory muscles during 
hyperventilation. The diaphragm and the recuts abdominis are two of the most important 
respiratory muscles at higher ventilation rates and contain around 45% Type II muscle fibers 
(68, 69). Obese individuals require a longer time to recover their PCr levels after exercise 
due to their slow metabolic recovery rate (70), but BRJ can lower the amount of PCr used 
(57). 
 VȮ2 
 Obese individuals have a decreased exercise capacity both at submaximal and 
maximal intensities (9). Their VȮ2peak in absolute terms is normal, but in relative terms, it is 
low, suggesting poor cardiorespiratory fitness. While there has been a plethora of studies 
looking at the effects of BRJ supplementation on normal weight recreationally active and 
trained men, there has only been one study to look at its effects on an obese sample. Rasica 
(27) supplemented 10 obese adolescents (8 girls, 2 boys) 5 mmol·day-1 for 6 days. There 
were no significant findings during moderate intensity cycling. A 23% increase in time until 
exhaustion during sever intensity exercise was observed following BRJ supplementation 
when compared to the placebo. The slow component of their VȮ2 response was also reduced. 
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The lack of statistical findings during the moderate intensity exercise may be due to the small 
dosage of NO3- they were given. 
 Reductions in VȮ2 are common during moderate intensity exercise. These reductions 
range from modest 3% reductions (25) to immense reductions of 19% (21). Phase II kinetics 
also consistently decrease (21, 41, 71, 72). Phase II kinetics are also called slow component, 
and slow component is the addition of the anaerobic energy systems during aerobic exercise. 
The more that the anaerobic systems are utilized, the more lactate and H+ ions that are 
produced. This will cause the pH of the blood to increase and bring about metabolic fatigue.  
 Ratings of Perceived Breathlessness (RPB) 
 Ratings of perceived breathlessness (RPB) is a self-reported measure of dyspnea, or 
the difficulty or the amount of labor felt during breathing. It results from multiple signal 
interactions with receptors in the central nervous system, peripheral receptors, 
chemoreceptors, and mechanoreceptors in the upper airway, lungs, and chest wall (73). 
Levels of perceived dyspnea are increased in obese men and women when there are no other 
health problems present such as asthma or COPD, which would explain it. Babb (19) 
reported that around one third of obese individuals experience dyspnea during exercise. 
Dyspnea would directly raise levels of RPB during exercise. Sjostrom (11) compared 
shortness of breath in normal weight and obese individuals directly after the subjects had 
walked up two flights of stairs. 80% of the obese individuals experienced shortness of breath, 
while only 16% of normal weight males did. The exact mechanism for the increased dyspnea 
in obese individuals is not completely understood, but it cannot be attributed to airflow 
obstruction (73).  
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 The only study to directly measure the RPB during exercise after BRJ 
supplementation was conducted by Thompson (50). There were no differences in RBP during 
exercise at 50%, 70%, or 90% of VȮ2peak. Previous studies have shown the potential of BRJ 
to make exercise more efficient particularly by lowering VȮ2 at relative workloads.  
Summary 
 The purpose of this study was to analyze the effects of BRJ supplementation on 
V̇O2RM and RPB during eucapnic voluntary hyperventilation and on the VȮ2 and RPB during 
moderate intensity cycling. 
   It was hypothesized that V̇O2RM of breathing and RPB would be lowered during 
eucapnic voluntary hyperventilation and that the VȮ2 and RPB would be lowered during 
moderate intensity cycling following BRJ supplementation when compared to placebo 
supplementation.  
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Chapter 3 
Methods 
 
Participants 
 After the study was approved by the Appalachian State University Institutional 
Review Board (IRB# 19-0021), class 1 (30 ≤ BMI ≤ 40) obese males aged 18-40 years were 
recruited to participate.  Subjects were initially screened over the telephone to ensure that 
they did not have any health complications that would prohibit them from taking part in the 
study. Subjects were excluded if they had known cardiovascular, respiratory, renal, or 
metabolic diseases, any signs/symptoms of disease, were a current smoker, or if they had a 
history of cigarette smoking over 0.5 pack-years. Subjects were excluded if they had 
participated in an exercise training program in the last six months, as they may have 
developed exercise adaptations that will limit the findings of this study. When subjects 
arrived at the laboratory for visit 1, they first signed an informed consent after a researcher 
had explained to them the requirements of the present study. Subjects then completed a 
medical history form. Prior to each visit, participants were instructed not to engage in 
strenuous physical activity in the 24 hours and refrain from caffeine and alcohol ingestion in 
the 12 hours prior to visiting the laboratory.  Subjects were encouraged to visit the laboratory 
in a rested and hydrated state.   
 
Experimental Design 
 A randomized, placebo-controlled experimental design was used to examine the 
effects of BRJ on V̇O2RM and RPB during moderate intensity exercise in obese male subjects. 
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All subjects visited the laboratory on three separate occasions. Subjects completed an 
informed consent document, and a medical history questionnaire. Following this, height and 
body mass were recorded, and then underwent tests to determine their body composition, 
pulmonary functioning, and VȮ2peak. During subsequent visits, subjects mimicked, at rest, the 
ventilation and breathing pattern corresponding to 50%, 70%, and 90% VȮ2peak, as measured 
during the initial visit, to measure V̇O2RM. Following a 20-min passive recovery period, 
subjects then completed 6-min of constant work rate exercise at 90% of the gas exchange 
threshold (GET) on a cycle ergometer. Maximal volitional mouth pressure was measured 
prior to the first hyperventilation challenge, immediately after the final hyperventilation 
challenge, and after the 20 minute rest period. At the beginning of all three visits, subjects 
had their resting blood pressure measured (SunTech Medical, Morrisville, NC); if their blood 
pressure was above 140/90, they were not allowed to participate that day. Subjects 
supplemented with either tomato juice (TJ; placebo beverage) or BRJ in the ten days prior to 
visits two and three. A 10-day washout period to separate the two supplementation periods 
was utilized. Subjects completed all laboratory visits at similar times of the day. 
 
Pulmonary Functioning Test 
 All subjects completed a spirometry and lung volume test in a whole body 
plethysmograph (Carefusion Vmax 62J Auto Box, Yorba Linda, CA) in accordance with 
ATS/ERS guidelines (74). The subjects were instructed to breathe through their mouth while 
wearing a nose-clip. The protocol for all spirometry tests included three breaths at a normal 
resting tidal volume, then a maximal inhalation, followed by a maximal exhalation, and 
finally another maximal inhalation. Each participant performed this protocol a minimum of 
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three times.  Forced vital capacity (FVC), forced expiratory volume in one second (FEV1), 
forced mid expiratory flow rate (FEV25-75%), and peak expiratory flow rate (PEFR) were 
recorded. Maximal voluntary ventilation (MVV) was measured as the maximal amount of air 
a participant could exhale in 12 seconds and reported as a one-minute value. During the 
MVV test, subjects were instructed to inspire and expire maximally, as fast as possible in 
order to expire the largest volume of air possible in the 12 seconds. Lung volumes that were 
measured (74) and reported parameters including total lung capacity (TLC), functional 
residual capacity (FRC), and residual volume (RV).   
 
Peak Aerobic Capacity 
 Subjects performed an incremental exercise test to determine V̇O2peak on an 
electronically braked, computer driven cycle ergometer (Lode Corival, Groningen, The 
Netherlands). Subjects were initially fitted to the cycle ergometer and the measurement 
settings were recorded to ensure the same position was utilized during the subsequent visits.  
Subjects were given verbal and written descriptions before testing for the evaluation of RPB, 
ratings of perceived unpleasantness (RPU), and ratings of perceived exertion (RPE). Subjects 
were instructed to point to the corresponding RPB, RPU (Borg 10 point scale), and RPE 
(Borg 6-20 rating scale) values during the test. Following description of the exercise 
protocol, the test began by sitting quietly on the cycle ergometer to obtain baseline measures. 
The exercise work rate started at 30 W and increased 30 W every minute thereafter (75). 
Subjects were instructed to maintain a cadence between 60 and 80 revolutions per minute. 
The test was terminated when the participant reached volitional exhaustion or if pedal rate 
fell below 60 revolutions per minute. Subjects breathed through a 2-way, low resistance non-
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rebreathing valve (2700 Hans Rudolph, Shawnee, KS). Expired gases were analyzed 
continuously through an automated metabolic cart (ParvoMedics True One 2400, Sandy, 
Utah). V̇O2 and the volume of carbon dioxide production (V̇CO2) were corrected to STPD 
conditions, and minute ventilation (V̇E) was corrected to BTPS conditions. Heart rate (HR) 
was recorded telemetrically (Polar, Kempele, Finland). Pulse oximetry was utilized to 
measure oxygen saturation (SpO2) with a pulse oximeter (Nellcor n-595).  
 
Determination of the Gas Exchange Threshold 
 Following the VȮ2peak test, the gas exchange threshold (GET) was determined 
through a cluster of measurements:  1) the first disproportionate increase in V̇CO2 vs. V̇O2; 
and 2) an increase in V̇E/ V̇O2 with no increase in V̇E/ V̇CO2 (21). Two members of the 
research team determined the GET independently. Their determinations had to be within 100 
mL of each other, and the average of the two values was recorded as the GET. If their 
determinations were over 100 mL, a third member of the research team evaluated the GET. 
Once the GET was determined, 90% of that value was used to set the workload for the 
constant intensity cycling protocol.   
 
Flow-Volume Loops 
 Inspiratory and expiratory airflow rates were measured using pneumotachs located on 
both sides of the ventilatory line. Analog output signals from both pneumotachs were 
converted to airflow, summed (inspiratory flow minus expiratory flow), and integrated to 
yield volume. Tidal flow-volume loops (tFVL) were collected 1) each minute of the VȮ2peak 
test, 2) during the last two minutes of the eucapnic voluntary hyperventilation test, and 3) 
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during the last two minutes of the 6-min moderate intensity cycling test. Inspiratory capacity 
(IC) maneuvers were performed by the subject to aid in the placement of the tFVL within the 
thoracic gas compression-free maximum flow-volume loops (MFVL) obtained during the 
pulmonary function testing. 
 
Supplementation Procedures 
 Following the initial V̇O2peak test, subjects were randomly assigned to receive BRJ or 
TJ. Subjects underwent two 10-day supplementation periods separated by a 10-day washout 
period. Subjects were asked to record their diet during the first 10-day period, and then they 
were asked to follow that diet as closely as possible for the second 10-day period. The 
subjects were given a list of foods that are high in nitrates and were asked to refrain from 
eating these foods. They were also required to refrain from using mouthwash for the entirety 
of the study. During the experimental 10-day phase, subjects drank a 70 mL container of BRJ 
(Beet It Sports, James White Drinks, Ipswich, UK) once in the morning and once in the 
evening. Each serving contained 6.45 mmol·day-1 of NO3- (12.9 mmol∙day-1). On day 10, 
before they arrived for testing, they were instructed to drink both containers two hours before 
their scheduled visit. Tomato juice (Sacramento, Red Gold LLC, Elwood, IN) served as the 
placebo, as it has negligible natural nitrate levels (76). The tomato juice was also 
administered in 70 mL containers, and subjects followed the same consumption protocol. 
During the informed consent process, subjects were informed that both beverages were test 
beverages and neither was a placebo. When subjects completed the study, they were 
informed that TJ was in fact a placebo beverage.  
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Eucapnic Hyperventilation Protocol 
 Subjects mimicked at rest the ventilation and breathing pattern corresponding to 50%, 
70%, and 90% V̇O2peak. The order in which they completed the ventilation rates was 
randomly determined via a random number generator. Subjects were seated on the same 
cycle ergometer and at the same height as they were during their V̇O2peak test to assure 
standardization. Before commencing the eucapnic voluntary hyperventilation trials, subjects 
sat quietly on the cycle ergometer, while four minutes of resting data were collected. 
Following the resting period, the inspiratory line was connected to a large balloon reservoir, 
which was filled with moistened room air, from which the subject breathed. Expired CO2 and 
O2 was continuously monitored using a second set of analyzers (CD-3A Carbon Dioxide 
Analyzer and S-3A Oxygen Analyzer, AEI Technologies, Bastrop, Texas) and maintained at 
approximately 5-6% by the addition of CO2 from the balloon reservoir. The VT and fB were 
set to match that for the corresponding V̇E measured during the V̇O2peak test. The subjects 
were given instantaneous visual feedback of their tidal volume via a computer monitor.  A 
metronome was set at the cadence of the desired breathing frequency.  The first three minutes 
of the hyperventilation test were used to ensure subjects reached steady state and achieved 
the desired V̇E. V̇O2 was recorded during the 4th and 5th minutes and the average was 
reported. The change in V̇O2 from rest to that measured during hyperventilation, divided by 
the change in V̇E from rest to that measured during hyperventilation was used calculate the 
V̇O2RM (V̇O2RM = ΔV̇O2 / ΔV̇E). tFVL were measured during the 5th minute of each eucapnic 
voluntary hyperventilation trial as previously described in the Flow-Volume Loops section. 
Following completion of the 5th minute of hyperventilation, subjects reported their RPB and 
RPU.   
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Maximum Volitional Mouth Pressure 
The maximal pressures that could be generated at the mouth during inspiration (PImax) 
and expiration (PEmax) were measured according to the joint statement on respiratory muscle 
testing between the ATS & ERS (77). PImax and PEmax were measured at baseline prior to 
hyperventilation, immediately following the third round of hyperventilation, and following 
the 20-minute passive recovery time prior to the moderate intensity cycling test. Using a 
mouthpiece connected to linear pressure transducer (Micro Direct Respiratory Pressure 
Meter, Vacumed, Ventura, California), subjects performed a maximal inspiratory effort a 
minimum of three times, from residual volume against an occluded airway for the 
measurement of PImax. In addition, a maximal expiratory effort was performed from total 
lung capacity for the measurement of PEmax. Each expiratory maneuver was repeated at least 
three times. The maneuvers were alternated with approximately 30 seconds separating each 
effort. All maneuvers were sustained for 3 to 4 seconds (77). The largest values sustained for 
one second during the inspiratory and expiratory maneuvers were considered to be the 
subject's PImax and PEmax.  
 
Constant Intensity Cycling 
 Following the eucapnic hyperventilation protocol, subjects were given 20 minutes to 
sit quietly before beginning the constant intensity cycling portion of the experiment.  
Subjects were seated on the cycle ergometer with the same seat and handle height as the 
previous V̇O2peak test. After obtaining three minutes of baseline measures, subjects began 
cycling at 90% of their aforementioned GET (21). The subjects were required to pedal at a 
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rate between 60 and 80 rpms. The subjects inspired room air and their expired air was 
measured using an automated metabolic cart. V̇E, V̇O2, and V̇CO2 were measured during the 
final three minutes of the test, as the first three minutes were to allow the subjects to reach 
steady state. Entering the final minute of the test, subjects were asked to point at the values 
that corresponded to their RPB, RPU, and RPE. PETCO2, SpO2, and HR were continuously 
monitored. 
 
Data Analysis 
Sample size estimates for changes in V̇O2 following BRJ range from 6 to 10 and our 
enrollment target was calibrated to yield 6 evaluable obese male subjects. Previous reports 
showed that the effect sizes for V̇O2-related variables are in the range of 1.2 – 1.7, which was 
determined to be detectable with these sample sizes at a power above 95%. Sample size 
calculations were performed using G*Power, and were based on data reported in published 
research (21). Data were analyzed using SPSS statistical software (SPSS Inc., Chicago, IL). 
The data were assessed for normality using the Kolmogorov-Smirnov test. Data was not 
deemed significant if it were not normally distributed. Pairwise comparisons were used to 
determine if statistically significant differences exist for the V̇O2RM, whole body V̇O2, and 
RPB during exercise following placebo and BRJ supplementations. Pearson’s correlation 
coefficient was calculated and the relationship tested for significance between changes in 
V̇O2RM and RPB during exercise. The overall type-I error rate was set at 5% (α ≤ 0.05). Data 
are expressed as mean ± standard deviation (SD).  
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Chapter 4 
Results 
Subject Characteristics  
 A total of seven subjects consented to participate in the study. One subject was 
excluded from the study for not adhering to study guidelines. Six (n=6) subjects completed 
all visits of the study and were included in subsequent data analyses. Two subjects data were 
excluded from the eucapnic voluntary hyperventilation data set due to analyzer difficulties, 
so four (n=4) subjects are included in the cost of breathing data. Anthropometric data for 
subjects are displayed in Table 1. In addition to being obese, subjects also exhibited a 
substantial amount of body fat (37.6 ± 5.8%) which was in agreeance with the subjects they 
we sought after to participate in this study. All subjects had no history of smoking. Subjects 
were recreationally active and not involved in any type of organized aerobic or anaerobic 
activity.  
 
Table 1. Characteristics of study participants (n=6). 
Age Ht Wt BMI 
(yr) (cm) (kg) (kg·m-2) 
23 ± 1 180.8 ± 11.5 114.1 ± 18.8 34.8 ± 3.2 
Values are mean ± SD. Ht, height; Wt, weight; BMI, body 
mass index 
 
Pulmonary Function 
 All subjects presented pulmonary function values that were above the lower limits of 
normal according to the prediction equations established by ATS/ERS (Table 2). However, 
FRC and RV were substantially lower than predicted (Table 3).  
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Table 2. Spirometry results of study subjects (n=6). 
  Measured % pred 
FVC (L)    5.65 ± 1.1  97 ± 10 
FEV1 (L)   4.58 ± 0.9 95 ± 10 
FEV1/FVC (%)   81.3 ± 7.0 94 ± 8 
PEF (L∙s-1)   9.08 ± 1.5 88 ± 18 
MVV (L∙min-1)  182.67 ± 38.2 95 ± 14 
Values are mean ± SD. FVC, forced vital capacity; 
FEV1, forced expiratory volume in 1 sec; PEF, peak 
expiratory flow;  MVV, maximal voluntary 
ventilation 
 
 
Table 3. Lung volumes of study subjects (n=6). 
TLC (L) FRC (L) FRC (%TLC) RV (L) RV (%TLC) 
%pred %pred %pred %pred %pred 
6.90 ± 0.9 2.47 ± 0.7 35.84 ± 7.7 0.96 ± 0.4 14.3 ± 6.4 
94 ± 7 75 ± 9 73 ± 16 56 ± 29 72 ± 32 
Values are mean ± SD. TLC, total lung capacity; FRC, functional residual capacity; 
RV, residual volume. 
 
 
Peak Aerobic Capacity 
 Subjects displayed V̇O2peak values which corresponded to 63 ± 12% of age predicted 
V̇O2peak values. Their absolute V̇O2peak values corresponded to 87 ± 12% of age predicted 
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values. At V̇O2peak, power was 245 ± 44 W and V̇E was 120.0 ± 26.8 L·min-1. Table 4 
displays additional metabolic data from the V̇O2peak test.  
 
Table 4 Metabolic data at maximal exercise (n=6). 
V̇O2  (L·min-1) 3.04 ± 0.66 
V̇O2 (mL·kg-1·min-1) 26.6 ± 5.2 
V̇CO2  (L·min-1) 3.47 ± 0.66 
HR (beats·min-1) 180 ± 20 
RER 1.15 ± 0.06 
V̇E/V̇O2  39.7 ± 4.4 
V̇E/V̇CO2 34.5 ± 2.7 
fB (breaths·min-1) 39.6 ± 5.2 
VT (L) 3.08 ± 0.63 
Values are mean ± SD. V̇O2, volume of oxygen; 
VCO2, volume of carbon dioxide; HR. heart rate; 
RER, respiratory exchange ratio; V̇E/V̇O2, 
ventilatory equivalent for oxygen; V̇E/V̇CO2, 
ventilatory equivalent for carbon dioxide; fB, 
breathing frequency; VT, tidal volume 
 
O2 Cost of Breathing 
 Rest 
 BRJ had a significant effect on lung volumes and respiratory mechanics at rest. IC 
was higher (BRJ: 4.05 ± 0.56 L, TJ: 3.58 ± 0.56 L; t(3)=-7.228, p = 0.005), EELV was lower 
(BRJ: 2.55 ± 0.91 L, TJ: 3.02 ± 0.88; t(3)=7.252, p = 0.005), the proportion of EELV to TLC 
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(EELV/TLC) was lower (t(3)=6.610, p = 0.007), and the total time spent inspiring during a 
respiratory duty cycle (Ti/TTot) was reduced (BRJ: 39.1 ± 4%, TJ: 42.6 ± 5%; t(3)=-4.645, p 
= 0.017). There were no significant differences within perceptual values. There were no other 
metabolic or ventilatory differences across conditions.  
 
Table 5.  Resting data before the EVH challenges (n=4). 
  BRJ TJ 
V̇O2 (L·min-1) 0.413 ± 0.08 0.416 ± 0.12 
V̇E (L·min-1) 14.94 ± 8.73 16.29 ± 11.51 
V̇T (L) 1.69 ± 1.12 1.76 ± 0.38 
fB (breaths·min-1) 12 ± 3 11 ± 3 
EELV (%TLC) 38.1 ± 9.3* 45.3 ± 8.6* 
EILV (%TLC) 62.3 ± 18.7 71.3 ± 12.6 
PETCO2 (mmHg) 32.5 ± 6.4 35.4 ± 11.2 
SpO2 (%) 98.4 ± 0.7 98.7 ± 0.5 
RPB 0 ± 0 0 ± 0 
RPU 0 ± 0 0 ± 0 
Values are mean ± SD. V̇O2, volume of oxygen; VE, 
ventilation; VT, tidal volume; fB, breathing frequency; EELV, 
end expiratory lung volume; TLC, total lung capacity; EILV, 
end inspiratory lung volume; PETCO2, end tidal CO2; SpO2, 
saturation of O2; RPB, rating of perceived breathlessness; 
RPU, rating of perceived unpleasantness; * indicates 
statistical significance (p<0.05) 
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50% EVH 
The desired V̇E was 34.75 ± 8.46 L·min-1. VT was larger in TJ (t(3)=3.202, p = 0.049) 
while breathing at V̇E corresponding to 50% V̇O2peak. There were no other significant 
differences among any variables during the EVH challenge at 50%. Metabolic and 
ventilatory data are presented in Table 6. 
 
Table 6.  Data from the 50% EVH challenge (n=4). 
  BRJ TJ 
V̇O2 (L·min-1) 0.446 ± 0.09 0.449 ± 0.11 
V̇E (L·min-1) 38.88 ± 10.61 39.61 ± 11.08 
V̇T (L)* 1.89 ± 0.45 * 2.20 ± 0.54 
fB (breaths·min-1) 20 ± 4 20 ± 3 
EELV (%TLC) 49.2 ± 12.1 57.9 ± 8.8 
EILV (%TLC) 78.6 ± 13.6 89.0 ± 10.1 
PETCO2 (mmHg) 48.2 ± 3.1 44.6 ± 2.8 
SpO2 (%) 98.3 ±1.2 99.3 ± 0.5 
RPB 0.6 ± 0.9 0.5 ± 1.0 
RPU 0.6 ± 0.9 0.8 ± 1.5 
Values are mean ± SD. V̇O2, volume of oxygen; VE, 
ventilation; VT, tidal volume; fB, breathing frequency; EELV, 
end expiratory lung volume; TLC, total lung capacity; EILV, 
end inspiratory lung volume; PETCO2, end tidal CO2; SpO2, 
saturation of O2; RPB, rating of perceived breathlessness; 
RPU, rating of perceived unpleasantness; * indicates 
statistical significance (p<0.05) 
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70% EVH 
The desired V̇E was 61.25 ± 20.21 L·min-1. During the EVH challenge at 70%, 
PETCO2 was significantly elevated in TJ conditions (t(3)=8.202, p = 0.004). There were no 
other significant differences among any variables. Metabolic and ventilatory data are 
presented in Table 7.  
 
Table 7.  Data from the 70% EVH challenge (n=4). 
  BRJ TJ 
V̇O2 (L·min-1) 0.474 ± 0.10 0.487 ± 0.12 
V̇E (L·min-1) 67.83 ± 20.89 67.76 ± 21.78 
V̇T (L) 2.55 ± 0.60 2.35 ± 0.50 
fB (breaths·min-1) 26 ± 5 26 ± 5 
EELV (%TLC) 48.8 ± 8.5 43.6 ± 8.3 
EILV (%TLC) 88.1 ± 13.6 79.6 ± 16.3 
PETCO2 (mmHg) 41.2 ± 2.4* 45.4 ± 2.0 
SpO2 (%) 98.6 ± 0.7 98.8 ± 0.9 
RPB 0.6 ± 0.9 0.1 ± 0.3 
RPU 0.6 ± 0.9 0.3 ± .5 
Values are mean ± SD. V̇O2, volume of oxygen; VE, 
ventilation; VT, tidal volume; fB, breathing frequency; EELV, 
end expiratory lung volume; TLC, total lung capacity; EILV, 
end inspiratory lung volume; PETCO2, end tidal CO2; SpO2, 
saturation of O2; RPB, rating of perceived breathlessness; 
RPU, rating of perceived unpleasantness; * indicates 
statistical significance (p<0.05) 
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90% EVH 
 
The desired V̇E was 94.75 ± 30.09 L·min-1. V̇E was significantly reduced during the 
EVH challenge at 90% in BRJ when compared with in TJ (t(3)=3.240, p = 0.048). There 
were no other significant differences among variables. Metabolic and ventilatory data are 
presented in Table 8.  
 
Table 8.  Data from the 90% EVH challenge (n=4). 
  BRJ TJ 
V̇O2 (L·min-1) 0.633 ± 0.19 0.685 ± 0.28 
V̇E (L·min-1) 107.72 ± 30.37 * 113.07 ± 32.46 
V̇T (L) 2.75 ± 0.51 2.74 ± 0.40 
fB (breaths·min-1) 34 ± 4 35 ± 4 
EELV (%TLC) 41.1 ± 7.0 38.1 ± 4.3 
EILV (%TLC) 82.9 ± 5.5 79.9 ± 8.6 
PETCO2 (mmHg) 41.3 ± 2.1 43.6 ± 3.4 
SpO2 (%) 98.1 ± 1.4 98.3 ± 1.2 
RPB 1.6 ± 2.3 1.1 ± 1.3 
RPU 1.4 ± 1.8 1.5 ± 1.9 
Values are mean ± SD. V̇O2, volume of oxygen; VE, 
ventilation; VT, tidal volume; fB, breathing frequency; EELV, 
end expiratory lung volume; TLC, total lung capacity; EILV, 
end inspiratory lung volume; PETCO2, end tidal CO2; SpO2, 
saturation of O2; RPB, rating of perceived breathlessness; 
RPU, rating of perceived unpleasantness; * indicates statistical 
significance (p<0.05)  
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V̇O2RM was 2.32 ± 1.39 mL O2/L during BRJ conditions and 2.78 ± 0.78 mL O2/L during TJ 
conditions (t(3)=0.808, p = 0.478), Figure 2. 
 
 
 
 
Figure 2: Individual subject responses in resting V̇O2RM across conditions. 
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Figure 3: V̇O2RM average trend lines across conditions, accompanied with average V̇O2RM 
data points.  
 
6 Minute Constant Intensity Cycling 
There were no significant differences between supplements at rest for any ventilatory 
mechanic or metabolic data. Resting metabolic and ventilatory data are presented in Table 9. 
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Table 9.  Resting data before 6-min cycling (n=6). 
  BRJ TJ 
HR (bpm) 80.3 ± 12.8 80.6 ± 10.4 
V̇O2 (mL·kg-1·min-1) 4.05 ± 0.65 4.22 ± 0.96 
V̇O2 (L·min-1) 0.473 ± 0.133 0.501 ± 0.173 
V̇E (L·min-1) 19.21 ± 8.00 19.54 ± 8.94 
V̇T (L) 1.39 ± 0.40 1.42 ± 0.51 
fB (breaths·min-1) 14 ± 3 14 ± 3 
EELV (%TLC) 42.8 ± 7.2 38.5 ± 6.2 
EILV (%TLC) 65.7 ± 12.0 59.9 ± 19.2 
Values are mean ± SD. HR, heart rate; V̇O2, volume of 
oxygen; VE, ventilation; VT, tidal volume; fB, breathing 
frequency; EELV, end expiratory lung volume; TLC, total 
lung capacity; EILV, end inspiratory lung volume; * indicates 
statistical difference(p>0.05)  
 
 
The average WR assigned to subjects was 132 ± 24 W (54 ± 8 % WRmax). Breathing pattern 
during exercise was altered: VT was significantly lower in BRJ compared with in TJ 
(t(5)=3.438, p = 0.018, d = 1.40); however, V̇E was unaltered between supplements 
(t(5)=0.442, p = 0.677, d = 0.18). There were no other significant differences for any 
perceptual, ventilatory mechanic, and metabolic data between supplements. The O2 cost of 
cycling was not significantly different (BRJ: 14.21 ± 2.81 mL·min-1·W-1, TJ: 14.59 ± 2.53 
mL·min-1·W-1; t(5)=1.595, p = 0.172). 
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Table 10.  6-min cycling data (n=6).  
  BRJ TJ 
HR (bpm) 136.7 ± 21.9 137.4 ± 14.1 
V̇O2 (mL·kg-1·min-1) 18.52 ± 3.64 19.07 ± 3.56 
V̇O2 (L·min-1) 2.107 ± 0.318 0.2.151 ± 0.338 
V̇E (L·min-1) 66.16 ± 9.43 67.68 ± 13.35 
V̇T (L) 2.56 ± 0.55* 2.83 ± 0.65 
fB (breaths·min-1) 27 ± 4 24 ± 4 
EELV (%TLC) 39.2 ± 13.9 31.1 ± 17.2 
EILV (%TLC) 77.5 ± 13.1 68.9 ± 19.7 
PETCO2 (mmHg) 38.3 ± 4.6 39.8 ± 2.9 
SpO2 (%) 96.0 ± 1.3 96.5 ± 1.5 
RPB 2.9 ± 2.6 3.4 ± 2.3 
RPU 2.7 ± 2.4 3.1 ± 2.5 
RPE 12.3 ± 3.7 11.8 ± 3.3 
Values are mean ± SD. HR, heart rate; V̇O2, volume of oxygen; 
VE, ventilation; VT, tidal volume; fB, breathing frequency; 
EELV, end expiratory lung volume; TLC, total lung capacity; 
EILV, end inspiratory lung volume; PETCO2, end tidal CO2; 
SpO2, saturation of O2; RPB, rating of perceived 
breathlessness; RPU, rating of perceived unpleasantness; RPE, 
rating of perceived exertion; * indicates statistical significance 
(p<0.05)  
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RER (BRJ: 0.979 ± 0.062, TJ: 1.018 ± 0.070; t(5)=1.531, p = 0.186, d = 0.63) and V̇CO2 
(BRJ: 2.064 ± 0.358, TJ: 2.193 ± 0.384; t(5)=2.295, p = 0.070, d = 0.94) were unaltered 
during exercise, suggesting no change in substrate utilization.  
 
 
 
Figure 4: Individual subject responses in V̇O2 (L·min-1) between supplements during 
constant-load cycling. There was no main effect (t(5)=1.210, p = 0.280, d = 0.49).  
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Figure 5: Individual subject responses in V̇O2 (mL·kg-1·min-1) during constant-load cycling 
between supplements. There was no main effect (t(5)=1.600, p = 0.170, d = 0.65). 
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Figure 6: Individual subject responses in V̇E during constant-load cycling between 
supplements. There was no main effect (t(5)=0.442, p = 0.677).  
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Figure 7: Individual subject responses in HR during constant-load cycling between 
supplements. There was no main effect (t(5)=0.121, p = 0.908). 
 
There were no significant differences among perceptual values during exercise (RPB (t(5) = 
1.225, p = 0.275), RPU (t(5)=1.536, p = 0.185), and RPE (t(5)=-1.464, p = 0.203)).  
 
The V̇O2RM during cycling was not significantly different between supplements (BRJ: 155.46 
± 83.21 mL, TJ: 180.46 ± 106.70 mL; t(3)=0.798, p = 0.640). This equates to 7.38% of total 
V̇O2 in BRJ conditions and 8.39% in TJ conditions.  
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Correlations of the Changes in V̇O2RM and RPB 
The changes between in V̇O2RM and RPB between supplements was not significantly 
correlated (p = 0.886). 
 
Maximal Volitional Mouth Pressure 
There were no differences for PImax at baseline, following the third bout of the EVH 
challenge, following the 20-minute recovery period, or the percent change from any of the 
time points. The inspiratory data is in Table 11. 
 
 
Table 11.  Inspiratory values from the maximal volitional 
mouth pressure measurements (n=6).  
  BRJ TJ 
Baseline (cm H2O) 136 ± 22 133 ± 15 
Post EVH (cm H2O) 129 ± 16 136 ± 18 
Change from baseline (%) -4 ± 12 2 ± 11 
Post Rest (cm H2O) 128 ± 12 128 ± 17 
Post Rest Change from 
Baseline % -3 ± 13 -5 ± 17 
Post Rest Change from 
Post EVH (%) -1 ± 11 -5 ± 10 
Values are mean ± SD.; cm H2O, centimeters of water. 
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There were no differences for PEmax at baseline, following the third bout of the EVH 
challenge, following the 20-minute recovery period, or the percent change from any of the 
time points. The expiratory data is in Table 12. 
 
 
 
 
Table 12.  Expiratory values from the maximal volitional 
mouth pressure measurements (n=6). 
  BRJ TJ 
Baseline (cm H2O) 166 ± 45 148 ± 33 
Post EVH (cm H2O) 163 ± 44 158 ± 36 
Change from baseline (%) -2 ± 11 7 ± 10 
Post Rest (cm H2O) 168 ± 32 155 ± 34 
Post Rest Change from 
Baseline % -3 ± 12 -6 ± 17 
Post Rest Change from 
Post EVH (%) 5 ± 11 -1 ± 10 
Values are mean ± SD.; cm H2O, centimeters of water. 
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Chapter 5 
Discussion 
 The purpose of this study was to examine the O2 cost of breathing (V̇O2RM) and 
ratings of perceived breathlessness (RPB) during eucapnic voluntary hyperventilation and to 
examine V̇O2 and RPB during moderate intensity cycling in young, obese males following 
beetroot juice (BRJ) supplementation. To our knowledge, this is the first to study to examine 
the efficacy of BRJ in relation to V̇O2RM during exercise in obese but otherwise healthy men.  
 These data demonstrate that BRJ did not alter V̇O2RM or any perceptual values during 
the eucapnic voluntary hyperventilation tests compared with those following TJ 
supplementation. Further, during moderate intensity cycling, BRJ did not have an effect on 
any metabolic or perceptual values. The changes in V̇O2RM and RPB from TJ to BRJ also did 
not correlate. Thus, our findings in obese men indicate that BRJ does not alter skeletal 
respiratory or locomotor muscle efficiency in obese men, and does not provide an ergogenic 
effect during moderate intensity exercise nor during eucapnic voluntary hyperventilation.  
 All subjects who participated were young and obese but otherwise healthy. Their 
medical histories were absent of any known cardiovascular, metabolic, respiratory, or renal 
diseases that would alter their performance. All subjects were recreationally active and did 
not partake in any type of organized aerobic or anaerobic training that would potentially give 
them exercise related physiological adaptations. The American College of Sports and 
Medicine recommends that adults participate in cardiorespiratory exercise training for at least 
150 min·wk-1 at a moderate intensity, or for 75 min·wk-1 at a vigorous intensity. In addition, 
they recommend that adults weight train 2-3 days per week with a focus on large muscle 
groups (78). Our subjects did not meet any of these recommendations, but they were not 
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sedentary. Subjects in our study engaged in activities 2-3 times per week that did not meet 
the criteria of cardiorespiratory training. Activities that our subjects participated in included 
light walking, hiking, and unstructured weight lifting a few times a month. 
Pulmonary Function 
 All subjects had normal spirometry measures based on their age, height, and sex. 
However, subjects did exhibit reduced lung volumes and capacities when compared to their 
predicted values, with notable reductions in FRC, ERV, and RV, which are consistent with 
other literature on obese populations (79, 80). One particular study reported that when obese 
men decreased their body weight by 11% and fat mass by 21%, that their FRC increased by 
18% (80). These changes were observed with the absence of changes in FEV1 and 
FEV1/FVC. Lung volumes decrease due to the increased fat surrounding the thorax in 
obesity, but lung function is often not altered until morbid obesity (BMI ≥ 40 kg·m-2). All 
pulmonary function data were collected according to ATS/ERS guidelines with well-
established and well-maintained equipment to ensure precise measurements.  
Peak Aerobic Capacity 
 Subjects exhibited normal cardiorespiratory functioning by achieving normal values 
for absolute V̇O2  (87 ± 12%), but displayed poor physical fitness as shown by their relative 
V̇O2 only reaching 63 ± 12% of their age predicted maximums. This is consistent with the 
work of Lorenzo and Babb, in which they reported that there was no statistical differences 
between the absolute V̇O2peak between normal weight and obese individuals, but normal 
weight individuals had a significantly higher relative V̇O2peak when compared with obese 
individuals. The average WR only reached 245 ± 44 W, which is also low compared to their 
predicted values.(64 ± 10%). These results confirm that we recruited individuals without 
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exercise based physiological adaptations. However, these results are similar to previous 
studies; there are negative correlations between BMI and WRmax in young males (r= -0.87, 
p=0.0001) (81), and BMI negatively correlates with relative V̇O2max (r= -0.48, p<0.01) (82). 
O2 Cost of Breathing 
 During resting conditions before the start of the EVH challenges, V̇O2 and V̇E were 
not different between conditions. However, respiratory mechanics were altered; EELV was 
elevated in TJ when compared to BRJ, as was EELV/TLC. IC was elevated in BRJ when 
compared to TJ, and the respiratory duty cycle was reduced after BRJ supplementation when 
compared to TJ. EELV/TLC at rest is at the point where FRC falls, which is approximately 
35% of TLC in normal, healthy-weight individuals. BRJ brought FRC to a point that was 
closer to normal (i.e., non-obese) when compared to TJ (BRJ: 38.1 ± 9.3, TJ: 45.3 ± 8.6; p = 
0.005). An elevation in EELV/TLC at rest is associated with expiratory flow limitation 
(EFL), which is where the expired portion of a tFVL touches the maximal FVL (83). This 
means that expiratory flow cannot be further increased by increasing expiratory muscle effort 
because it is maximum at that tidal volume. It is typical for EELV to increase as exercise 
increases, but an increase at rest is associated with negative health outcomes. For example, 
COPD is associated with EFL, and BRJ could be a means of decreasing this. Only one study 
has analyzed the effects of BRJ on COPD patients, but they only analyzed its effects on 
exercise tolerance, in which there was no benefit following BRJ supplementation on 
moderate intensity exercise, and did not report any pulmonary function or respiratory 
mechanics data (84). In the current study, IC was lower in TJ conditions simply as a function 
of the elevated EELV. Neither condition has the ability to alter TLC, so IC was increased in 
BRJ conditions. 
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 Ti/TTot or the respiratory duty cycle was decreased at rest following BRJ 
supplementation when compared to TJ. Obese individuals express an elevated respiratory 
duty cycle at rest (85), which, since inspiration requires active respiratory muscle 
contraction, means that they spend more time with their muscles contracted during resting 
breathing. At rest, expiration is passive and does not require muscle contraction. The more 
time that musculature is contracting, the more energy that is used per respiratory cycle. BRJ 
may have the potential to lower the time the respiratory muscles spend contracting per 
respiratory cycle. However, in the current study we did not see this manifest as a meaningful 
reduction in oxygen consumption. 
 V̇O2RM was unaffected by BRJ supplementation, contrary to our initial hypothesis. 
Not only were whole body V̇O2 values while breathing at 50%, 70%, and 90% V̇O2peak not 
different between the two conditions, but the slopes relating V̇O2 to V̇E were not different; 
V̇O2RM was 2.8 ± 0.78 mL O2·L-1 and 2.3 ± 1.39 mL O2·L-1 in TJ and BRJ, respectively. 
These values are smaller than the values reported by Cherniak (62). Cherniak reported that 
the average V̇O2RM in obese individuals was 3.45 mL O2·L-1, which was roughly 3 times 
more than his value (1.2 ± 0.6 mL O2·L-1) of normal weight individuals. While our V̇O2RM 
data are around double the values that have been reported in normal weight men, they still 
are reduced when compared to that in obese subjects of previous studies. It is well known 
that V̇O2RM increases with age (64, 86). This has been attributed to a number of factors such 
as increased airway resistance with age. Thus, differences in the ages of study participants 
may partially, at least, explain why our values are lower. The data of Cherniak were collected 
from middle aged participants (46 ± 10), which included some women, who have a higher 
V̇O2RM (55). Our data were collected in young obese males (23 ± 1). There were also glaring 
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methodological differences between the studies, as we had subjects breath at a predetermined 
VT and fb, while Cherniak allowed for spontaneous breathing. We also used the addition of 
CO2 to inspired air to increase the drive to breathe, while he used an increased dead space to 
achieve this.  
 In summary, a cluster of factors could explain why are values were substantially 
lower than those reported by Cherniak. His inclusion of women and a middle aged 
population would yield significant elevations in V̇O2RM. His use of spontaneous breathing 
was much different from our protocol. Our subjects had to be consciously aware of their 
breathing, which causes conscious centers of the brain such as the motor cortex to become 
involved. Spontaneous breathing is more natural as well, whereas our fB and VT values were 
assigned based off of their V̇O2peak data.  
 During the EVH challenge at 90%, subjects who had consumed BRJ had a 
significantly lower V̇E than when they had consumed TJ. The target V̇E was 94.75 ± 30.09 
L·min-1, so both groups overshot the desired V̇E, but the TJ group overshot it significantly 
more. This could not be attributed to familiarization, as out of our four subjects, two began 
with BRJ and two began with TJ. We had subjects hyperventilate at each rate for five 
minutes, but we did not sample data until the last two minutes. It is possible that subjects 
became fatigued during those last two minutes during BRJ supplementation and were unable 
to reach the same V̇E. However, elevations in perceptual responses did not accompany this. 
Due to two subjects being omitted from statistical analysis, and we could only analyze four 
subjects, this could produce a type I error. It is unlikely that respiratory fatigue was to blame 
for this, as Aaron et al. (16) had subjects hyperventilate at 100% of their V̇O2max, and five out 
of the six subjects were able to do this for over 15 minutes. As stated above, there was also 
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no increases in perceptual responses accompanying the reduced V̇E following BRJ 
conditions. Perceptual values, in particular, are multi-faceted, and are not all physiological 
based, with implications being tied in with gender, age, emotional state, and previous 
experiences (87). These influences accompanied with BRJ’s inability to lower V̇O2RM, all 
account for the lack of statistical significance among perceptual values. While V̇E was 
elevated at 90% in TJ conditions, V̇O2RM was not, indicating that there was no increased 
metabolic efficiency in the respiratory muscles. The failure to increase metabolic efficiency 
is consistent with the failure to lower perceptual values in BRJ conditions.  
Moderate Intensity Cycling 
BRJ supplementation did not affect metabolic parameters during moderate intensity 
cycling. However, it did decrease VT, while fB and V̇E were unaltered. One function of an 
increased VT is to remove CO2 from the body. V̇CO2 was elevated in TJ conditions, but the 
difference between V̇CO2 in BRJ and TJ failed to reach statistical significance (p = 0.07, d = 
0.94). However, there was a large effect size for V̇CO2. If BRJ was able to reduce the amount 
of CO2 in the blood, less CO2 would be expired which could reduce VT. I believe with more 
subjects, V̇CO2 would have reached statistical significance and would have been able to 
explain our reduction in VT. 
Our subjects displayed an elevated O2 cost of cycling compared to normal weight 
individuals. In normal weight individuals values of 9-10 mL·min-1·W-1 are considered typical 
(88), while our subjects had values of 14.21 ± 2.81 mL·min-1·W-1 in BRJ and 14.59 ± 2.53 
mL·min-1·W-1. These findings are similar to the only other BRJ study that has been 
conducted within an obese population (27). Obese adolescents in that study displayed an O2 
cost of exercise that was 12.9 ± 1.1 mL·min-1·W-1 in BRJ and 13.3 ± 1.7 mL·min-1·W-1 in 
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their placebo. Both studies used a moderate intensity exercise; however, the previous study 
also examined the O2 cost during severe intensity exercise until exhaustion. In agreement 
with our study, they also reported that BRJ did not lower V̇O2 during moderate intensity 
exercise; however, subjects were able to exercise longer during severe intensity exercise. 
Breese (49) and Thompson (50) also recorded results that showed that BRJ did not improve 
exercise efficiency at moderate intensities in normal weight men, but did specifically during 
vigorous intensity. If BRJ does preserve PCr more efficiently during exercise when 
compared to baseline (57), we would expect to see greater effects at higher exercise 
intensities, as more Type II muscle fibers would be recruited, and it is well known that Type 
II muscle fibers have higher concentrations of PCr. When cycling at 75% of V̇O2max, normal 
weight men and women recruit 55% of type II muscle fibers when estimated via a PCr/Cr 
ratio method (89). Our subjects exercised at 69.3% of V̇O2peak during BRJ conditions and 
70.8% during TJ conditions. From this it can be interpreted that our subjects recruited at least 
half of their type II muscle fibers. More research is needed in the field of BRJ 
supplementation to obese individuals. The additional adipose tissue could slow down the 
metabolic rate to the point where the NO3- supplementation is blunted.  
Dosage 
 In the present study we had subjects consume 12.9 mmol·day-1 NO3-. This amount 
was chosen because we were giving the supplement to obese men. BRJ supplementation is 
under-researched in obesity, so the dosage was chosen to ensure that there was enough NO3- 
being consumed to be metabolized. Our dosage was approximately double of that of normal 
weight subjects (21, 23), but our subjects did not weigh double compared to those subjects. 
This would suggest that our subjects were not under dosed and received a large enough dose 
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to possibly exhibit physiological effects. Rasica et al. supplemented obese adolescent 
subjects with only 5 mmol·day-1 of NO3-, and they did not find significant effects at moderate 
intensity exercise (27). Other studies have yielded positive physiological responses to BRJ at 
moderate intensity exercise including dosages of 5.5 mmol·day-1 and 6.2 mmol·day-1 of NO3- 
for 5 and 6 days respectively (21, 23). Based on previous studies, our dosage and 
supplementation period was sufficient to elicit changes. Furthermore, subjects were given a 
list of foods that were high in NO3- and asked not to eat them, to ensure that diet would not 
have an effect on our results. Thus, subjects consumed more than enough NO3- in order for it 
to be at elevated concentrations in the body and have the potential to elicit physiological 
changes in the body.  
Limitations  
 The small sample size is the main limitation of this study. Many of the variables in 
the present study have moderate to large effects sizes but no statistically significant 
differences. A larger sample size may yield statistical significance for the variables studied. 
Our analyzers that measured expired gases malfunctioned for two subjects which resulted in 
the omission of their V̇O2RM data, further reducing our sample size. If those other two 
subjects had been included with viable data, we may have seen a significant effect. 
Additionally, we did not directly measure plasma NO2- levels orally, so it is unknown if 
subjects had elevated levels of NO2-, and therefore NO3-. However, previous studies have 
reported elevated NO3- and NO2- using an identical supplementation protocol in normal 
weight subjects (21, 22, 23, 25). If subjects followed the supplementation procedures, we 
expect that their values would have been similar.  
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Conclusion 
 In conclusion, the consumption of 12.9 mmol·day-1 of NO3- in the form of BRJ does 
not lower V̇O2RM at rest or during exercise, nor does it lower whole-body V̇O2 during 
moderate intensity cycling in obese young men. During moderate intensity exercise, VT was 
reduced following BRJ conditions and V̇CO2 was reduced as well but the reduction in V̇CO2 
was not significant (p = 0.07, d = 0.94). A larger sample size may have made this value 
significant indicating less CO2 production during moderate intensity exercise in obese young 
men following BRJ supplementation.  
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Appendices  
 
Appendix A.a: Subject Information 
 
 
 
 
ID STATUS RACE AGE DOB SEX
001 Complete Caucasian 23 06/11/95 M
002 Complete Caucasian 24 03/25/94 M
003 Complete Caucasian 23 09/17/95 M
004 Complete Caucasian 24 11/02/94 M
005 Complete Caucasian 22 08/05/96 M
007 Complete Caucasian 21 07/25/97 M
ID HT (cm) WT (kg) WT:HT BMI %BF FM (kg) FFM (kg) Body Density
001 185.0 116.0 0.627 33.9 34.70 40.25 75.74343 1.0212
002 191.0 113.3 0.593 31.1 29.20 33.09 80.24047 1.0329
003 161.5 93.3 0.577 35.8 40.50 37.77 55.4897 1.0092
004 189.0 142.2 0.753 39.8 46.40 65.99 76.23206 0.9971
005 186.0 125.7 0.676 36.3 35.80 45.01 80.7116 1.0190
007 172.0 93.8 0.546 31.7 38.80 36.41 57.43069 1.0127
ID HxDOE snore- subjective
snore-
objective Hx Asth
Asthma 
Info
Smoke 
HX Pks/day
Years 
Sm Pks/yr
001 N Y Y N NA N 0 0 0
002 N N N N NA N 0 0 0
003 N N N N NA N 0 0 0
004 N N N N NA N 0 0 0
005 N Y Y N NA N 0 0 0
007 N Y Y N NA N 0 0 0
ID Ex Type Ex ExFreq  (per/wk)
ExDurati
on (min)
001 Y Hiking 2-3 60-120
002 Y Hiking, some weights at house 2-3 120.0
003 Y some resistance training 3 60.0
004 Y some resistance training 2-3 60.0
005 Y walking 2-3 20.0
007 Y Run 1 15.0
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Appendix A.a: Subject Information continued 
 
 
Appendix A.b: Pulmonary Function 
 
 
 
 
ID Meds
001 None
002 None
003 Xyzal
004 None
005 Terbinafine, Doxycycline
007 None
ID SPIRO FVC FVC PP NHANES
FVC P 
Knudson
FVC PP 
Knudson FEV1
FEV1 PP 
NHANES
001 Spiro 6.11 101 5.728 107 5.60 112
002 Spiro 7.37 114 6.156 120 5.26 99
003 Spiro 4.37 97 4.342 101 3.39 89
004 Spiro 5.91 93 6.038 98 5.07 98
005 Spiro 5.58 91 5.713 98 4.57 90
007 Spiro 4.54 87 4.813 94 3.61 82
ID FEV1 P Knudson
FEV1 PP 
Knudson FEV1/FVC
FEV1/FVC 
PP 
Knudson
25-75% 25-75% PP
001 4.946 113 91.653028 10614.348 7.55 148
002 5.321 99 71.370421 8256.849 4.68 89
003 3.727 91 77.574371 9037.9747 2.86 67
004 5.217 97 85.786802 9928.1115 6.19 119
005 4.935 93 81.899642 9482.5661 4.76 92
007 4.144 87 79.515419 9235.3236 3.25 69
ID PEF PEF PP FET100% MVV MVV PP
001 12.36 114 7.15 245 123
002 6.88 60 7.35 197 93
003 8.14 93 13.76 133 87
004 8.65 77 7.40 180 87
005 9.09 84 9.05 185 91
007 9.35 97 7.43 156 89
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Appendix A.b: Pulmonary Function continued 
 
 
 
 
 
 
 
ID LUNG VOL TLC TLC P G/B
TLC PP 
G/B
TLC P 
ATS/ERS
TLC PP 
ATS/ERS
001 LungVol 6.55 7.88 83 7.70 85
002 LungVol 8.11 8.43 96 8.18 99
003 LungVol 5.93 5.67 105 5.82 102
004 LungVol 7.50 8.24 91 8.02 94
005 LungVol 7.49 7.99 94 7.78 96
007 LungVol 5.80 6.69 87 6.66 87
ID Vtg FRC PL FRC %TLC
Pred 
FRC 
%TLC
PP FRC 
%TLC
FRC 
Pred G/B
FRC PP 
G/B
001 3.25 2.74 41.83 48.63 86.02 3.50 78
002 4.98 3.46 42.66 48.84 87.35 3.97 87
003 2.55 1.54 25.97 48.63 53.40 2.31 67
004 2.18 2.00 26.67 48.84 54.60 3.30 61
005 3.12 2.70 36.05 48.42 74.45 3.39 80
007 3.70 2.40 41.38 48.21 85.83 3.03 79
ID FRC P ATS/ERS
FRC PP 
ATS/ERS ERV RV RV P G/B
RV PP 
G/B
001 3.45 80 2.21 0.37 1.94 19
002 3.60 96 2.61 0.58 2.12 27
003 2.90 53 0.25 1.26 1.30 97
004 3.55 56 0.72 1.09 2.06 53
005 3.46 78 1.07 1.36 1.95 70
007 3.12 77 1.20 1.10 1.55 71
ID RV P ATS/ERS
RV PP 
ATS/ERS RV/TLC VC VC PP
001 1.70 22 6 6.18 102
002 1.80 32 7 7.53 116
003 1.39 91 21 4.67 104
004 1.77 61 15 6.41 101
005 1.69 80 18 6.13 100
007 1.49 74 19 4.80 92
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Appendix A.b: Pulmonary Function continued 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ID IC IC P G/B IC PP G/B
IC P 
ATS/ERS
IC PP 
ATS/ERS Raw Raw PP
001 3.81 4.38 87 4.26 90 1.96 158
002 4.65 4.46 104 4.59 101 1.69 157
003 4.39 3.36 131 2.93 150 3.56 167
004 5.49 4.94 111 4.47 123 1.97 153
005 4.79 4.60 104 4.32 111 2.22 173
007 3.40 3.66 93 3.54 96 2.30 155
ID Gaw Gaw PP sRaw sRaw PP sGaw sGaw PP
001 0.509 59 6.38 143 0.157 70
002 0.593 61 8.39 193 0.119 52
003 0.281 49 9.10 177 0.110 56
004 0.507 61 4.29 95 0.233 105
005 0.451 53 6.93 154 0.144 65
007 0.430 58 8.60 185 0.120 54
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Appendix A.c: V̇O2peak 
 
 
 
 
 
 
 
 
 
ID Stage IETWatts IETMax Time PB VE IET VT IET fB IET
001 . 30 1 682.0 20.16 1.24 16.21
001 60 2 682.0 23.61 1.59 16.76
001 . 90 3 682.0 31.41 1.55 20.24
001 120 4 682.0 40.66 2.00 20.37
001 . 150 5 682.0 51.83 2.11 24.54
001 . 180 6 682.0 68.38 2.70 25.30
001 . 210 7 682.0 84.11 2.95 28.51
001 . 240 8 682.0 112.08 3.05 36.71
001 . 270 9 682.0 150.19 3.07 48.98
001 Max . . 682.0 150.19 3.07 48.98
002 . 30 1 677.0 21.33 1.16 18.35
002 60 2 677.0 28.96 1.28 22.60
002 . 90 3 677.0 32.62 1.47 22.24
002 120 4 677.0 41.92 1.76 23.86
002 . 150 5 677.0 54.65 2.08 26.27
002 . 180 6 677.0 64.94 2.39 27.13
002 . 210 7 677.0 77.41 2.40 32.21
002 . 240 8 677.0 95.40 2.83 33.72
002 . 270 9 677.0 113.23 3.20 35.37
002 . 300 10 677.0 140.63 3.50 40.13
002 Max . . 677.0 140.63 3.50 40.13
003 . 30 1 676.0 19.84 1.59 12.49
003 60 2 676.0 25.04 1.43 17.56
003 . 90 3 676.0 32.27 1.56 20.70
003 120 4 676.0 42.14 1.79 23.53
003 . 150 5 676.0 57.99 2.09 27.74
003 . 180 6 676.0 84.29 2.30 36.59
003 Max . . 676.0 84.29 2.30 36.59
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Appendix A.c: V̇O2peak continued 
 
 
 
 
 
 
 
 
 
ID Stage IETWatts IETMax Time PB VE IET VT IET fB IET
004 . 30 1 680.0 30.35 1.52 19.91
004 60 2 680.0 32.22 1.72 18.77
004 . 90 3 680.0 36.26 1.81 20.00
004 120 4 680.0 45.63 2.37 19.24
004 . 150 5 680.0 54.73 2.72 20.12
004 . 180 6 680.0 70.75 3.04 23.29
004 . 210 7 680.0 89.99 3.45 26.11
004 . 240 8 680.0 115.56 3.98 29.01
004 . 270 9 680.0 139.48 3.68 37.92
004 Max . . 680.0 139.48 3.98 37.92
005 . 30 1 687.0 30.16 1.65 18.25
005 60 2 687.0 33.62 2.12 15.88
005 . 90 3 687.0 37.31 2.34 15.94
005 120 4 687.0 42.72 2.22 19.20
005 . 150 5 687.0 45.76 2.52 18.13
005 . 180 6 687.0 56.38 2.89 19.53
005 . 210 7 687.0 72.70 3.17 22.92
005 . 240 8 687.0 104.84 3.11 33.73
005 Max . . 687.0 104.84 3.17 33.73
007 . 30 1 685.0 22.18 1.48 14.96
007 60 2 685.0 29.17 2.20 13.25
007 . 90 3 685.0 32.91 1.88 17.47
007 120 4 685.0 42.75 1.72 24.91
007 . 150 5 685.0 54.72 2.39 22.88
007 . 180 6 685.0 71.48 2.33 30.73
007 . 210 7 685.0 100.64 2.48 40.52
007 Max . . 685.0 100.64 2.48 40.52
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Appendix A.c: V̇O2peak continued 
 
 
 
 
 
 
 
 
 
ID Stage IETWatts VO2 IET
VO2 
ml/kg IET
Peak VO₂ 
IET
PerVO₂ 
IET VCO2 IET RER IET
001 . 30 0.818 7.0 3.35 24.38 0.55 0.67
001 60 1.155 9.9 3.35 34.44 0.81 0.70
001 . 90 1.318 11.3 3.35 39.30 0.98 0.74
001 120 1.649 14.1 3.35 49.17 1.34 0.81
001 . 150 1.855 15.9 3.35 55.31 1.67 0.90
001 . 180 2.276 19.5 3.35 67.86 2.2 0.97
001 . 210 2.513 21.5 3.35 74.93 2.65 1.05
001 . 240 2.970 25.4 3.35 88.55 3.34 1.12
001 . 270 3.354 28.7 3.35 100.00 3.94 1.17
001 Max . 3.354 28.7 3.35 100.00 3.94 1.17
002 . 30 0.749 6.6 3.84 19.51 0.45 0.60
002 60 1.215 10.7 3.84 31.67 0.71 0.58
002 . 90 1.456 12.8 3.84 37.96 0.898328 0.62
002 120 1.854 16.3 3.84 48.31 1.229556 0.66
002 . 150 2.166 19.1 3.84 56.44 1.663023 0.77
002 . 180 2.355 20.7 3.84 61.38 2.04385 0.87
002 . 210 2.614 23.0 3.84 68.13 2.472945 0.95
002 . 240 2.998 26.4 3.84 78.13 3.026569 1.01
002 . 270 3.306 29.1 3.84 86.16 3.527342 1.07
002 . 300 3.873 34.1 3.84 100.94 4.212956 1.09
002 Max . 3.873 34.1 3.84 100.94 4.212956 1.09
003 . 30 0.661 7.0 1.91 34.58 0.59 0.89
003 60 0.962 10.2 1.91 50.34 0.77 0.80
003 . 90 1.162 12.3 1.91 60.78 1.01623 0.87
003 120 1.434 15.1 1.91 75.02 1.400026 0.98
003 . 150 1.644 17.3 1.91 85.99 1.838763 1.12
003 . 180 1.912 20.2 1.91 99.98 2.373558 1.24
003 Max . 1.912 20.2 1.91 100.00 2.37356 1.24
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Appendix A.c: V̇O2peak continued 
 
 
 
 
 
 
 
 
 
ID Stage IETWatts VO2 IET
VO2 
ml/kg IET
Peak VO₂ 
IET
PerVO₂ 
IET VCO2 IET RER IET
004 . 30 0.856 6.0 3.30 25.90 0.81 0.95
004 60 1.126 7.9 3.30 34.09 0.95 0.85
004 . 90 1.388 9.8 3.30 42.02 1.149158 0.83
004 120 1.679 11.8 3.30 50.84 1.489439 0.89
004 . 150 1.993 14.0 3.30 60.33 1.873099 0.94
004 . 180 2.296 16.2 3.30 69.50 2.342919 1.02
004 . 210 2.643 18.6 3.30 80.02 2.829495 1.07
004 . 240 3.035 21.4 3.30 91.89 3.408691 1.12
004 . 270 3.303 23.3 3.30 99.99 3.822419 1.16
004 Max . 3.303 23.3 3.30 100.09 3.82242 1.16
005 . 30 1.138 9.0 2.95 38.61 0.81 0.72
005 60 1.333 10.5 2.95 45.22 1.01 0.76
005 . 90 1.532 12.1 2.95 51.99 1.172745 0.77
005 120 1.767 13.9 2.95 59.97 1.409288 0.80
005 . 150 2.031 16.0 2.95 68.91 1.615465 0.80
005 . 180 2.400 18.9 2.95 81.43 2.084781 0.87
005 . 210 2.836 22.3 2.95 96.23 2.684601 0.95
005 . 240 2.947 23.2 2.95 100.00 3.224397 1.09
005 Max . 2.947 23.2 2.95 100.00 3.224397 1.09
007 . 30 0.846 9.0 3.01 28.11 0.74 0.87
007 60 1.265 13.4 3.01 42.02 1.04 0.82
007 . 90 1.466 15.6 3.01 48.72 1.219888 0.83
007 120 1.755 18.6 3.01 58.29 1.603364 0.91
007 . 150 2.028 21.5 3.01 67.37 2.066415 1.02
007 . 180 2.403 25.5 3.01 79.84 2.589382 1.08
007 . 210 2.835 30.1 3.01 94.19 3.2536 1.15
007 Max . 2.835 30.1 3.01 94.19 3.2536 1.15
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Appendix A.c: V̇O2peak continued 
 
 
 
 
 
 
 
 
 
ID Stage IETWatts VE/VO2 IET
VE/VCO2 
IET
Pred WT 
IET
PVO2 
PWT  IET
PPVO2 
PWT  IET
001 . 30 24.65 36.65 85.45 4.932 16.578
001 60 20.44 29.22 85.45 4.932 23.416
001 . 90 23.83 32.05 85.45 4.932 26.721
001 120 24.66 30.34 85.45 4.932 33.431
001 . 150 27.94 31.04 85.45 4.932 37.608
001 . 180 30.04 31.08 85.45 4.932 46.143
001 . 210 33.47 31.74 85.45 4.932 50.948
001 . 240 37.74 33.56 85.45 4.932 60.213
001 . 270 44.78 38.12 85.45 4.932 67.998
001 Max . 44.78 38.12 85.45 4.932 67.998
002 . 30 28.50 47.60 90.19 4.751 15.758
002 60 23.83 40.83 90.19 4.751 25.576
002 . 90 22.40 36.31 90.19 4.751 30.656
002 120 22.61 34.09 90.19 4.751 39.015
002 . 150 25.23 32.86 90.19 4.751 45.581
002 . 180 27.57 31.77 90.19 4.751 49.570
002 . 210 29.61 31.30 90.19 4.751 55.020
002 . 240 31.82 31.52 90.19 4.751 63.102
002 . 270 34.25 32.10 90.19 4.751 69.588
002 . 300 36.31 33.38 90.19 4.751 81.518
002 Max . 36.31 33.38 90.19 4.751 81.520
003 . 30 30.00 33.80 66.89 4.000 16.528
003 60 26.02 32.47 66.89 4.000 24.059
003 . 90 27.77 31.75 66.89 4.000 29.053
003 120 29.38 30.10 66.89 4.000 35.856
003 . 150 35.27 31.54 66.89 4.000 41.098
003 . 180 44.09 35.51 66.89 4.000 47.788
003 Max . 44.08 35.51 66.89 4.000 47.796
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Appendix A.c: V̇O2peak continued 
 
 
 
 
 
 
 
 
 
ID Stage IETWatts VE/VO2 IET
VE/VCO2 
IET
Pred WT 
IET
PVO2 
PWT  IET
PPVO2 
PWT  IET
004 . 30 35.48 37.25 88.61 5.939 14.407
004 60 28.62 33.77 88.61 5.939 18.959
004 . 90 26.13 31.56 88.61 5.939 23.368
004 120 27.17 30.64 88.61 5.939 28.279
004 . 150 27.46 29.22 88.61 5.939 33.555
004 . 180 30.82 30.20 88.61 5.939 38.653
004 . 210 34.05 31.80 88.61 5.939 44.505
004 . 240 38.07 33.90 88.61 5.939 51.106
004 . 270 42.23 36.49 88.61 5.939 55.613
004 Max . 42.23 36.49 88.61 5.939 55.618
005 . 30 26.50 37.05 86.24 5.406 21.050
005 60 25.23 33.30 86.24 5.406 24.651
005 . 90 24.35 31.82 86.24 5.406 28.343
005 120 24.18 30.31 86.24 5.406 32.690
005 . 150 22.53 28.32 86.24 5.406 37.565
005 . 180 23.49 27.04 86.24 5.406 44.391
005 . 210 25.64 27.08 86.24 5.406 52.457
005 . 240 35.58 32.52 86.24 5.406 54.516
005 Max . 35.58 32.51 86.24 5.406 54.515
007 . 30 26.22 30.10 75.18 4.049 20.894
007 60 23.06 27.97 75.18 4.049 31.235
007 . 90 22.44 26.98 75.18 4.049 36.216
007 120 24.37 26.66 75.18 4.049 43.332
007 . 150 26.99 26.48 75.18 4.049 50.084
007 . 180 29.74 27.61 75.18 4.049 59.354
007 . 210 35.50 30.93 75.18 4.049 70.016
007 Max . 35.50 30.93 75.18 4.049 70.016
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Appendix A.c: V̇O2peak continued 
 
 
 
 
 
 
 
 
 
 
ID Stage IETWatts PVO2+C PWT IET
PPVO2+C 
PWT IET HR IET PHR IET
HR PP 
IET
O2Pul 
IET
PetCO2    
IET
001 . 30 5.121 15.967 110 202 0.54 7.468 26
001 60 5.121 22.553 109 202 0.54 10.596 29
001 . 90 5.121 25.736 118 202 0.58 11.169 29
001 120 5.121 32.200 129 202 0.64 12.783 31
001 . 150 5.121 36.222 134 202 0.66 13.843 30
001 . 180 5.121 44.443 158 202 0.78 14.405 30
001 . 210 5.121 49.071 171 202 0.84 14.696 30
001 . 240 5.121 57.994 181 202 0.89 16.409 28
001 . 270 5.121 65.493 192 202 0.95 17.469 25
001 Max . 5.121 65.493 192 202 0.95 17.469 31
002 . 30 4.891 15.305 86 201 0.43 8.705 20
002 60 4.891 24.841 93 201 0.46 13.066 23
002 . 90 4.891 29.775 98 201 0.49 14.862 26
002 120 4.891 37.894 106 201 0.53 17.487 28
002 . 150 4.891 44.272 115 201 0.57 18.831 29
002 . 180 4.891 48.146 126 201 0.63 18.691 30
002 . 210 4.891 53.440 136 201 0.68 19.220 30
002 . 240 4.891 61.290 151 201 0.75 19.920 30
002 . 270 4.891 67.590 161 201 0.80 20.535 29
002 . 300 4.891 79.178 171 201 0.85 22.649 28
002 Max . 4.891 79.179 171 201 0.85 22.649 30
003 . 30 4.168 15.864 125 202 0.62 5.289 28
003 60 4.168 23.092 127 202 0.63 7.578 29
003 . 90 4.168 27.885 143 202 0.71 8.127 30
003 120 4.168 34.415 154 202 0.76 9.314 31
003 . 150 4.168 39.446 170 202 0.84 9.671 30
003 . 180 4.168 45.867 177 202 0.87 10.800 26
003 Max . 4.168 45.875 177 202 0.87 10.802 31
80 
 
Appendix A.c: V̇O2peak continued 
 
 
 
 
 
 
 
 
 
 
ID Stage IETWatts PVO2+C PWT IET
PPVO2+C 
PWT IET HR IET PHR IET
HR PP 
IET
O2Pul 
IET
PetCO2    
IET
004 . 30 6.259 13.669 129 201 0.64 6.632 25
004 60 6.259 17.988 135 201 0.67 8.340 28
004 . 90 6.259 22.172 150 201 0.74 9.252 30
004 120 6.259 26.831 158 201 0.78 10.629 31
004 . 150 6.259 31.837 173 201 0.86 11.552 32
004 . 180 6.259 36.675 182 201 0.90 12.613 31
004 . 210 6.259 42.227 196 201 0.97 13.519 30
004 . 240 6.259 48.490 203 201 1.01 14.951 28
004 . 270 6.259 52.767 208 201 1.03 15.878 26
004 Max . 6.259 52.771 208 201 1.03 15.880 32
005 . 30 5.650 20.139 95 204 0.47 11.978 25
005 60 5.650 23.584 96 204 0.47 13.881 28
005 . 90 5.650 27.117 100 204 0.49 15.322 29
005 120 5.650 31.275 107 204 0.53 16.516 31
005 . 150 5.650 35.939 115 204 0.57 17.658 33
005 . 180 5.650 42.469 127 204 0.62 18.895 34
005 . 210 5.650 50.186 137 204 0.67 20.775 35
005 . 240 5.650 52.156 148 204 0.73 19.913 29
005 Max . 5.650 52.155 148 204 0.73 19.912 35
007 . 30 4.164 20.318 131 205 0.64 6.458 45
007 60 4.164 30.374 136 205 0.66 9.299 42
007 . 90 4.164 35.218 139 205 0.68 10.550 45
007 120 4.164 42.138 146 205 0.71 12.017 44
007 . 150 4.164 48.704 157 205 0.77 12.917 47
007 . 180 4.164 57.719 166 205 0.81 14.478 44
007 . 210 4.164 68.087 181 205 0.88 15.663 37
007 Max . 4.164 68.087 181 205 0.88 15.663 47
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Appendix A.c: V̇O2peak continued 
 
 
 
 
 
 
 
 
 
ID Stage IETWatts RPB IET RPU IET RPE IET
001 . 30 0 0 7
001 60 0.5 0 7
001 . 90 0.5 0 7
001 120 0.5 0 8
001 . 150 0.5 0 8
001 . 180 1 0.5 9
001 . 210 3 3 11
001 . 240 4 4 13
001 . 270 7 7 17
001 Max . 7 7 17
002 . 30 0 0 7
002 60 0 0 7
002 . 90 0 0 7
002 120 0 0 7
002 . 150 0.5 0 7
002 . 180 0.5 0.5 7
002 . 210 0.5 0.5 7
002 . 240 1 1 8
002 . 270 2 1 11
002 . 300 3 4 15
002 Max . 3 4 15
003 . 30 0.5 0.5 7
003 60 1 1 8
003 . 90 4 3 10
003 120 4 3 12
003 . 150 5 5 14
003 . 180 8 7 15
003 Max . 8 7 15
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Appendix A.c: V̇O2peak continued 
 
 
 
 
 
 
 
 
 
ID Stage IETWatts RPB IET RPU IET RPE IET
004 . 30 0 0 7
004 60 0 0 7
004 . 90 0.5 0.5 7
004 120 0.5 0.5 8
004 . 150 1 0.5 8
004 . 180 2 2 10
004 . 210 3 3 13
004 . 240 5 5 15
004 . 270 8 7 17
004 Max . 8 7 17
005 . 30 3 0 9
005 60 3 0 9
005 . 90 3 0.5 9
005 120 3 1 11
005 . 150 4 3 13
005 . 180 5 4 15
005 . 210 7 5 15
005 . 240 7 7 15
005 Max . 7 7 15
007 . 30 2 2 9
007 60 2 2 9
007 . 90 2 3 11
007 120 4 3 13
007 . 150 4 4 14
007 . 180 6 5 14
007 . 210 8 9 16
007 Max . 8 9 16
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Appendix A.d: Eucapnic Voluntary Hyperventilation Beetroot Juice 
 
 
ID Slope from rest
Y 
intercept Stage PB VE
VE/MVV 
6MIN
1 . . RestMin1 686.0 11.44700 4.672
1 0.00047 0.451 50 686.0 48.72900 19.889
1 0.00083 0.442 70 686.0 85.51900 34.906
1 0.00306 0.358 90 686.0 133.43800 54.464
2 . . RestMin1 687.0 27.82000 14.122
2 0.0008 0.468 50 687.0 44.98400 22.835
2 0.00118 0.455 70 687.0 83.43200 42.351
2 0.00225 0.408 90 687.0 124.14500 63.018
3 . . RestMin1 689.0 8.41200 6.325
3 0.00061 0.303 50 689.0 24.72600 18.591
3 0.00062 0.303 70 689.0 41.21500 30.989
3 0.00123 0.291 90 689.0 64.87700 48.780
7 . . RestMin1 684.0 12.06900 7.737
7 0.00358 0.353 50 684.0 37.06300 23.758
7 0.00197 0.386 70 684.0 61.15700 39.203
7 0.00199 0.385 90 684.0 108.42800 69.505
ID VO2 COB
VO2 
ml/kg 
COB
VE/VO2 
COB RPB COB RPU COB
MinVi 
Mech 
COB
MinVe 
Mech 
COB
1 0.4560 0.004 25.103 0.000 0.000 -13.989 14.134
1 0.4740 0.004 102.804 0.000 0.000 -46.568 44.910
1 0.5180 0.005 165.095 0.000 0.000 -80.612 83.101
1 0.8390 0.008 159.044 0.500 0.500 -116.158 116.566
2 0.4910 0.004 56.660 0.000 0.000 -33.470 35.248
2 0.5050 0.004 89.077 0.000 0.000 -44.941 41.131
2 0.5550 0.005 150.328 0.000 0.000 -78.486 77.384
2 0.7110 0.006 174.606 0.000 0.500 -106.208 107.156
3 0.3090 0.003 27.223 0.000 0.000 -10.445 10.288
3 0.3190 0.003 77.511 0.500 0.500 -23.920 23.779
3 0.3290 0.003 125.274 0.500 0.500 -38.616 40.166
3 0.3790 0.004 171.179 1.000 0.500 -58.375 58.207
7 0.3960 0.004 30.477 0.000 0.000 -11.676 11.176
7 0.4860 0.005 76.261 2.000 2.000 -39.270 39.940
7 0.4920 0.005 124.303 2.000 2.000 -60.673 61.366
7 0.6010 0.006 180.413 5.000 4.000 -94.130 94.600
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Appendix A.d: Eucapnic Voluntary Hyperventilation Beetroot Juice continued 
 
 
ID
VE/MVV 
Mech 
COB
Vt Mech 
COB
Vt/FVC 
Mech 
COB
fB Mech 
COB
Avg IC 
COB
Typ IC 
COB
EELVavg 
Mech 
COB
EELVtyp 
Mech 
COB
1 5.769 1.894 30.996 7.534 4.215 4.268 2.336 2.28
1 18.331 2.240 36.665 20.035 4.359 4.086 2.191 2.46
1 33.919 3.193 52.257 26.046 3.218 3.271 3.332 3.28
1 47.578 3.166 51.811 37.032 4.414 5.087 2.136 1.46
2 17.892 3.204 43.477 12.684 4.379 4.327 3.731 3.78
2 20.879 1.623 22.025 25.401 3.260 2.500 4.850 5.61
2 39.281 2.344 31.806 33.059 4.897 5.385 3.213 2.72
2 54.394 3.137 42.564 34.295 4.999 4.964 3.111 3.15
3 7.735 0.835 19.101 12.972 4.391 4.394 1.539 1.54
3 17.879 1.396 31.949 17.034 3.201 3.283 2.729 2.65
3 30.200 1.819 41.633 22.100 2.403 2.953 3.527 2.98
3 43.765 2.086 47.734 27.937 3.067 2.954 2.863 2.98
7 7.164 0.836 18.409 13.877 3.212 3.017 2.588 2.78
7 25.603 2.316 51.010 17.271 2.472 2.617 3.328 3.18
7 39.337 2.828 62.292 21.707 3.176 2.600 2.624 3.20
7 60.641 2.609 57.469 36.251 3.183 2.898 2.617 2.90
ID
EELVavg  
%TLC 
COB
EELVTyp  
%TLC 
COB
EILVavg 
Mech 
COB
EILVtyp 
Mech 
COB
EILVavg 
%TLC 
COB
EILVtyp 
%TLC 
COB
Ti Mech 
COB
Te Mech 
COB
1 35.65649 34.83969 4.229338 4.175838 64.57005 63.75325 3.48645 4.528713
1 33.44602 37.61985 4.43095 4.704336 67.64809 71.82192 1.3351 1.669157
1 50.86591 50.06565 6.524609 6.472192 99.61235 98.81209 1.168642 1.140092
1 32.61545 22.33588 5.301953 4.628641 80.94585 70.66627 0.844218 0.732082
2 46.00049 46.64242 6.93486 6.98692 85.50999 86.15191 2.06001 3.29719
2 59.80222 69.16893 6.4732 7.23284 79.81751 89.18422 0.92864 1.36089
2 39.61977 33.59556 5.557231 5.068668 68.52319 62.49899 0.8506 0.9687
2 38.36609 38.79162 6.24849 6.283 77.04673 77.47226 0.797925 0.9597
3 25.94793 25.91062 2.373412 2.3712 40.02381 39.98651 1.761713 3.522525
3 46.02602 44.63406 4.1255 4.042957 69.56998 68.17803 1.604764 1.934764
3 59.47519 50.20573 5.34625 4.796571 90.15599 80.88653 1.247986 1.470971
3 48.27187 50.18718 4.948516 5.062094 83.44884 85.36415 0.974194 1.176622
7 44.61495 47.99138 3.423442 3.619275 59.02486 62.40129 1.818383 2.901383
7 57.38459 54.87241 5.644165 5.498459 97.31319 94.80102 1.722588 1.769894
7 45.23459 55.16552 5.451684 6.027678 93.99455 103.9255 1.495261 1.323444
7 45.12517 50.04138 5.226335 5.511475 90.10922 95.02543 0.85402 0.811275
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Appendix A.d: Eucapnic Voluntary Hyperventilation Beetroot Juice continued 
 
 
 
 
 
 
 
 
 
 
 
 
ID
TI/Ttot 
Mech 
COB
Vt/Ti 
Mech 
COB
Vt/Te 
Mech 
COB
PetCO2 
Mech 
COB
Max Pi 
Mech 
COB
Max Pe 
Mech 
COB
P to P 
Mech 
COB
1 43.62684 0.5432 0.418185 32.21295 -1.23563 1.603538 2.839168
1 44.44999 1.677954 1.342136 41.09651 -3.57271 3.015264 6.587974
1 50.59287 2.732139 2.800556 38.5034 -5.61303 8.09265 13.70568
1 51.94679 3.749791 4.324162 39.76576 -7.96451 15.02786 22.99237
2 38.10324 1.555439 0.971803 23.7278 -2.08644 2.81875 4.90519
2 38.70657 1.747976 1.192778 45.83608 -3.14384 2.79541 5.93925
2 46.74832 2.755782 2.419808 40.30351 -4.20832 4.895095 9.103415
2 45.4219 3.931447 3.26873 41.22527 -7.50541 6.773485 14.2789
3 34.20705 0.4738 0.236961 38.60786 -1.09069 1.056713 2.147403
3 45.27634 0.870008 0.721616 44.00782 -1.5505 1.460286 3.010786
3 45.92601 1.457846 1.23685 44.28624 -2.20429 2.256143 4.460433
3 45.28784 2.141251 1.772867 44.28539 -3.96403 4.232539 8.196569
7 40.39304 0.459625 0.288061 35.52933 -1.25498 1.100742 2.355722
7 49.26685 1.344407 1.308473 47.55831 -3.84285 4.219324 8.062174
7 52.63119 1.891361 2.136908 41.72172 -4.19679 5.156106 9.352896
7 51.03046 3.055051 3.216018 39.7848 -7.09735 7.629535 14.72689
86 
 
Appendix A.e: Eucapnic Voluntary Hyperventilation Tomato Juice 
 
 
ID Slope from rest
Y 
intercept Stage PB VE
VE/MVV 
6MIN
1 . . RestMin1 687.0 14.07600 5.745
1 0.00085 0.489 50 687.0 50.95800 20.799
1 0.00081 0.49 70 687.0 82.52900 33.685
1 0.00267 0.415 90 687.0 138.02800 56.338
2 . . RestMin1 688.0 32.90700 16.704
2 0.00032 0.499 50 688.0 44.65000 22.665
2 0.00152 0.453 70 688.0 86.73200 44.026
2 0.0047 0.306 90 688.0 134.25800 68.151
3 . . RestMin1 685.0 6.56700 4.938
3 0.00242 0.23 50 685.0 25.08300 18.859
3 0.00211 0.234 70 685.0 39.13200 29.423
3 0.00159 0.244 90 685.0 67.36400 50.650
7 . . RestMin1 684.0 11.61200 7.444
7 0.00187 0.386 50 684.0 37.76500 24.208
7 0.00161 0.391 70 684.0 62.65200 40.162
7 0.00169 0.389 90 684.0 112.64400 72.208
ID VO2 COB
VO2 
ml/kg 
COB
VE/VO2 
COB RPB COB RPU COB
MinVi 
Mech 
COB
MinVe 
Mech 
COB
1 0.5010 0.004 28.096 0.000 0.000 -17.063 17.007
1 0.5330 0.005 95.606 0.000 0.000 -46.753 47.567
1 0.5570 0.005 148.167 0.000 0.000 -72.753 73.337
1 0.8340 0.007 165.501 1.000 2.000 -105.190 106.659
2 0.5090 0.004 64.650 0.000 0.000 -31.609 33.238
2 0.5130 0.004 87.037 0.000 0.000 -47.727 48.759
2 0.5870 0.005 147.755 0.000 0.000 -82.017 80.354
2 0.9820 0.008 136.719 0.000 0.000 -113.551 115.159
3 0.2460 0.003 26.695 0.000 0.000 -10.638 10.837
3 0.2910 0.003 86.196 0.000 0.000 -26.018 26.826
3 0.3150 0.003 124.229 0.000 0.000 -37.440 36.121
3 0.3450 0.004 195.258 0.500 0.000 -64.611 63.361
7 0.4080 0.004 28.461 0.000 0.000 -12.607 12.630
7 0.4570 0.005 82.637 2.000 3.000 -36.624 36.189
7 0.4900 0.005 127.861 0.500 1.000 -60.096 59.801
7 0.5800 0.006 194.214 3.000 4.000 -101.672 102.582
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Appendix A.e: Eucapnic Voluntary Hyperventilation Tomato Juice continued 
 
 
ID
VE/MVV 
Mech 
COB
Vt Mech 
COB
Vt/FVC 
Mech 
COB
fB Mech 
COB
Avg IC 
COB
Typ IC 
COB
EELVavg 
Mech 
COB
EELVtyp 
Mech 
COB
1 6.942 2.284 37.388 7.641 3.549 3.633 3.001 2.92
1 19.415 2.369 38.770 20.131 2.502 2.426 4.048 4.12
1 29.934 2.820 46.149 26.010 3.314 3.445 3.236 3.11
1 43.534 2.788 45.630 38.113 4.162 4.130 2.388 2.42
2 16.872 2.500 33.920 13.538 3.991 3.957 4.119 4.15
2 24.751 2.026 27.485 24.319 2.586 1.992 5.524 6.12
2 40.789 2.423 32.878 33.229 4.700 4.122 3.410 3.99
2 58.456 3.125 42.395 36.940 4.719 4.888 3.391 3.22
3 8.148 1.283 29.364 9.155 3.968 3.914 1.962 2.02
3 20.170 1.566 35.846 17.121 3.067 2.925 2.863 3.00
3 27.159 1.645 37.637 22.040 4.002 4.024 1.928 1.91
3 47.640 2.179 49.858 29.086 3.984 4.181 1.946 1.75
7 8.096 0.954 21.012 13.479 2.803 2.806 2.997 2.99
7 23.198 2.138 47.087 17.027 2.696 2.880 3.104 2.92
7 38.334 2.503 55.128 23.934 2.866 3.091 2.934 2.71
7 65.758 2.852 62.822 36.005 3.404 3.178 2.396 2.62
ID
EELVavg  
%TLC 
COB
EELVTyp  
%TLC 
COB
EILVavg 
Mech 
COB
EILVtyp 
Mech 
COB
EILVavg 
%TLC 
COB
EILVtyp 
%TLC 
COB
Ti Mech 
COB
Te Mech 
COB
1 45.82012 44.53588 5.285609 5.201491 80.69632 79.41208 3.784118 4.317727
1 61.80356 62.95573 6.41698 6.492447 97.96916 99.12133 1.60046 1.39426
1 49.40063 47.40916 6.055429 5.924988 92.4493 90.45783 1.0762 1.2314
1 36.46342 36.95115 5.176346 5.208292 79.02818 79.51591 0.823623 0.754908
2 50.78915 51.20838 6.61887 6.65287 81.61369 82.03292 1.93807 2.75515
2 68.11905 75.43403 7.55011 8.143355 93.0963 100.4113 1.066882 4.433064
2 42.05015 49.17263 5.833407 6.41104 71.92857 79.05105 0.865227 0.947087
2 41.81856 39.72503 6.516 6.346215 80.34525 78.25173 0.742985 0.885946
3 33.09157 33.99831 3.24554 3.29931 54.73086 55.63761 2.66603 4.9542
3 48.27474 50.67285 4.429154 4.571362 74.69062 77.08874 1.487477 2.023592
3 32.50872 32.13828 3.572517 3.55055 60.24481 59.87437 1.211133 1.519058
3 32.81034 29.49747 4.124446 3.927993 69.55221 66.23934 0.929287 1.135793
7 51.67384 51.61552 3.951041 3.947658 68.1214 68.06307 2.072833 2.51945
7 53.52188 50.34655 5.242019 5.05785 90.37964 87.20431 1.88165 1.6643
7 50.58595 46.70345 5.436785 5.2116 93.73767 89.85517 1.392245 1.151175
7 41.30517 45.2069 5.247818 5.474118 90.47962 94.38134 0.828455 0.839314
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Appendix A.e: Eucapnic Voluntary Hyperventilation Tomato Juice continued 
 
 
 
 
 
 
 
 
 
 
 
 
ID
TI/Ttot 
Mech 
COB
Vt/Ti 
Mech 
COB
Vt/Te 
Mech 
COB
PetCO2 
Mech 
COB
Max Pi 
Mech 
COB
Max Pe 
Mech 
COB
P to P 
Mech 
COB
1 46.57683 0.603679 0.529073 34.56196 -1.40454 1.825936 3.230476
1 53.41075 1.480104 1.698999 47.31385 -3.26193 3.538487 6.800417
1 46.63728 2.620041 2.289823 43.84544 -5.82556 5.578453 11.40401
1 52.25595 3.385034 3.693155 43.4724 -6.78911 10.69372 17.48283
2 42.42583 1.289876 0.907344 20.26014 -2.04716 4.67208 6.71924
2 42.95927 1.898668 0.456942 44.62446 -2.87552 2.361764 5.237284
2 47.78448 2.800583 2.558519 43.60093 -4.33079 4.73274 9.06353
2 45.64239 4.205354 3.526756 43.45972 -8.42559 7.079869 15.50546
3 35.8376 0.481319 0.259015 46.78002 -1.14938 1.31964 2.46902
3 42.36257 1.0531 0.7741 52.12438 -1.75581 1.737115 3.492925
3 44.32728 1.358026 1.082743 47.65117 -2.12198 2.701042 4.823022
3 44.99091 2.344586 1.918301 47.93096 -3.80007 4.944087 8.744157
7 45.39123 0.460219 0.378637 39.8945 -0.96207 1.335733 2.297803
7 53.07749 1.136104 1.284474 48.73433 -1.96338 3.0299 4.99328
7 54.37868 1.797672 2.174126 46.48693 -3.60329 5.841455 9.444745
7 49.6698 3.442695 3.398154 39.67271 -7.59001 9.081895 16.67191
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Appendix A.f: 6-Minute Cycling Beetroot Juice 
 
 
 
 
 
 
ID Stage PB
Watts 
6MIN VE 6MIN
VE/MVV 
6MIN VT 6MIN fB 6MIN
001 RestMin1 686.0 0.0 21 8.608 2 12.1
001 RestMin2 686.0 0.0 21 8.378 1 14.1
001 RestMin3 686.0 0.0 25 10.095 2 12.0
001 MeanRest 686 0.0 22.11645 9.027124 1.746128 12.75277
001 Min1 686.0 155.0 34 13.824 2 19.6
001 Min2 686.0 155.0 60 24.394 3 21.6
001 Min3 686.0 155.0 60 24.540 3 21.3
001 Min4 686.0 155.0 68 27.695 3 23.9
001 Min5 686.0 155.0 73 29.738 3 25.4
001 Min6 686.0 155.0 78 31.665 3 25.6
001 MeanEx 686 155.0 72.76305 29.6992 2.910547 24.98483
002 RestMin1 687.0 0.0 34 17.256 2 20.5
002 RestMin2 687.0 0.0 21 10.528 2 12.3
002 RestMin3 687.0 0.0 27 13.509 2 12.2
002 MeanRest 687 0.0 27.1158 13.76437 1.837349 15.03397
002 Min1 687.0 150.0 29 14.613 1 23.1
002 Min2 687.0 150.0 47 23.655 2 30.4
002 Min3 687.0 150.0 59 29.766 2 26.2
002 Min4 687.0 150.0 64 32.578 2 29.5
002 Min5 687.0 150.0 69 35.123 2 32.9
002 Min6 687.0 150.0 75 38.213 2 32.8
002 MeanEx 687 150.0 69.55004 35.30459 2.191341 31.73305
003 RestMin1 689.0 0.0 8 5.869 1 5.5
003 RestMin2 689.0 0.0 7 5.131 1 11.7
003 RestMin3 689.0 0.0 9 6.941 1 14.0
003 MeanRest 689 0.0 7.953934 5.980401 0.88826 10.40076
003 Min1 689.0 102.0 20 14.840 1 15.4
003 Min2 689.0 102.0 33 24.524 2 20.0
003 Min3 689.0 102.0 41 30.555 2 23.1
003 Min4 689.0 102.0 46 34.290 2 24.0
003 Min5 689.0 102.0 47 35.544 2 25.1
003 Min6 689.0 102.0 51 38.290 2 27.7
003 MeanEx 689 102.0 47.93515 36.04147 1.875154 25.58639
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Appendix A.f: 6-Minute Cycling Beetroot Juice continued 
 
 
 
 
 
 
ID Stage PB
Watts 
6MIN VE 6MIN
VE/MVV 
6MIN VT 6MIN fB 6MIN
004 RestMin1 682.0 0.0 25 13.685 1 18.5
004 RestMin2 682.0 0.0 30 16.700 2 18.2
004 RestMin3 682.0 0.0 28 15.642 1 20.9
004 MeanRest 682 0.0 27.61582 15.34212 1.441899 19.22105
004 Min1 682.0 108.0 45 25.139 2 19.2
004 Min2 682.0 108.0 49 27.061 2 19.5
004 Min3 682.0 108.0 62 34.419 3 19.5
004 Min4 682.0 108.0 63 35.227 3 24.1
004 Min5 682.0 108.0 64 35.538 3 23.4
004 Min6 682.0 108.0 66 36.502 3 23.4
004 MeanEx 682 108.0 64.36035 35.75575 2.723534 23.63854
005 RestMin1 686.0 0.0 19 10.482 2 12.4
005 RestMin2 686.0 0.0 21 11.398 2 12.6
005 RestMin3 686.0 0.0 15 8.021 1 11.5
005 MeanRest 686 0.0 18.43902 9.967037 1.509174 12.1651
005 Min1 686.0 152.0 35 18.764 2 16.5
005 Min2 686.0 152.0 45 24.380 3 15.1
005 Min3 686.0 152.0 54 29.161 3 15.7
005 Min4 686.0 152.0 59 32.099 4 16.6
005 Min5 686.0 152.0 72 38.717 4 19.2
005 Min6 686.0 152.0 78 42.348 3 27.7
005 MeanEx 686 152.0 69.78412 37.72115 3.382657 21.15302
007 RestMin1 684.0 0.0 10 6.541 1 10.2
007 RestMin2 684.0 0.0 16 10.458 1 13.9
007 RestMin3 684.0 0.0 10 6.169 1 11.8
007 MeanRest 684 0.0 12.04709 7.722493 0.92283 11.99014
007 Min1 684.0 125.0 28 17.831 2 16.5
007 Min2 684.0 125.0 48 30.574 2 19.5
007 Min3 684.0 125.0 58 37.064 2 26.9
007 Min4 684.0 125.0 66 42.151 2 28.6
007 Min5 684.0 125.0 72 45.901 2 33.1
007 Min6 684.0 125.0 80 51.541 2 35.3
007 MeanEx 684 125.0 72.58819 46.53089 2.248601 32.30639
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Appendix A.f: 6-Minute Cycling Beetroot Juice continued 
 
 
 
 
 
 
ID Stage VO2 6MIN
VO2 
ml/kg 
6MIN
Peak 
VO
₂
 
6MIN
PerVO  
6MIN
VCO2 
6MIN RER 6MIN
001 RestMin1 0.4411 0.004 2.391 18.448 0.464 1.052
001 RestMin2 0.4824 0.004 2.391 20.176 0.445 0.922
001 RestMin3 0.5603 0.005 2.391 23.434 0.527 0.940
001 MeanRest 0.494574 0.00444 2.390871 20.68595 0.478476 0.9713074
001 Min1 1.3817 0.012 2.391 57.792 0.874 0.632
001 Min2 1.8714 0.017 2.391 78.271 1.662 0.888
001 Min3 2.1114 0.019 2.391 88.311 1.847 0.875
001 Min4 2.2243 0.020 2.391 93.033 2.044 0.919
001 Min5 2.2811 0.020 2.391 95.408 2.134 0.936
001 Min6 2.3909 0.021 2.391 100.000 2.251 0.941
001 MeanEx 2.298751 0.020635 2.390871 96.14701 2.142991 0.93198217
002 RestMin1 0.5445 0.005 2.355 23.124 0.593 1.088
002 RestMin2 0.3936 0.003 2.355 16.714 0.379 0.962
002 RestMin3 0.6622 0.006 2.355 28.123 0.527 0.796
002 MeanRest 0.533409 0.00452 2.3546 22.6539 0.49948 0.948934
002 Min1 0.9535 0.008 2.355 40.494 0.673 0.706
002 Min2 2.0565 0.017 2.355 87.341 1.394 0.678
002 Min3 2.2286 0.019 2.355 94.650 1.961 0.880
002 Min4 2.1985 0.019 2.355 93.371 2.121 0.965
002 Min5 2.1910 0.019 2.355 93.053 2.159 0.986
002 Min6 2.3546 0.020 2.355 100.002 2.321 0.986
002 MeanEx 2.248069 0.019051 2.3546 95.47564 2.200461 0.97866302
003 RestMin1 0.3013 0.003 1.564 19.267 0.204 0.677
003 RestMin2 0.2555 0.003 1.564 16.338 0.188 0.734
003 RestMin3 0.3254 0.003 1.564 20.809 0.234 0.719
003 MeanRest 0.294047 0.003118 1.5637 18.80456 0.208397 0.70974524
003 Min1 0.6745 0.007 1.564 43.137 0.567 0.840
003 Min2 1.3466 0.014 1.564 86.115 1.104 0.820
003 Min3 1.3857 0.015 1.564 88.615 1.330 0.960
003 Min4 1.4796 0.016 1.564 94.621 1.484 1.003
003 Min5 1.4947 0.016 1.564 95.584 1.507 1.008
003 Min6 1.5637 0.017 1.564 99.998 1.576 1.008
003 MeanEx 1.512637 0.016041 1.5637 96.73448 1.522192 1.00628154
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Appendix A.f: 6-Minute Cycling Beetroot Juice continued 
 
 
 
 
 
 
ID Stage VO2 6MIN
VO2 
ml/kg 
6MIN
Peak 
VO
₂
 
6MIN
PerVO  
6MIN
VCO2 
6MIN RER 6MIN
004 RestMin1 0.6707 0.005 2.041 32.864 0.559 0.834
004 RestMin2 0.7619 0.005 2.041 37.330 0.682 0.895
004 RestMin3 0.6162 0.004 2.041 30.195 0.579 0.940
004 MeanRest 0.682949 0.00471 2.040923 33.46277 0.606683 0.88941827
004 Min1 1.2203 0.008 2.041 59.793 1.059 0.867
004 Min2 1.5923 0.011 2.041 78.018 1.321 0.830
004 Min3 1.9511 0.013 2.041 95.599 1.714 0.878
004 Min4 1.8896 0.013 2.041 92.583 1.701 0.900
004 Min5 2.0409 0.014 2.041 100.000 1.773 0.869
004 Min6 1.9915 0.014 2.041 97.577 1.760 0.884
004 MeanEx 1.973979 0.013614 2.040923 96.71992 1.744726 0.88426232
005 RestMin1 0.4349 0.003 2.553 17.037 0.457 1.050
005 RestMin2 0.5375 0.004 2.553 21.055 0.505 0.940
005 RestMin3 0.3617 0.003 2.553 14.170 0.356 0.983
005 MeanRest 0.444712 0.003382 2.552802 17.42055 0.439085 0.99085983
005 Min1 1.2316 0.009 2.553 48.245 1.045 0.849
005 Min2 1.8825 0.014 2.553 73.744 1.683 0.894
005 Min3 2.1022 0.016 2.553 82.348 2.111 1.004
005 Min4 2.2336 0.017 2.553 87.495 2.307 1.033
005 Min5 2.5528 0.019 2.553 100.000 2.641 1.035
005 Min6 2.2179 0.017 2.553 86.882 2.452 1.106
005 MeanEx 2.334773 0.017755 2.552802 91.45924 2.466691 1.05765562
007 RestMin1 0.3213 0.003 3.354 9.580 0.300 0.935
007 RestMin2 0.4998 0.005 3.354 14.902 0.387 0.773
007 RestMin3 0.3463 0.004 3.354 10.326 0.280 0.808
007 MeanRest 0.389148 0.004118 3.354 11.6025 0.322244 0.83870802
007 Min1 1.1219 0.012 3.354 33.449 0.866 0.772
007 Min2 1.8192 0.019 3.354 54.241 1.722 0.947
007 Min3 1.9485 0.021 3.354 58.095 2.011 1.032
007 Min4 2.1772 0.023 3.354 64.912 2.234 1.026
007 Min5 2.2747 0.024 3.354 67.820 2.296 1.009
007 Min6 2.3626 0.025 3.354 70.440 2.397 1.014
007 MeanEx 2.271467 0.024037 3.354 67.72411 2.309018 1.01669725
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Appendix A.f: 6-Minute Cycling Beetroot Juice continued 
 
 
 
 
 
 
ID Stage VE/VO2 6MIN
VE/VCO2 
6MIN
Vent 
Resp Ex 
6MIN
HR 6MIN PHR 6MIN
HR PP 
6MIN
O2Pul 
6MIN
001 RestMin1 47.813 45.46 . 102.07 202.46 50.417 4.321
001 RestMin2 42.553 46.16 . 98.85 202.46 48.823 4.880
001 RestMin3 44.146 46.94 . 99.45 202.46 49.121 5.634
001 MeanRest 44.83728 46.18927 . 100.12 202.459 49.45375 4.944961
001 Min1 24.511 38.76 . 124.93 202.46 61.705 11.060
001 Min2 31.937 35.96 . 147.23 202.46 72.721 12.710
001 Min3 28.475 32.56 . 157.60 202.46 77.845 13.397
001 Min4 30.506 33.20 . 164.33 202.46 81.166 13.536
001 Min5 31.940 34.14 . 167.49 202.46 82.728 13.619
001 Min6 32.448 34.46 . 171.28 202.46 84.601 13.959
001 MeanEx 31.63102 33.934 30.42723 167.7006 202.459 82.83187 13.7045
002 RestMin1 62.435 57.36 . 65.18 202.46 32.194 8.353
002 RestMin2 52.700 54.75 . 64.77 202.46 31.993 6.076
002 RestMin3 40.188 50.50 . 62.69 202.46 30.965 10.563
002 MeanRest 51.77448 54.20402 . 64.21 202.459 31.71741 8.330682
002 Min1 30.192 42.78 . 83.72 202.46 41.350 11.389
002 Min2 22.660 33.44 . 96.90 202.46 47.863 21.223
002 Min3 26.312 29.90 . 103.35 202.46 51.050 21.563
002 Min4 29.191 30.27 . 105.67 202.46 52.194 20.805
002 Min5 31.580 32.04 . 110.67 202.46 54.663 19.798
002 Min6 31.971 32.43 . 111.51 202.46 55.080 21.115
002 MeanEx 30.91396 31.57844 24.94692 109.2853 202.459 53.97897 20.5728
003 RestMin1 25.911 38.30 . 65.54 202.46 32.374 4.596
003 RestMin2 26.710 36.38 . 67.81 202.46 33.495 3.768
003 RestMin3 28.371 39.48 . 77.30 202.46 38.183 4.209
003 MeanRest 26.99742 38.05526 . 70.22033 202.459 34.68373 4.191039
003 Min1 29.261 34.84 . 101.88 202.46 50.323 6.621
003 Min2 24.222 29.56 . 110.27 202.46 54.467 12.211
003 Min3 29.328 30.56 . 119.04 202.46 58.797 11.640
003 Min4 30.823 30.74 . 127.22 202.46 62.838 11.630
003 Min5 31.628 31.37 . 133.88 202.46 66.126 11.164
003 Min6 32.569 32.32 . 137.53 202.46 67.930 11.370
003 MeanEx 31.67335 31.47442 30.43186 132.8759 202.459 65.63103 11.38804
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Appendix A.f: 6-Minute Cycling Beetroot Juice continued 
 
 
 
 
 
 
ID Stage VE/VO2 6MIN
VE/VCO2 
6MIN
Vent 
Resp Ex 
6MIN
HR 6MIN PHR 6MIN
HR PP 
6MIN
O2Pul 
6MIN
004 RestMin1 36.725 44.04 . 83.34 202.46 41.163 8.048
004 RestMin2 39.454 44.09 . 83.99 202.46 41.483 9.071
004 RestMin3 45.689 48.63 . 87.71 202.46 43.323 7.026
004 MeanRest 40.6228 45.58716 . 85.01154 202.459 41.98951 8.048543
004 Min1 37.081 42.75 . 112.69 202.46 55.662 10.829
004 Min2 30.591 36.87 . 129.63 202.46 64.026 12.284
004 Min3 31.754 36.15 . 134.70 202.46 66.531 14.485
004 Min4 33.558 37.28 . 132.24 202.46 65.315 14.289
004 Min5 31.343 36.07 . 136.46 202.46 67.401 14.956
004 Min6 32.992 37.33 . 138.01 202.46 68.167 14.430
004 MeanEx 32.63108 36.89504 32.28744 135.5685 202.459 66.96098 14.55844
005 RestMin1 44.585 42.46 . 77.74 202.46 38.398 5.595
005 RestMin2 39.231 41.76 . 75.80 202.46 37.439 7.091
005 RestMin3 41.025 41.74 . 76.46 202.46 37.765 4.731
005 MeanRest 41.61365 41.98347 . 76.66539 202.459 37.86712 5.805558
005 Min1 28.186 33.21 . 94.74 202.46 46.796 13.000
005 Min2 23.958 26.80 . 102.57 202.46 50.663 18.353
005 Min3 25.663 25.55 . 110.03 202.46 54.349 19.105
005 Min4 26.586 25.74 . 115.56 202.46 57.078 19.328
005 Min5 28.058 27.12 . 118.91 202.46 58.733 21.468
005 Min6 35.323 31.95 . 122.85 202.46 60.678 18.054
005 MeanEx 29.98897 28.27046 25.32302 119.1065 202.459 58.82995 19.61691
007 RestMin1 31.755 33.97 . 82.73 202.46 40.865 3.884
007 RestMin2 32.642 42.20 . 86.88 202.46 42.911 5.753
007 RestMin3 27.786 34.39 . 87.18 202.46 43.059 3.973
007 MeanRest 30.72795 36.85576 . 85.59562 202.459 42.278 4.536485
007 Min1 24.795 32.12 . 120.31 202.46 59.427 9.325
007 Min2 26.218 27.70 . 140.49 202.46 69.394 12.949
007 Min3 29.674 28.75 . 146.41 202.46 72.315 13.309
007 Min4 30.202 29.43 . 150.28 202.46 74.225 14.488
007 Min5 31.480 31.19 . 155.28 202.46 76.699 14.648
007 Min6 34.032 33.55 . 161.24 202.46 79.641 14.652
007 MeanEx 31.90473 31.388 30.47207 155.6006 202.459 76.85534 14.59618
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Appendix A.f: 6-Minute Cycling Beetroot Juice continued 
 
 
 
 
 
 
ID Stage PetCO2 6MIN
PulseOx 
6MIN
RPB 
6MIN
RPU 
6MIN
RPE 
6MIN
FECO2 
6MIN
PmeCO2 
calc 
6MIN
001 RestMin1 . . . 0.030 19.237
001 RestMin2 . . . 0.030 18.952
001 RestMin3 0.000 0.000 0.000 0.029 18.640
001 MeanRest #DIV/0! #DIV/0! 0 0 0 0.029645 18.94311
001 Min1 30.900 91.600 . . . 0.035 22.523
001 Min2 34.400 95.600 0.500 0.000 8.000 0.038 24.255
001 Min3 37.300 92.700 . . 0.042 26.766
001 Min4 35.500 92.700 0.500 0.500 9.000 0.041 26.251
001 Min5 35.500 95.000 . . 0.040 25.536
001 Min6 35.500 95.000 0.500 0.500 11.000 0.040 25.297
001 MeanEx 35.5 94.23333 0.5 0.5 10 0.040211 25.69458
002 RestMin1 . . . . 0.024 15.301
002 RestMin2 . . . . 0.025 16.018
002 RestMin3 . 0.000 0.000 0.000 0.027 17.348
002 MeanRest #DIV/0! #DIV/0! 0 0 0 0.025347 16.2221
002 Min1 32.900 95.630 . . . 0.032 20.434
002 Min2 43.700 95.630 0.000 0.000 7.000 0.041 26.070
002 Min3 40.300 95.630 . . . 0.046 29.123
002 Min4 39.700 96.810 0.000 0.000 7.000 0.045 28.771
002 Min5 36.900 96.810 . . . 0.042 27.190
002 Min6 36.900 95.630 1.000 0.500 7.000 0.042 26.869
002 MeanEx 37.83333 96.41667 0.5 0.25 7 0.043141 27.60992
003 RestMin1 . . . . 0.036 22.794
003 RestMin2 . . . . 0.037 23.980
003 RestMin3 . 0.000 0.000 0.000 0.034 22.118
003 MeanRest #DIV/0! #DIV/0! 0 0 0 0.035769 22.964
003 Min1 40.500 98.750 . . . 0.039 25.029
003 Min2 43.900 96.810 0.500 0.500 9.000 0.046 29.458
003 Min3 39.800 97.500 . . . 0.044 28.494
003 Min4 39.800 97.500 1.000 1.000 10.000 0.044 28.331
003 Min5 39.800 97.500 . . . 0.043 27.770
003 Min6 40.500 97.500 1.000 1.000 12.000 0.042 26.961
003 MeanEx 40.03333 97.5 1 1 11 0.043127 27.68752
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Appendix A.f: 6-Minute Cycling Beetroot Juice continued 
 
 
 
 
 
 
 
 
ID Stage PetCO2 6MIN
PulseOx 
6MIN
HR Mech 
6MIN
RPB 
6MIN
RPU 
6MIN
RPE 
6MIN
FECO2 
6MIN
PmeCO2 
calc 
6MIN
004 RestMin1 . . . . . 0.031 19.851
004 RestMin2 . . . . . 0.031 19.828
004 RestMin3 . . 0.000 0.000 0.000 0.028 18.001
004 MeanRest #DIV/0! #DIV/0! #DIV/0! 0 0 0 0.030278 19.22674
004 Min1 30.480 98.830 . . . . 0.032 20.444
004 Min2 32.490 98.830 . 2.000 2.000 11.000 0.037 23.664
004 Min3 34.510 97.660 . . . . 0.038 24.129
004 Min4 30.480 97.660 . 3.000 3.000 11.000 0.037 23.402
004 Min5 34.510 97.010 . . . . 0.038 24.181
004 Min6 33.160 91.680 . 3.000 3.000 11.000 0.037 23.373
004 MeanEx 32.71667 95.45 #DIV/0! 3 3 11 0.037247 23.65194
005 RestMin1 . . . . . 0.032 20.581
005 RestMin2 . . . . . 0.033 20.924
005 RestMin3 . . 1.000 0.000 0.000 0.033 20.934
005 MeanRest #DIV/0! #DIV/0! #DIV/0! 1 0 0 0.032571 20.8128
005 Min1 37.000 99.900 . . . . 0.041 26.244
005 Min2 44.300 97.400 . 3.000 2.000 13.000 0.051 32.455
005 Min3 46.200 99.000 . . . . 0.053 34.029
005 Min4 46.200 97.600 . 4.000 2.000 14.000 0.053 33.779
005 Min5 46.200 96.700 . . . . 0.050 32.080
005 Min6 46.200 97.600 . 5.000 5.000 17.000 0.043 27.265
005 MeanEx 46.2 97.3 #DIV/0! 4.5 3.5 15.5 0.048578 31.04123
007 RestMin1 . . . . . . 0.043 27.273
007 RestMin2 . . . . . . 0.040 25.315
007 RestMin3 . . . . . . 0.040 25.348
007 MeanRest #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 0.041 25.97895
007 Min1 43.700 95.630 . . . . 0.043 27.128
007 Min2 43.100 95.630 . 3.000 4.000 13.000 0.049 31.415
007 Min3 36.900 95.630 . . . . 0.048 30.273
007 Min4 39.100 94.800 . 5.000 6.000 15.000 0.046 29.579
007 Min5 36.300 95.510 . . . . 0.044 27.927
007 Min6 38.000 95.510 . 7.000 6.000 16.000 0.041 25.980
007 MeanEx 37.8 95.27333 #DIV/0! 6 6 15.5 0.045 27.82833
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Appendix A.f: 6-Minute Cycling Beetroot Juice continued 
 
 
 
 
 
 
 
 
 
ID Stage
Vd/Vt 
calc 
6MIN
MinVi 
Mech 
6MIN
MinVe 
Mech 
6MIN
VE/MVV 
Mech 
6MIN
Vt Mech 
6MIN
Vt/FVC 
Mech 
6MIN
fB Mech 
6MIN
Avg IC 
6MIN
Typ IC 
6MIN
001 RestMin1 #VALUE! . . #VALUE! . #VALUE! . . .
001 RestMin2 #VALUE! . . #VALUE! . #VALUE! . . .
001 RestMin3 0.253 -24.116 24.410 9.963 2.005 32.811 12.300 3.217 3.431
001 MeanRest #VALUE! -24.1157 24.4103 #VALUE! 2.004725 #VALUE! 12.29978 3.217319 3.4312
001 Min1 #VALUE! . . #VALUE! . #VALUE! . . .
001 Min2 #VALUE! . . #VALUE! . #VALUE! . . .
001 Min3 #VALUE! . . #VALUE! . #VALUE! . . .
001 Min4 #VALUE! . . #VALUE! . #VALUE! . . .
001 Min5 #VALUE! . . #VALUE! . #VALUE! . . .
001 Min6 0.253 -75.255 77.649 31.693 2.711 44.368 28.778 2.618 2.598
001 MeanEx #VALUE! -75.2554 77.64885 #VALUE! 2.710879 #VALUE! 28.77849 2.618171 2.5975
002 RestMin1 #VALUE! . . #VALUE! . #VALUE! . . .
002 RestMin2 #VALUE! . . #VALUE! . #VALUE! . . .
002 RestMin3 0.325 -31.717 31.602 16.041 2.344 31.803 17.389 4.206 3.896
002 MeanRest #VALUE! -31.7165 31.60172 #VALUE! 2.34391 #VALUE! 17.38881 4.206227 3.8963
002 Min1 #VALUE! . . #VALUE! . #VALUE! . . .
002 Min2 #VALUE! . . #VALUE! . #VALUE! . . .
002 Min3 #VALUE! . . #VALUE! . #VALUE! . . .
002 Min4 #VALUE! . . #VALUE! . #VALUE! . . .
002 Min5 #VALUE! . . #VALUE! . #VALUE! . . .
002 Min6 0.266 -77.040 77.378 39.278 2.315 31.414 33.520 3.752 3.779
002 MeanEx #VALUE! -77.0395 77.37843 #VALUE! 2.315233 #VALUE! 33.51958 3.752306 3.7792
003 RestMin1 0.402 8.128 18.479
003 RestMin2 #VALUE! . . #VALUE! . #VALUE! . . .
003 RestMin3 #REF! -10.536 10.810 #REF! 0.808 #REF! 13.414 3.745 3.707
003 MeanRest #VALUE! -10.5359 10.8097 #VALUE! 0.80754 #VALUE! 13.41405 3.74451 3.7066
003 Min1 #VALUE! . . #VALUE! . #VALUE! . . .
003 Min2 #VALUE! . . #VALUE! . #VALUE! . . .
003 Min3 #VALUE! . . #VALUE! . #VALUE! . . .
003 Min4 #VALUE! . . #VALUE! . #VALUE! . . .
003 Min5 #VALUE! . . #VALUE! . #VALUE! . . .
003 Min6 0.287 -55.011 55.281 41.564 1.986 45.455 28.302 3.995 3.975
003 MeanEx #VALUE! -55.0105 55.28061 #VALUE! 1.986371 #VALUE! 28.30174 3.994996 3.9745
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Appendix A.f: 6-Minute Cycling Beetroot Juice continued 
 
 
 
 
 
 
 
 
 
ID Stage
Vd/Vt 
calc 
6MIN
MinVi 
Mech 
6MIN
MinVe 
Mech 
6MIN
VE/MVV 
Mech 
6MIN
Vt Mech 
6MIN
Vt/FVC 
Mech 
6MIN
fB Mech 
6MIN
Avg IC 
6MIN
Typ IC 
6MIN
004 RestMin1 #VALUE! . . #VALUE! . #VALUE! . . .
004 RestMin2 #VALUE! . . #VALUE! . #VALUE! . . .
004 RestMin3 0.327 -32.985 34.076 18.931 1.928 32.627 18.063 4.571 4.657
004 MeanRest #VALUE! -32.9854 34.07603 #VALUE! 1.928267 #VALUE! 18.06302 4.571175 4.6565
004 Min1 #VALUE! . . #VALUE! . #VALUE! . . .
004 Min2 #VALUE! . . #VALUE! . #VALUE! . . .
004 Min3 #VALUE! . . #VALUE! . #VALUE! . . .
004 Min4 #VALUE! . . #VALUE! . #VALUE! . . .
004 Min5 #VALUE! . . #VALUE! . #VALUE! . . .
004 Min6 0.284 -69.610 70.356 39.087 3.182 53.833 25.761 5.191 5.331
004 MeanEx #VALUE! -69.6095 70.35574 #VALUE! 3.181544 #VALUE! 25.76069 5.191269 5.3305
005 RestMin1 #VALUE! . . #VALUE! . #VALUE! . . .
005 RestMin2 #VALUE! . . #VALUE! . #VALUE! . . .
005 RestMin3 0.316 -17.639 17.397 9.404 1.623 29.093 11.168 4.962 4.795
005 MeanRest #VALUE! -17.6394 17.39671 #VALUE! 1.6234 #VALUE! 11.168 4.961782 4.7946
005 Min1 #VALUE! . . #VALUE! . #VALUE! . . .
005 Min2 #VALUE! . . #VALUE! . #VALUE! . . .
005 Min3 #VALUE! . . #VALUE! . #VALUE! . . .
005 Min4 #VALUE! . . #VALUE! . #VALUE! . . .
005 Min5 #VALUE! . . #VALUE! . #VALUE! . . .
005 Min6 0.321 -78.522 80.158 43.329 2.939 52.671 35.428 5.402 5.659
005 MeanEx #VALUE! -78.5217 80.15794 #VALUE! 2.939021 #VALUE! 35.42796 5.4018 5.6586
007 RestMin1 #VALUE! . . #VALUE! . #VALUE! . . .
007 RestMin2 #VALUE! . . #VALUE! . #VALUE! . . .
007 RestMin3 0.266 -9.167 11.358 7.281 0.951 20.954 16.554 2.994 3.257
007 MeanRest #VALUE! -9.16703 11.35762 #VALUE! 0.95132 #VALUE! 16.5535 2.99418 3.2566
007 Min1 #VALUE! . . #VALUE! . #VALUE! . . .
007 Min2 #VALUE! . . #VALUE! . #VALUE! . . .
007 Min3 #VALUE! . . #VALUE! . #VALUE! . . .
007 Min4 #VALUE! . . #VALUE! . #VALUE! . . .
007 Min5 #VALUE! . . #VALUE! . #VALUE! . . .
007 Min6 0.249 -93.512 93.581 59.988 2.574 56.692 36.847 4.047 3.868
007 MeanEx #VALUE! -93.5115 93.5813 #VALUE! 2.573817 #VALUE! 36.84669 4.047256 3.8683
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Appendix A.f: 6-Minute Cycling Beetroot Juice continued 
 
 
 
 
 
 
ID Stage
EELVavg 
Mech 
6MIN
EELVtyp 
Mech 
6MIN
EELVavg  
%TLC 
6MIN
EELVTyp  
%TLC 
6MIN
EILVavg 
Mech 
6MIN
EILVtyp 
Mech 
6MIN
001 RestMin1 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
001 RestMin2 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
001 RestMin3 3.333 3.12 50.88063 47.61527 5.337406 5.123525
001 MeanRest #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
001 Min1 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
001 Min2 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
001 Min3 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
001 Min4 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
001 Min5 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
001 Min6 3.932 3.95 60.02792 60.34351 6.642708 6.663379
001 MeanEx #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
002 RestMin1 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
002 RestMin2 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
002 RestMin3 3.904 4.21 48.1353 51.95684 6.247683 6.55761
002 MeanRest #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
002 Min1 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
002 Min2 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
002 Min3 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
002 Min4 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
002 Min5 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
002 Min6 4.358 4.33 53.73236 53.40074 6.672927 6.646033
002 MeanEx #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
003 RestMin1 2.185 2.22 36.85481 37.4941 2.99303 3.03094
003 RestMin2 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
003 RestMin3 #REF! #REF! #REF! #REF! #REF! #REF!
003 MeanRest #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
003 Min1 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
003 Min2 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
003 Min3 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
003 Min4 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
003 Min5 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
003 Min6 1.935 1.96 32.63076 32.97639 3.921375 3.941871
003 MeanEx #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
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Appendix A.f: 6-Minute Cycling Beetroot Juice continued 
 
 
 
 
 
 
ID Stage
EELVavg 
Mech 
6MIN
EELVtyp 
Mech 
6MIN
EELVavg  
%TLC 
6MIN
EELVTyp  
%TLC 
6MIN
EILVavg 
Mech 
6MIN
EILVtyp 
Mech 
6MIN
004 RestMin1 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
004 RestMin2 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
004 RestMin3 2.929 2.84 39.051 37.91333 4.857092 4.771767
004 MeanRest #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
004 Min1 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
004 Min2 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
004 Min3 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
004 Min4 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
004 Min5 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
004 Min6 2.309 2.17 30.78308 28.92667 5.490275 5.351044
004 MeanEx #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
005 RestMin1 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
005 RestMin2 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
005 RestMin3 2.528 2.70 33.75458 35.98665 4.151618 4.3188
005 MeanRest #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
005 Min1 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
005 Min2 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
005 Min3 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
005 Min4 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
005 Min5 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
005 Min6 2.088 1.83 27.87984 24.45127 5.027221 4.770421
005 MeanEx #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
007 RestMin1 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
007 RestMin2 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
007 RestMin3 2.806 2.54 48.37621 43.85172 3.75714 3.49472
007 MeanRest #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
007 Min1 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
007 Min2 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
007 Min3 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
007 Min4 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
007 Min5 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
007 Min6 1.753 1.93 30.21972 33.30517 4.326561 4.505517
007 MeanEx #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
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Appendix A.f: 6-Minute Cycling Beetroot Juice continued 
 
 
 
 
 
 
ID Stage
EILVavg 
%TLC 
6MIN
EILVtyp 
%TLC 
6MIN
Ti Mech 
6MIN
Te Mech 
6MIN
TI/Ttot 
Mech 
6MIN
Vt/Ti 
Mech 
6MIN
001 RestMin1 #VALUE! #VALUE! . . . #VALUE!
001 RestMin2 #VALUE! #VALUE! . . . #VALUE!
001 RestMin3 81.48711 78.22176 2.260363 2.770531 44.56443 0.886904
001 MeanRest #VALUE! #VALUE! 2.260363 2.770531 44.56443 #VALUE!
001 Min1 #VALUE! #VALUE! . . . #VALUE!
001 Min2 #VALUE! #VALUE! . . . #VALUE!
001 Min3 #VALUE! #VALUE! . . . #VALUE!
001 Min4 #VALUE! #VALUE! . . . #VALUE!
001 Min5 #VALUE! #VALUE! . . . #VALUE!
001 Min6 101.4154 101.731 0.90935 1.201543 43.57531 2.981117
001 MeanEx #VALUE! #VALUE! 0.90935 1.201543 43.57531 #VALUE!
002 RestMin1 #VALUE! #VALUE! . . . #VALUE!
002 RestMin2 #VALUE! #VALUE! . . . #VALUE!
002 RestMin3 77.03678 80.85832 1.968445 2.330527 44.27231 1.190742
002 MeanRest #VALUE! #VALUE! 1.968445 2.330527 44.27231 #VALUE!
002 Min1 #VALUE! #VALUE! . . . #VALUE!
002 Min2 #VALUE! #VALUE! . . . #VALUE!
002 Min3 #VALUE! #VALUE! . . . #VALUE!
002 Min4 #VALUE! #VALUE! . . . #VALUE!
002 Min5 #VALUE! #VALUE! . . . #VALUE!
002 Min6 82.28023 81.94862 0.809278 0.991317 44.89003 2.860862
002 MeanEx #VALUE! #VALUE! 0.809278 0.991317 44.89003 #VALUE!
003 RestMin1 50.47268 51.11197 0.489231
003 RestMin2 #VALUE! #VALUE! . . . #VALUE!
003 RestMin3 #REF! #REF! 1.65063 2.91815 35.5194 #REF!
003 MeanRest #VALUE! #VALUE! 1.65063 2.91815 35.5194 #VALUE!
003 Min1 #VALUE! #VALUE! . . . #VALUE!
003 Min2 #VALUE! #VALUE! . . . #VALUE!
003 Min3 #VALUE! #VALUE! . . . #VALUE!
003 Min4 #VALUE! #VALUE! . . . #VALUE!
003 Min5 #VALUE! #VALUE! . . . #VALUE!
003 Min6 66.12774 66.47337 1.016313 1.1507 46.34649 1.954487
003 MeanEx #VALUE! #VALUE! 1.016313 1.1507 46.34649 #VALUE!
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Appendix A.f: 6-Minute Cycling Beetroot Juice continued 
 
 
 
 
 
 
ID Stage
EILVavg 
%TLC 
6MIN
EILVtyp 
%TLC 
6MIN
Ti Mech 
6MIN
Te Mech 
6MIN
TI/Ttot 
Mech 
6MIN
Vt/Ti 
Mech 
6MIN
004 RestMin1 #VALUE! #VALUE! . . . #VALUE!
004 RestMin2 #VALUE! #VALUE! . . . #VALUE!
004 RestMin3 64.76123 63.62356 1.575183 1.9682 44.48399 1.224154
004 MeanRest #VALUE! #VALUE! 1.575183 1.9682 44.48399 #VALUE!
004 Min1 #VALUE! #VALUE! . . . #VALUE!
004 Min2 #VALUE! #VALUE! . . . #VALUE!
004 Min3 #VALUE! #VALUE! . . . #VALUE!
004 Min4 #VALUE! #VALUE! . . . #VALUE!
004 Min5 #VALUE! #VALUE! . . . #VALUE!
004 Min6 73.20367 71.34725 1.292163 1.298288 50.70133 2.462185
004 MeanEx #VALUE! #VALUE! 1.292163 1.298288 50.70133 #VALUE!
005 RestMin1 #VALUE! #VALUE! . . . #VALUE!
005 RestMin2 #VALUE! #VALUE! . . . #VALUE!
005 RestMin3 55.42881 57.66088 2.376073 3.250536 42.5571 0.683228
005 MeanRest #VALUE! #VALUE! 2.376073 3.250536 42.5571 #VALUE!
005 Min1 #VALUE! #VALUE! . . . #VALUE!
005 Min2 #VALUE! #VALUE! . . . #VALUE!
005 Min3 #VALUE! #VALUE! . . . #VALUE!
005 Min4 #VALUE! #VALUE! . . . #VALUE!
005 Min5 #VALUE! #VALUE! . . . #VALUE!
005 Min6 67.11911 63.69053 1.151629 1.089421 49.55026 2.552055
005 MeanEx #VALUE! #VALUE! 1.151629 1.089421 49.55026 #VALUE!
007 RestMin1 #VALUE! #VALUE! . . . #VALUE!
007 RestMin2 #VALUE! #VALUE! . . . #VALUE!
007 RestMin3 64.77828 60.25379 2.23283 2.67616 46.03638 0.42606
007 MeanRest #VALUE! #VALUE! 2.23283 2.67616 46.03638 #VALUE!
007 Min1 #VALUE! #VALUE! . . . #VALUE!
007 Min2 #VALUE! #VALUE! . . . #VALUE!
007 Min3 #VALUE! #VALUE! . . . #VALUE!
007 Min4 #VALUE! #VALUE! . . . #VALUE!
007 Min5 #VALUE! #VALUE! . . . #VALUE!
007 Min6 74.59588 77.68133 0.881906 0.799239 51.27189 2.918471
007 MeanEx #VALUE! #VALUE! 0.881906 0.799239 51.27189 #VALUE!
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Appendix A.f: 6-Minute Cycling Beetroot Juice continued 
 
 
 
 
 
 
ID Stage
Vt/Te 
Mech 
6MIN
PetCO2 
Mech 
6MIN
expBTPS 
Mech 
6MIN
Max Pi 
Mech 
6MIN
Max Pe 
Mech 
6MIN
P to P 
Mech 
6MIN
001 RestMin1 #VALUE! . . . . .
001 RestMin2 #VALUE! . . . . .
001 RestMin3 0.723589 24.96956 . -1.71813 2.075931 3.79406
001 MeanRest #VALUE! 24.96956 #DIV/0! -1.71813 2.075931 3.79406
001 Min1 #VALUE! . . . . .
001 Min2 #VALUE! . . . . .
001 Min3 #VALUE! . . . . .
001 Min4 #VALUE! . . . . .
001 Min5 #VALUE! . . . . .
001 Min6 2.256165 33.87436 . -3.53713 5.121136 8.65827
001 MeanEx #VALUE! 33.87436 #DIV/0! -3.53713 5.121136 8.65827
002 RestMin1 #VALUE! . . . . .
002 RestMin2 #VALUE! . . . . .
002 RestMin3 1.005742 25.7057 . -1.67063 3.311418 4.982048
002 MeanRest #VALUE! 25.7057 #DIV/0! -1.67063 3.311418 4.982048
002 Min1 #VALUE! . . . . .
002 Min2 #VALUE! . . . . .
002 Min3 #VALUE! . . . . .
002 Min4 #VALUE! . . . . .
002 Min5 #VALUE! . . . . .
002 Min6 2.335512 36.59469 . -2.80608 4.484633 7.290713
002 MeanEx #VALUE! 36.59469 #DIV/0! -2.80608 4.484633 7.290713
003 RestMin1 0.27673 .
003 RestMin2 #VALUE! . . . . .
003 RestMin3 #REF! 38.12225 . -1.10509 1.15501 2.2601
003 MeanRest #VALUE! 38.12225 #DIV/0! -1.10509 1.15501 2.2601
003 Min1 #VALUE! . . . . .
003 Min2 #VALUE! . . . . .
003 Min3 #VALUE! . . . . .
003 Min4 #VALUE! . . . . .
003 Min5 #VALUE! . . . . .
003 Min6 1.726228 37.82935 . -2.31877 3.713683 6.032453
003 MeanEx #VALUE! 37.82935 #DIV/0! -2.31877 3.713683 6.032453
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Appendix A.f: 6-Minute Cycling Beetroot Juice continued 
 
 
 
 
 
 
ID Stage
Vt/Te 
Mech 
6MIN
PetCO2 
Mech 
6MIN
expBTPS 
Mech 
6MIN
Max Pi 
Mech 
6MIN
Max Pe 
Mech 
6MIN
P to P 
Mech 
6MIN
004 RestMin1 #VALUE! . . . . .
004 RestMin2 #VALUE! . . . . .
004 RestMin3 0.979711 26.74448 . -1.78473 2.452342 4.237072
004 MeanRest #VALUE! 26.74448 #DIV/0! -1.78473 2.452342 4.237072
004 Min1 #VALUE! . . . . .
004 Min2 #VALUE! . . . . .
004 Min3 #VALUE! . . . . .
004 Min4 #VALUE! . . . . .
004 Min5 #VALUE! . . . . .
004 Min6 2.450569 32.65206 . -2.56997 4.503369 7.073339
004 MeanEx #VALUE! 32.65206 #DIV/0! -2.56997 4.503369 7.073339
005 RestMin1 #VALUE! . . . . .
005 RestMin2 #VALUE! . . . . .
005 RestMin3 0.499425 30.58471 . -1.36693 1.848527 3.215457
005 MeanRest #VALUE! 30.58471 #DIV/0! -1.36693 1.848527 3.215457
005 Min1 #VALUE! . . . . .
005 Min2 #VALUE! . . . . .
005 Min3 #VALUE! . . . . .
005 Min4 #VALUE! . . . . .
005 Min5 #VALUE! . . . . .
005 Min6 2.697783 40.13618 . -3.11614 5.885436 9.001576
005 MeanEx #VALUE! 40.13618 #DIV/0! -3.11614 5.885436 9.001576
007 RestMin1 #VALUE! . . . . .
007 RestMin2 #VALUE! . . . . .
007 RestMin3 0.355479 34.54452 . -0.99667 0.84569 1.84236
007 MeanRest #VALUE! 34.54452 #DIV/0! -0.99667 0.84569 1.84236
007 Min1 #VALUE! . . . . .
007 Min2 #VALUE! . . . . .
007 Min3 #VALUE! . . . . .
007 Min4 #VALUE! . . . . .
007 Min5 #VALUE! . . . . .
007 Min6 3.220335 34.59155 . -3.72741 6.728739 10.45615
007 MeanEx #VALUE! 34.59155 #DIV/0! -3.72741 6.728739 10.45615
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Appendix A.g: 6-Minute Cycling Tomato Juice 
 
 
 
 
 
 
ID Stage PB
Watts 
6MIN VE 6MIN
VE/MVV 
6MIN VT 6MIN fB 6MIN
001 RestMin1 687.0 0.0 20 8.176 2 10.4
001 RestMin2 687.0 0.0 18 7.487 2 9.2
001 RestMin3 687.0 0.0 20 8.032 2 12.0
001 MeanRest 687 0.0 19.35113 7.89842 1.858457 10.50832
001 Min1 687.0 155.0 34 13.837 2 14.7
001 Min2 687.0 155.0 48 19.614 3 17.0
001 Min3 687.0 155.0 62 25.306 3 20.6
001 Min4 687.0 155.0 70 28.517 3 20.4
001 Min5 687.0 155.0 77 31.528 3 24.8
001 Min6 687.0 155.0 86 34.936 3 28.0
001 MeanEx 687 155.0 77.56839 31.66057 3.201291 24.38334
002 RestMin1 688.0 0.0 39 20.016 2 18.1
002 RestMin2 688.0 0.0 34 17.370 2 16.8
002 RestMin3 688.0 0.0 24 12.165 1 17.4
002 MeanRest 688 0.0 32.53915 16.51733 1.864704 17.43091
002 Min1 688.0 150.0 44 22.394 2 22.5
002 Min2 688.0 150.0 45 23.061 2 23.5
002 Min3 688.0 150.0 60 30.699 2 24.5
002 Min4 688.0 150.0 63 31.751 3 22.9
002 Min5 688.0 150.0 67 34.217 3 25.7
002 Min6 688.0 150.0 73 37.298 3 26.0
002 MeanEx 688 150.0 67.81152 34.42209 2.724313 24.88754
003 RestMin1 685.0 0.0 8 5.770 1 12.0
003 RestMin2 685.0 0.0 9 6.686 1 13.1
003 RestMin3 685.0 0.0 8 5.727 1 12.1
003 MeanRest 685 0.0 8.06119 6.061045 0.650042 12.3854
003 Min1 685.0 102.0 23 17.384 2 15.4
003 Min2 685.0 102.0 33 24.908 1 22.5
003 Min3 685.0 102.0 41 30.982 2 21.4
003 Min4 685.0 102.0 47 35.642 2 24.6
003 Min5 685.0 102.0 50 37.649 2 26.1
003 Min6 685.0 102.0 51 38.575 2 24.4
003 MeanEx 685 102.0 49.594 37.28872 1.98216 25.04267
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Appendix A.g: 6-Minute Cycling Tomato Juice continued 
 
 
 
 
 
 
ID Stage PB
Watts 
6MIN VE 6MIN
VE/MVV 
6MIN VT 6MIN fB 6MIN
004 RestMin1 681.0 0.0 23 12.637 1 15.7
004 RestMin2 681.0 0.0 28 15.287 2 18.1
004 RestMin3 681.0 0.0 24 13.376 1 18.6
004 MeanRest 681 0.0 24.77984 13.76658 1.42125 17.46545
004 Min1 681.0 108.0 36 19.744 2 14.6
004 Min2 681.0 108.0 50 27.653 3 16.0
004 Min3 681.0 108.0 55 30.698 3 17.6
004 Min4 681.0 108.0 58 32.074 3 17.7
004 Min5 681.0 108.0 54 29.834 3 18.6
004 Min6 681.0 108.0 57 31.416 3 18.4
004 MeanEx 681 108.0 55.99475 31.10819 3.074764 18.2314
005 RestMin1 686.0 0.0 18 9.563 1 12.5
005 RestMin2 686.0 0.0 21 11.153 2 10.3
005 RestMin3 686.0 0.0 25 13.688 2 13.7
005 MeanRest 686 0.0 21.21631 11.46828 1.759423 12.13795
005 Min1 686.0 152.0 40 21.651 2 16.8
005 Min2 686.0 152.0 57 30.930 3 17.7
005 Min3 686.0 152.0 59 31.795 3 17.4
005 Min4 686.0 152.0 62 33.536 4 16.8
005 Min5 686.0 152.0 65 34.891 4 17.7
005 Min6 686.0 152.0 131 70.634 4 33.1
005 MeanEx 686 152.0 85.75434 46.3537 3.760245 22.54497
007 RestMin1 684.0 0.0 11 6.897 1 10.0
007 RestMin2 684.0 0.0 11 6.943 1 11.5
007 RestMin3 684.0 0.0 12 7.822 1 12.8
007 MeanRest 684 0.0 11.26385 7.220415 0.991395 11.42296
007 Min1 684.0 125.0 28 17.888 2 17.6
007 Min2 684.0 125.0 49 31.155 2 24.7
007 Min3 684.0 125.0 54 34.878 2 27.0
007 Min4 684.0 125.0 62 39.564 2 26.7
007 Min5 684.0 125.0 70 44.556 2 31.6
007 Min6 684.0 125.0 77 49.218 2 34.9
007 MeanEx 684 125.0 69.33563 44.44592 2.239461 31.03342
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Appendix A.g: 6-Minute Cycling Tomato Juice continued 
 
 
 
 
 
 
ID Stage VO2 6MIN
VO2 
ml/kg 
6MIN
Peak 
VO
₂
 
6MIN
PerVO  
6MIN
VCO2 
6MIN RER 6MIN
001 RestMin1 0.4654 0.004 2.398 19.410 0.498 1.071
001 RestMin2 0.5028 0.004 2.398 20.967 0.484 0.963
001 RestMin3 0.4944 0.004 2.398 20.616 0.518 1.048
001 MeanRest 0.48752 0.004295 2.397877 20.33132 0.500238 1.027312
001 Min1 1.0914 0.010 2.398 45.517 0.962 0.881
001 Min2 1.8763 0.017 2.398 78.247 1.687 0.899
001 Min3 2.1953 0.019 2.398 91.552 2.256 1.028
001 Min4 2.3023 0.020 2.398 96.013 2.439 1.059
001 Min5 2.3853 0.021 2.398 99.474 2.505 1.050
001 Min6 2.3979 0.021 2.398 100.000 2.541 1.060
001 MeanEx 2.361807 0.020809 2.397877 98.49577 2.495152 1.05648529
002 RestMin1 0.7951 0.007 2.381 33.388 0.728 0.916
002 RestMin2 0.5423 0.005 2.381 22.771 0.593 1.094
002 RestMin3 0.5588 0.005 2.381 23.465 0.462 0.828
002 MeanRest 0.632035 0.005397 2.38132 26.54138 0.594585 0.94579131
002 Min1 1.4306 0.012 2.381 60.074 1.054 0.737
002 Min2 1.8913 0.016 2.381 79.423 1.406 0.744
002 Min3 2.2660 0.019 2.381 95.157 1.954 0.862
002 Min4 2.1675 0.019 2.381 91.021 2.041 0.942
002 Min5 2.3170 0.020 2.381 97.299 2.161 0.933
002 Min6 2.3813 0.020 2.381 100.000 2.260 0.949
002 MeanEx 2.288607 0.019544 2.38132 96.10663 2.15413 0.94118163
003 RestMin1 0.2724 0.003 1.663 16.385 0.200 0.735
003 RestMin2 0.3040 0.003 1.663 18.285 0.225 0.740
003 RestMin3 0.2557 0.003 1.663 15.381 0.199 0.777
003 MeanRest 0.277407 0.002908 1.662742 16.68371 0.207936 0.75051312
003 Min1 0.7761 0.008 1.663 46.678 0.720 0.927
003 Min2 1.2978 0.014 1.663 78.052 1.152 0.887
003 Min3 1.4262 0.015 1.663 85.777 1.448 1.015
003 Min4 1.5397 0.016 1.663 92.597 1.655 1.075
003 Min5 1.5688 0.016 1.663 94.350 1.688 1.076
003 Min6 1.6627 0.017 1.663 100.000 1.765 1.061
003 MeanEx 1.590394 0.016671 1.662742 95.64887 1.702561 1.07073809
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Appendix A.g: 6-Minute Cycling Tomato Juice continued 
 
 
 
 
 
 
ID Stage VO2 6MIN
VO2 
ml/kg 
6MIN
Peak 
VO
₂
 
6MIN
PerVO  
6MIN
VCO2 
6MIN RER 6MIN
004 RestMin1 0.6435 0.004 1.966 32.732 0.571 0.888
004 RestMin2 0.7531 0.005 1.966 38.310 0.686 0.911
004 RestMin3 0.5718 0.004 1.966 29.085 0.567 0.991
004 MeanRest 0.656118 0.004588 1.965859 33.37561 0.608199 0.93023725
004 Min1 1.2617 0.009 1.966 64.178 1.024 0.812
004 Min2 1.7680 0.012 1.966 89.937 1.590 0.899
004 Min3 1.8982 0.013 1.966 96.558 1.771 0.933
004 Min4 1.9142 0.013 1.966 97.370 1.798 0.939
004 Min5 1.9110 0.013 1.966 97.207 1.722 0.901
004 Min6 1.9659 0.014 1.966 100.000 1.814 0.923
004 MeanEx 1.930329 0.013499 1.965859 98.19265 1.77788 0.9209997
005 RestMin1 0.6487 0.005 2.893 22.422 0.527 0.813
005 RestMin2 0.6140 0.005 2.893 21.222 0.551 0.897
005 RestMin3 0.6725 0.005 2.893 23.244 0.650 0.966
005 MeanRest 0.645055 0.004861 2.893164 22.29582 0.576124 0.89232192
005 Min1 1.4589 0.011 2.893 50.426 1.214 0.832
005 Min2 2.0511 0.015 2.893 70.895 1.910 0.931
005 Min3 1.9939 0.015 2.893 68.916 2.025 1.016
005 Min4 2.2586 0.017 2.893 78.068 2.214 0.980
005 Min5 2.4227 0.018 2.893 83.740 2.328 0.961
005 Min6 2.8932 0.022 2.893 100.000 3.328 1.150
005 MeanEx 2.524846 0.019027 2.893164 87.26936 2.623659 1.03061514
007 RestMin1 0.1832 0.002 2.414 7.589 0.329 1.794
007 RestMin2 0.3328 0.004 2.414 13.785 0.343 1.030
007 RestMin3 0.4030 0.004 2.414 16.694 0.365 0.907
007 MeanRest 0.306338 0.003269 2.414086 12.68961 0.345549 1.24333476
007 Min1 1.1117 0.012 2.414 46.051 1.003 0.902
007 Min2 1.9008 0.020 2.414 78.736 1.899 0.999
007 Min3 1.9345 0.021 2.414 80.133 2.074 1.072
007 Min4 2.0215 0.022 2.414 83.736 2.243 1.110
007 Min5 2.2020 0.024 2.414 91.216 2.391 1.086
007 Min6 2.4141 0.026 2.414 100.000 2.580 1.069
007 MeanEx 2.21253 0.023613 2.414086 91.65083 2.404696 1.08806347
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Appendix A.g: 6-Minute Cycling Tomato Juice continued 
 
 
 
 
 
 
ID Stage VE/VO2 6MIN
VE/VCO2 
6MIN
Vent 
Resp Ex 
6MIN
HR 6MIN PHR 6MIN
HR PP 
6MIN
O2Pul 
6MIN
001 RestMin1 43.039 40.20 . 85.80 202.46 42.380 5.424
001 RestMin2 36.483 37.89 . 87.69 202.46 43.310 5.734
001 RestMin3 39.807 37.97 . 80.50 202.46 39.759 6.141
001 MeanRest 39.77646 38.68593 . 84.66136 202.459 41.81655 5.766547
001 Min1 31.061 35.26 . 83.32 202.46 41.154 13.099
001 Min2 25.611 28.49 . 120.72 202.46 59.625 15.543
001 Min3 28.242 27.48 . 135.81 202.46 67.080 16.165
001 Min4 30.347 28.65 . 137.55 202.46 67.941 16.737
001 Min5 32.384 30.83 . 146.50 202.46 72.362 16.281
001 Min6 35.695 33.68 . 150.96 202.46 74.562 15.885
001 MeanEx 32.80884 31.05362 29.18285 145.0045 202.459 71.62166 16.30106
002 RestMin1 49.596 54.16 . 72.32 202.46 35.722 10.993
002 RestMin2 63.106 57.68 . 75.74 202.46 37.410 7.160
002 RestMin3 42.889 51.82 . 71.42 202.46 35.278 7.823
002 MeanRest 51.8637 54.55483 . 73.16 202.459 36.13675 8.658743
002 Min1 30.838 41.85 . 94.65 202.46 46.748 15.115
002 Min2 24.020 32.30 . 110.48 202.46 54.571 17.118
002 Min3 26.689 30.95 . 118.25 202.46 58.405 19.163
002 Min4 28.858 30.64 . 120.69 202.46 59.610 17.960
002 Min5 29.093 31.19 . 124.11 202.46 61.303 18.668
002 Min6 30.856 32.52 . 128.62 202.46 63.531 18.514
002 MeanEx 29.60209 31.44853 22.61709 124.4741 202.459 61.48116 18.38073
003 RestMin1 28.169 38.34 . 66.59 202.46 32.890 4.091
003 RestMin2 29.248 39.54 . 64.53 202.46 31.873 4.712
003 RestMin3 29.782 38.32 . 67.22 202.46 33.201 3.805
003 MeanRest 29.06653 38.7348 . 66.11287 202.459 32.65494 4.202509
003 Min1 29.789 32.12 . 102.56 202.46 50.659 7.567
003 Min2 25.526 28.76 . 108.74 202.46 53.712 11.934
003 Min3 28.892 28.45 . 115.61 202.46 57.105 12.336
003 Min4 30.789 28.64 . 122.21 202.46 60.363 12.598
003 Min5 31.918 29.66 . 123.01 202.46 60.757 12.754
003 Min6 30.856 29.07 . 130.39 202.46 64.401 12.752
003 MeanEx 31.18757 29.12676 27.78811 125.2013 202.459 61.84033 12.70147
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Appendix A.g: 6-Minute Cycling Tomato Juice continued 
 
 
 
 
 
 
ID Stage VE/VO2 6MIN
VE/VCO2 
6MIN
Vent 
Resp Ex 
6MIN
HR 6MIN PHR 6MIN
HR PP 
6MIN
O2Pul 
6MIN
004 RestMin1 35.350 39.80 . 95.29 202.46 47.067 6.753
004 RestMin2 36.537 40.09 . 98.52 202.46 48.660 7.645
004 RestMin3 42.108 42.48 . 95.34 202.46 47.091 5.997
004 MeanRest 37.99846 40.79153 . 96.38279 202.459 47.60608 6.798111
004 Min1 28.169 34.71 . 124.62 202.46 61.554 10.124
004 Min2 28.153 31.30 . 147.28 202.46 72.747 12.004
004 Min3 29.109 31.19 . 148.47 202.46 73.336 12.785
004 Min4 30.161 32.11 . 145.66 202.46 71.944 13.142
004 Min5 28.102 31.18 . 149.38 202.46 73.784 12.792
004 Min6 28.766 31.18 . 149.30 202.46 73.742 13.167
004 MeanEx 29.00955 31.49174 26.6867 148.112 202.459 73.15656 13.03383
005 RestMin1 27.273 33.54 . 81.17 202.46 40.093 7.992
005 RestMin2 33.606 37.44 . 77.10 202.46 38.084 7.963
005 RestMin3 37.657 38.97 . 80.42 202.46 39.721 8.362
005 MeanRest 32.84522 36.65113 . 79.56497 202.459 39.2993 8.105653
005 Min1 27.455 33.00 . 96.33 202.46 47.578 15.145
005 Min2 27.898 29.95 . 107.73 202.46 53.212 19.039
005 Min3 29.501 29.04 . 115.45 202.46 57.021 17.271
005 Min4 27.469 28.02 . 118.25 202.46 58.409 19.100
005 Min5 26.643 27.72 . 123.39 202.46 60.947 19.635
005 Min6 45.166 39.26 . 133.90 202.46 66.139 21.606
005 MeanEx 33.09251 31.66739 31.51986 125.1834 202.459 61.83148 20.11352
007 RestMin1 58.728 32.74 . 83.91 202.46 41.445 2.183
007 RestMin2 32.544 31.61 . 84.42 202.46 41.697 3.942
007 RestMin3 30.276 33.40 . 82.17 202.46 40.585 4.905
007 MeanRest 40.516 32.58124 . 83.49917 202.459 41.24251 3.676748
007 Min1 25.101 27.83 . 128.85 202.46 63.641 8.628
007 Min2 25.570 25.59 . 137.96 202.46 68.143 13.777
007 Min3 28.127 26.23 . 141.09 202.46 69.689 13.711
007 Min4 30.533 27.51 . 149.18 202.46 73.683 13.551
007 Min5 31.565 29.07 . 157.53 202.46 77.807 13.979
007 Min6 31.805 29.76 . 162.35 202.46 80.189 14.870
007 MeanEx 31.30072 28.78184 28.20186 156.3513 202.459 77.22615 14.13308
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Appendix A.g: 6-Minute Cycling Tomato Juice continued 
 
 
 
 
 
 
ID Stage PetCO2 6MIN
PulseOx 
6MIN
RPB 
6MIN
RPU 
6MIN
RPE 
6MIN
FECO2 
6MIN
PmeCO2 
calc 
6MIN
001 RestMin1 . . . 0.034 21.721
001 RestMin2 . . . 0.036 23.035
001 RestMin3 0.000 0.000 0.000 0.036 22.986
001 MeanRest #DIV/0! #DIV/0! 0 0 0 0.035282 22.58063
001 Min1 43.020 93.700 0.039 24.735
001 Min2 45.670 87.400 0.500 0.500 8.000 0.048 30.554
001 Min3 42.310 93.000 0.049 31.456
001 Min4 40.380 93.700 2.000 2.000 9.000 0.047 30.378
001 Min5 41.830 94.400 . . . 0.041 26.472
001 Min6 37.020 96.500 2.000 2.000 11.000 0.040 25.878
001 MeanEx 39.74333 94.86667 2 2 10 0.043088 27.57627
002 RestMin1 . . . . 0.025 16.190
002 RestMin2 . . . . 0.024 15.217
002 RestMin3 . 0.000 0.000 0.000 0.026 16.912
002 MeanRest #DIV/0! #DIV/0! 0 0 0 0.025127 16.10654
002 Min1 30.300 98.700 . . . 0.033 20.881
002 Min2 36.700 98.700 0.000 0.000 7.000 0.042 26.976
002 Min3 40.200 98.700 . . . 0.044 28.142
002 Min4 39.000 98.700 0.000 0.000 7.000 0.043 27.819
002 Min5 37.900 98.900 . . . 0.044 27.930
002 Min6 36.700 98.900 0.500 0.500 7.000 0.042 26.796
002 MeanEx 37.86667 98.83333 0.25 0.25 7 0.042925 27.51487
003 RestMin1 . . . . 0.036 22.768
003 RestMin2 . . . . 0.035 22.085
003 RestMin3 . 0.000 0.000 0.000 0.036 22.776
003 MeanRest #DIV/0! #DIV/0! 0 0 0 0.035333 22.54273
003 Min1 44.140 98.850 . . . 0.043 27.125
003 Min2 44.140 95.660 1.000 1.000 8.000 0.047 30.261
003 Min3 50.790 96.720 . . . 0.048 30.585
003 Min4 47.770 96.720 2.000 1.000 9.000 0.048 30.383
003 Min5 45.350 96.720 . . . 0.046 29.346
003 Min6 43.350 95.550 3.000 2.000 11.000 0.047 29.940
003 MeanEx 45.49 96.33 2.5 1.5 10 0.046849 29.88976
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Appendix A.g: 6-Minute Cycling Tomato Juice continued 
 
 
 
 
 
 
ID Stage PetCO2 6MIN
PulseOx 
6MIN
RPB 
6MIN
RPU 
6MIN
RPE 
6MIN
FECO2 
6MIN
PmeCO2 
calc 
6MIN
004 RestMin1 . . . . 0.035 21.937
004 RestMin2 . . . . 0.034 21.781
004 RestMin3 . 0.000 0.000 0.000 0.032 20.568
004 MeanRest #DIV/0! #DIV/0! 0 0 0 0.033799 21.42873
004 Min1 38.300 98.820 . . . 0.040 25.122
004 Min2 38.300 97.550 2.000 2.000 11.000 0.044 27.824
004 Min3 38.300 97.550 . . . 0.044 27.922
004 Min4 37.800 96.760 2.000 3.000 11.000 0.043 27.130
004 Min5 41.100 96.760 . . . 0.044 27.931
004 Min6 36.900 96.760 3.000 2.000 11.000 0.044 27.931
004 MeanEx 38.6 96.76 2.5 2.5 11 0.043634 27.66392
005 RestMin1 . . . . 0.041 25.985
005 RestMin2 . . . . 0.036 23.305
005 RestMin3 . 2.000 0.000 0.000 0.035 22.404
005 MeanRest #DIV/0! #DIV/0! 2 0 0 0.037399 23.89795
005 Min1 36.700 97.700 . . . 0.041 26.407
005 Min2 41.900 96.700 3.000 1.000 10.000 0.045 29.068
005 Min3 41.900 96.700 . . . 0.047 29.969
005 Min4 41.900 96.700 3.000 3.000 12.000 0.049 31.059
005 Min5 44.200 96.700 . . . 0.049 31.388
005 Min6 28.000 98.800 5.000 5.000 15.000 0.035 22.234
005 MeanEx 38.03333 97.4 4 4 13.5 0.044173 28.22678
007 RestMin1 . . . . . 0.042 26.611
007 RestMin2 . . . . . 0.043 27.556
007 RestMin3 . . 0.000 0.000 0.000 0.041 26.098
007 MeanRest #DIV/0! #DIV/0! 0 0 0 0.042001 26.7549
007 Min1 44.200 99.770 . . . 0.049 31.261
007 Min2 44.200 98.710 2.000 3.000 13.000 0.053 33.978
007 Min3 41.900 98.710 . . . 0.052 33.153
007 Min4 39.600 97.540 3.000 4.000 15.000 0.050 31.623
007 Min5 39.600 98.710 . . . 0.047 29.936
007 Min6 37.300 100.000 7.000 7.000 16.000 0.046 29.253
007 MeanEx 38.83333 98.75 5 5.5 15.5 0.047521 30.27069
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Appendix A.g: 6-Minute Cycling Tomato Juice continued 
 
 
 
 
 
 
 
 
 
ID Stage
Vd/Vt 
calc 
6MIN
MinVi 
Mech 
6MIN
MinVe 
Mech 
6MIN
VE/MVV 
Mech 
6MIN
Vt Mech 
6MIN
Vt/FVC 
Mech 
6MIN
fB Mech 
6MIN
Avg IC 
6MIN
Typ IC 
6MIN
001 RestMin1 #VALUE! . . #VALUE! . #VALUE! . . .
001 RestMin2 #VALUE! . . #VALUE! . #VALUE! . . .
001 RestMin3 0.256 -20.187 19.870 8.110 1.842 30.147 11.253 4.077 3.866
001 MeanRest #VALUE! -20.1873 19.87023 #VALUE! 1.842 #VALUE! 11.25272 4.07687 3.8656
001 Min1 #VALUE! . . #VALUE! . #VALUE! . . .
001 Min2 #VALUE! . . #VALUE! . #VALUE! . . .
001 Min3 #VALUE! . . #VALUE! . #VALUE! . . .
001 Min4 #VALUE! . . #VALUE! . #VALUE! . . .
001 Min5 #VALUE! . . #VALUE! . #VALUE! . . .
001 Min6 0.311 -73.227 73.217 29.885 2.593 42.433 28.074 4.115 4.069
001 MeanEx #VALUE! -73.2272 73.21729 #VALUE! 2.592686 #VALUE! 28.07361 4.114621 4.069
002 RestMin1 #VALUE! . . #VALUE! . #VALUE! . . .
002 RestMin2 #VALUE! . . #VALUE! . #VALUE! . . .
002 RestMin3 0.326 -24.941 23.925 12.145 1.421 19.282 19.968 4.368 4.100
002 MeanRest #VALUE! -24.9412 23.92495 #VALUE! 1.421053 #VALUE! 19.96844 4.36806 4.0996
002 Min1 #VALUE! . . #VALUE! . #VALUE! . . .
002 Min2 #VALUE! . . #VALUE! . #VALUE! . . .
002 Min3 #VALUE! . . #VALUE! . #VALUE! . . .
002 Min4 #VALUE! . . #VALUE! . #VALUE! . . .
002 Min5 #VALUE! . . #VALUE! . #VALUE! . . .
002 Min6 0.249 -79.187 78.648 39.923 2.688 36.473 30.903 4.794 4.768
002 MeanEx #VALUE! -79.1867 78.64845 #VALUE! 2.68807 #VALUE! 30.90264 4.793686 4.7676
003 RestMin1 #VALUE! . . #VALUE! . #VALUE! . . .
003 RestMin2 #VALUE! . . #VALUE! . #VALUE! . . .
003 RestMin3 0.478 -9.099 9.315 7.003 0.770 17.609 12.065 3.894 3.880
003 MeanRest #VALUE! -9.09901 9.314513 #VALUE! 0.769525 #VALUE! 12.06484 3.89355 3.8803
003 Min1 #VALUE! . . #VALUE! . #VALUE! . . .
003 Min2 #VALUE! . . #VALUE! . #VALUE! . . .
003 Min3 #VALUE! . . #VALUE! . #VALUE! . . .
003 Min4 #VALUE! . . #VALUE! . #VALUE! . . .
003 Min5 #VALUE! . . #VALUE! . #VALUE! . . .
003 Min6 0.362 -54.563 55.397 41.652 2.252 51.537 24.570 3.008 2.856
003 MeanEx #VALUE! -54.5627 55.39656 #VALUE! 2.252167 #VALUE! 24.56983 3.007694 2.8555
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Appendix A.g: 6-Minute Cycling Tomato Juice continued 
 
 
 
 
 
 
 
 
 
ID Stage
Vd/Vt 
calc 
6MIN
MinVi 
Mech 
6MIN
MinVe 
Mech 
6MIN
VE/MVV 
Mech 
6MIN
Vt Mech 
6MIN
Vt/FVC 
Mech 
6MIN
fB Mech 
6MIN
Avg IC 
6MIN
Typ IC 
6MIN
004 RestMin1 #VALUE! . . #VALUE! . #VALUE! . . .
004 RestMin2 #VALUE! . . #VALUE! . #VALUE! . . .
004 RestMin3 0.363 -25.487 24.588 13.660 1.404 23.759 18.191 5.066 4.811
004 MeanRest #VALUE! -25.4873 24.58824 #VALUE! 1.404133 #VALUE! 18.19136 5.065647 4.8109
004 Min1 #VALUE! . . #VALUE! . #VALUE! . . .
004 Min2 #VALUE! . . #VALUE! . #VALUE! . . .
004 Min3 #VALUE! . . #VALUE! . #VALUE! . . .
004 Min4 #VALUE! . . #VALUE! . #VALUE! . . .
004 Min5 #VALUE! . . #VALUE! . #VALUE! . . .
004 Min6 0.231 -61.273 60.352 33.529 3.321 56.195 18.547 5.655 5.987
004 MeanEx #VALUE! -61.2732 60.35234 #VALUE! 3.321144 #VALUE! 18.54681 5.654638 5.9868
005 RestMin1 #VALUE! . . #VALUE! . #VALUE! . . .
005 RestMin2 #VALUE! . . #VALUE! . #VALUE! . . .
005 RestMin3 0.249 -31.546 31.354 16.948 2.355 42.213 13.250 4.935 4.701
005 MeanRest #VALUE! -31.5457 31.35434 #VALUE! 2.35547 #VALUE! 13.25013 4.93541 4.7006
005 Min1 #VALUE! . . #VALUE! . #VALUE! . . .
005 Min2 #VALUE! . . #VALUE! . #VALUE! . . .
005 Min3 #VALUE! . . #VALUE! . #VALUE! . . .
005 Min4 #VALUE! . . #VALUE! . #VALUE! . . .
005 Min5 #VALUE! . . #VALUE! . #VALUE! . . .
005 Min6 0.250 -154.473 155.061 83.817 4.364 78.206 35.536 9.564 9.932
005 MeanEx #VALUE! -154.473 155.0611 #VALUE! 4.363878 #VALUE! 35.53581 9.5641 9.9315
007 RestMin1 #VALUE! . . #VALUE! . #VALUE! . . .
007 RestMin2 #VALUE! . . #VALUE! . #VALUE! . . .
007 RestMin3 0.319 -13.576 13.120 8.410 1.064 23.426 12.922 3.117 3.369
007 MeanRest #VALUE! -13.5764 13.11963 #VALUE! 1.06356 #VALUE! 12.92225 3.11683 3.3688
007 Min1 #VALUE! . #VALUE! . #VALUE! . . .
007 Min2 #VALUE! . . #VALUE! . #VALUE! . . .
007 Min3 #VALUE! . . #VALUE! . #VALUE! . . .
007 Min4 #VALUE! . . #VALUE! . #VALUE! . . .
007 Min5 #VALUE! . . #VALUE! . #VALUE! . . .
007 Min6 0.223 -83.313 83.409 53.467 2.403 52.940 34.723 3.803 3.813
007 MeanEx #VALUE! -83.3125 83.40891 #VALUE! 2.403493 #VALUE! 34.72285 3.802536 3.8131
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Appendix A.g: 6-Minute Cycling Tomato Juice continued 
 
 
 
 
 
 
ID Stage
EELVavg 
Mech 
6MIN
EELVtyp 
Mech 
6MIN
EELVavg  
%TLC 
6MIN
EELVTyp  
%TLC 
6MIN
EILVavg 
Mech 
6MIN
EILVtyp 
Mech 
6MIN
001 RestMin1 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
001 RestMin2 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
001 RestMin3 2.473 2.68 37.75771 40.98321 4.31513 4.5264
001 MeanRest #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
001 Min1 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
001 Min2 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
001 Min3 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
001 Min4 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
001 Min5 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
001 Min6 2.435 2.48 37.18136 37.87786 5.028065 5.073686
001 MeanEx #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
002 RestMin1 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
002 RestMin2 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
002 RestMin3 3.742 4.01 46.13983 49.45006 5.162993 5.431453
002 MeanRest #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
002 Min1 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
002 Min2 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
002 Min3 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
002 Min4 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
002 Min5 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
002 Min6 3.316 3.34 40.89166 41.21332 6.004384 6.03047
002 MeanEx #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
003 RestMin1 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
003 RestMin2 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
003 RestMin3 2.036 2.05 34.34148 34.56492 2.805975 2.819225
003 MeanRest #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
003 Min1 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
003 Min2 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
003 Min3 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
003 Min4 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
003 Min5 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
003 Min6 2.922 3.07 49.28003 51.84654 5.174473 5.326667
003 MeanEx #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
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ID Stage
EELVavg 
Mech 
6MIN
EELVtyp 
Mech 
6MIN
EELVavg  
%TLC 
6MIN
EELVTyp  
%TLC 
6MIN
EILVavg 
Mech 
6MIN
EILVtyp 
Mech 
6MIN
004 RestMin1 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
004 RestMin2 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
004 RestMin3 2.434 2.69 32.45804 35.85467 3.838486 4.093233
004 MeanRest #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
004 Min1 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
004 Min2 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
004 Min3 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
004 Min4 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
004 Min5 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
004 Min6 1.845 1.51 24.60483 20.176 5.166506 4.834344
004 MeanEx #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
005 RestMin1 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
005 RestMin2 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
005 RestMin3 2.555 2.79 34.10668 37.24166 4.91006 5.14487
005 MeanRest #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
005 Min1 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
005 Min2 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
005 Min3 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
005 Min4 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
005 Min5 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
005 Min6 0.000 0.00 0 0 2.289778 1.922378
005 MeanEx #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
007 RestMin1 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
007 RestMin2 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
007 RestMin3 2.683 2.43 46.26155 41.91724 3.74673 3.49476
007 MeanRest #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
007 Min1 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
007 Min2 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
007 Min3 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
007 Min4 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
007 Min5 #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
007 Min6 1.997 1.99 34.43903 34.2569 4.400957 4.390393
007 MeanEx #VALUE! #VALUE! #VALUE! #VALUE! #VALUE! #VALUE!
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ID Stage
EILVavg 
%TLC 
6MIN
EILVtyp 
%TLC 
6MIN
Ti Mech 
6MIN
Te Mech 
6MIN
TI/Ttot 
Mech 
6MIN
Vt/Ti 
Mech 
6MIN
001 RestMin1 #VALUE! #VALUE! . . . #VALUE!
001 RestMin2 #VALUE! #VALUE! . . . #VALUE!
001 RestMin3 65.87985 69.10534 2.47262 3.02405 45.86527 0.744959
001 MeanRest #VALUE! #VALUE! 2.47262 3.02405 45.86527 #VALUE!
001 Min1 #VALUE! #VALUE! . . . #VALUE!
001 Min2 #VALUE! #VALUE! . . . #VALUE!
001 Min3 #VALUE! #VALUE! . . . #VALUE!
001 Min4 #VALUE! #VALUE! . . . #VALUE!
001 Min5 #VALUE! #VALUE! . . . #VALUE!
001 Min6 76.76435 77.46085 1.03905 1.149107 46.87564 2.495247
001 MeanEx #VALUE! #VALUE! 1.03905 1.149107 46.87564 #VALUE!
002 RestMin1 #VALUE! #VALUE! . . . #VALUE!
002 RestMin2 #VALUE! #VALUE! . . . #VALUE!
002 RestMin3 63.66206 66.97229 1.28476 2.461607 37.14003 1.106084
002 MeanRest #VALUE! #VALUE! 1.28476 2.461607 37.14003 #VALUE!
002 Min1 #VALUE! #VALUE! . . . #VALUE!
002 Min2 #VALUE! #VALUE! . . . #VALUE!
002 Min3 #VALUE! #VALUE! . . . #VALUE!
002 Min4 #VALUE! #VALUE! . . . #VALUE!
002 Min5 #VALUE! #VALUE! . . . #VALUE!
002 Min6 74.03679 74.35845 1.1388 1.2766 47.1474 2.360441
002 MeanEx #VALUE! #VALUE! 1.1388 1.2766 47.1474 #VALUE!
003 RestMin1 #VALUE! #VALUE! . . . #VALUE!
003 RestMin2 #VALUE! #VALUE! . . . #VALUE!
003 RestMin3 47.3183 47.54174 1.504613 3.522175 29.95464 0.511444
003 MeanRest #VALUE! #VALUE! 1.504613 3.522175 29.95464 #VALUE!
003 Min1 #VALUE! #VALUE! . . . #VALUE!
003 Min2 #VALUE! #VALUE! . . . #VALUE!
003 Min3 #VALUE! #VALUE! . . . #VALUE!
003 Min4 #VALUE! #VALUE! . . . #VALUE!
003 Min5 #VALUE! #VALUE! . . . #VALUE!
003 Min6 87.25924 89.82575 1.15775 1.307244 46.40758 1.945296
003 MeanEx #VALUE! #VALUE! 1.15775 1.307244 46.40758 #VALUE!
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ID Stage
EILVavg 
%TLC 
6MIN
EILVtyp 
%TLC 
6MIN
Ti Mech 
6MIN
Te Mech 
6MIN
TI/Ttot 
Mech 
6MIN
Vt/Ti 
Mech 
6MIN
004 RestMin1 #VALUE! #VALUE! . . . #VALUE!
004 RestMin2 #VALUE! #VALUE! . . . #VALUE!
004 RestMin3 51.17981 54.57644 1.495633 1.898633 44.97419 0.938822
004 MeanRest #VALUE! #VALUE! 1.495633 1.898633 44.97419 #VALUE!
004 Min1 #VALUE! #VALUE! . . . #VALUE!
004 Min2 #VALUE! #VALUE! . . . #VALUE!
004 Min3 #VALUE! #VALUE! . . . #VALUE!
004 Min4 #VALUE! #VALUE! . . . #VALUE!
004 Min5 #VALUE! #VALUE! . . . #VALUE!
004 Min6 68.88675 64.45792 1.583831 1.698531 48.15909 2.096906
004 MeanEx #VALUE! #VALUE! 1.583831 1.698531 48.15909 #VALUE!
005 RestMin1 #VALUE! #VALUE! . . . #VALUE!
005 RestMin2 #VALUE! #VALUE! . . . #VALUE!
005 RestMin3 65.55487 68.68985 2.27279 2.44575 49.21096 1.036378
005 MeanRest #VALUE! #VALUE! 2.27279 2.44575 49.21096 #VALUE!
005 Min1 #VALUE! #VALUE! . . . #VALUE!
005 Min2 #VALUE! #VALUE! . . . #VALUE!
005 Min3 #VALUE! #VALUE! . . . #VALUE!
005 Min4 #VALUE! #VALUE! . . . #VALUE!
005 Min5 #VALUE! #VALUE! . . . #VALUE!
005 Min6 30.57113 25.66593 0.9406 0.8 54.0382 4.639462
005 MeanEx #VALUE! #VALUE! 0.9406 0.8 54.0382 #VALUE!
007 RestMin1 #VALUE! #VALUE! . . . #VALUE!
007 RestMin2 #VALUE! #VALUE! . . . #VALUE!
007 RestMin3 64.59879 60.25448 2.38247 2.49455 47.69781 0.446411
007 MeanRest #VALUE! #VALUE! 2.38247 2.49455 47.69781 #VALUE!
007 Min1 #VALUE! #VALUE! . . . #VALUE!
007 Min2 #VALUE! #VALUE! . . . #VALUE!
007 Min3 #VALUE! #VALUE! . . . #VALUE!
007 Min4 #VALUE! #VALUE! . . . #VALUE!
007 Min5 #VALUE! #VALUE! . . . #VALUE!
007 Min6 75.87857 75.69643 0.939607 0.836371 51.63681 2.557977
007 MeanEx #VALUE! #VALUE! 0.939607 0.836371 51.63681 #VALUE!
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ID Stage
Vt/Te 
Mech 
6MIN
PetCO2 
Mech 
6MIN
expBTPS 
Mech 
6MIN
Max Pi 
Mech 
6MIN
Max Pe 
Mech 
6MIN
P to P 
Mech 
6MIN
004 RestMin1 #VALUE! . . . . .
004 RestMin2 #VALUE! . . . . .
004 RestMin3 0.739549 32.27237 . -1.52099 1.5446 3.06559
004 MeanRest #VALUE! 32.27237 #DIV/0! -1.52099 1.5446 3.06559
004 Min1 #VALUE! . . . . .
004 Min2 #VALUE! . . . . .
004 Min3 #VALUE! . . . . .
004 Min4 #VALUE! . . . . .
004 Min5 #VALUE! . . . . .
004 Min6 1.955304 36.34428 . -2.43609 3.433369 5.869459
004 MeanEx #VALUE! 36.34428 #DIV/0! -2.43609 3.433369 5.869459
005 RestMin1 #VALUE! . . . . .
005 RestMin2 #VALUE! . . . . .
005 RestMin3 0.963087 29.84333 . -1.64345 2.87054 4.51399
005 MeanRest #VALUE! 29.84333 #DIV/0! -1.64345 2.87054 4.51399
005 Min1 #VALUE! . . . . .
005 Min2 #VALUE! . . . . .
005 Min3 #VALUE! . . . . .
005 Min4 #VALUE! . . . . .
005 Min5 #VALUE! . . . . .
005 Min6 5.454848 29.6429 . -5.6721 11.6399 17.312
005 MeanEx #VALUE! 29.6429 #DIV/0! -5.6721 11.6399 17.312
007 RestMin1 #VALUE! . . . . .
007 RestMin2 #VALUE! . . . . .
007 RestMin3 0.426353 38.3033 . -1.00411 1.464 2.46811
007 MeanRest #VALUE! 38.3033 #DIV/0! -1.00411 1.464 2.46811
007 Min1 #VALUE! . . . . .
007 Min2 #VALUE! . . . . .
007 Min3 #VALUE! . . . . .
007 Min4 #VALUE! . . . . .
007 Min5 #VALUE! . . . . .
007 Min6 2.873716 37.67021 . -3.10673 5.627714 8.734444
007 MeanEx #VALUE! 37.67021 #DIV/0! -3.10673 5.627714 8.734444
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Appalachian State University 
Informed Consent for Participants in 
Research Projects Involving Human Subjects 
 
 
 
IRB Study #: 19-0021   
  
Principal    
Investigator:  Dalton Fletcher, B.S.   Email: fletcherds@appstate.edu 
     
Advisor:  Jonathon Stickford, Ph.D.  Email: stickfordjl@appstate.edu 
Advisor:  R. Andrew Shanely, Ph.D.  Email: shanelyra@appstate.edu  
Advisor:  Abigail Stickford, Ph.D.  Email: stickfordas@appstate.edu 
 
Research Assistants: Jayvaughn Oliver, B.S.  Email: oliverjt@appstate.edu 
   Erica Larson, M.S.         Email: larsone@appstate.edu 
   John Cantu    Email: cantujw@appstate.edu  
    
    
     
 
This is to certify that I,                                                                             have been given the following 
information with respect to my participation as a volunteer in a program of investigation under 
the supervision of Dalton Fletcher B.S. to which Jonathon Stickford, Ph.D., Andrew Shanely, 
Ph.D., Abigail Stickford, Ph.D., Erica Larson M.S., John Cantu, and/or Jayvaughn Oliver B.S. 
may be assisting. 
 
1. Purpose of the study: 
Obesity increases the energy needed to breath. Obesity may make breathing feel tough or hard, 
making exercise feel tough or hard. Beetroot juice and tomato juice are drinks you can buy. 
Both drinks have natural ingredients that may lower the energy your breathing muscles need 
during exercise and make exercise feel easier. We want to know if beetroot juice or tomato 
juice is better at lowering the energy your breathing muscles need during exercise and makes 
exercise feel easier. You will be 1 of 10 participants if you decide to be in the study. We 
estimate that being in the study will take about 5 hours. 
 
 
2. Inclusion Criteria: You may participate in the study if the following apply to you: 
• Sex: Males will be included in the study.  
• Ethnicity: Any 
• Age: 18 – 40 years of age 
• Interest in participating in the research study 
• Obese (30 kg/m2 ≤ BMI ≤ 40 kg/m2) and otherwise healthy 
• Able to speak and read English 
122 
 
Appendix C: Informed Consent Statement continued 
 
• Provide informed consent 
• Available during times the data collection is offered. 
• Current non-smoker 
• Smoking history less than ½ pack-years. 
• Willing to not use mouthwash during the entire time you are taking part in the study 
• Resting blood pressure under 140/90 
• Is currently not taking any medications or supplements that are known vasodilators 
 
Exclusion Criteria: You should not participate in this study if any of the following apply to 
you: 
• Known cardiovascular, metabolic or kidney disease, or signs/symptoms of cardiovascular, 
metabolic or kidney disease will exclude you from this study 
• Currently or you have been involved in an organized exercise program in the past 6 months 
• If lung function is not in the range we are looking for you will not be allowed in the study  
• BMI under 30 or above 40 kg/m2 
• Current smoker 
• Smoking history equal to or greater than ½ pack-years 
• Unwilling to stop using of mouthwash 
• Resting blood pressure above 140/90 
• Is currently taking medications or supplements that are known vasodilators 
 
 
3. Procedures: Please read the descriptions of each experimental day and write your initials in the 
space provided.  
 
You could be asked to repeat a trial, procedure, or test. This could happen for many reasons 
such as equipment failure, power outage, inconclusive test results, etc. However, you do not 
have to repeat a trial, procedure, and/or test if you do not wish to do so. If we ask you to 
repeat a trial we will not give you more money. 
 
Below is a timeline showing all visits and experiments which you will complete in this study. 
 
Visit 1 Visits 2 and 3 
Informed consent 
Lung function testing 
Body composition  
Maximal exercise test 
Resting seated hyperventilation 
Moderate intensity cycling  
 
________initial      Prescreen: You may be telephoned by the Principle Investigator or a Research 
Assistant (see page 1) and asked screening questions to determine your eligibility for the study. 
 
Visit 1:  
 
________ initial      Consent and Questionnaires: Potential participants who meet inclusion criteria 
will be invited to a screening interview within the laboratory located on campus (Leon Levine Hall of  
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Health Sciences). At this screening visit, the study will be explained in-depth to you by the PI or a 
trained research assistant. You will be provided time to consider your options and have all questions 
answered - if you agree to participate, you will then provide your written informed consent. 
 
After you have provided consent (~30 minutes), you will be asked to complete a medical history 
questionnaire (~10 minutes). You will be asked to bring a list of all current medications and 
supplements that you are currently taking. If any of these medications or supplements are vasodilators 
you will not be allowed to participate in the study. You will also have your resting blood pressure 
measured to ensure that it is under 140/90. If it is not, you will not be allowed to participate in the study. 
 
________ initial      Lung Function Testing: You will be asked to perform tests of breathing function. 
The protocol will follow that described by the American Thoracic Society. These tests include 
measurement of the total amount of air your lungs can hold, the amount of air that you can push out 
with one maximal breath, the amount of air that you can breathe out as hard as you can in one second, 
and the maximum amount of air that you can in and out of your lungs in 12 seconds. For all these 
procedures, you will wear a nose clip and breathe through a disposable mouthpiece. These tests will 
take about 30 minutes. 
 
 
_________initial      Body Composition: Following completion of the questionnaires, we will measure 
your height, weight, and body composition. Your percent body fat will be estimates using a BodPod. 
You will sit in the BodPod, an enclosed chamber, and may hear some clicking while air pressure 
changes to estimate your body volume. This piece of equipment estimates your body’s fat and muscle 
by air movement. This is an accurate method to estimate your body composition. These procedures will 
take about 15 minutes. 
 
________ initial      Maximal Exercise Test (V̇O2peak): You will be asked to exercise as hard as you 
can to measure your physical fitness. This test is often described as a V̇O2peak test. You should be rested, 
well nourished, and hydrated for the test and avoid caffeine 3 hours before the test, and not drink alcohol 
for 12 hours before the test. Avoid exercise in the 24 hours before the test and report any medication 
that you are using to the testing staff before the test. When you are ready for the test, the investigators 
will help you equipment to assure your comfort. You will be fitted with a rubber mouthpiece and nose 
clip. Your breathing pattern, exercise energy use, blood pressure, and blood oxygen level will be 
monitored during the test. This takes about 45 minutes, with exercise lasting about 15 minutes. 
 
Cycling Protocol 
You will exercise on a stationary bicycle. Prior to exercise, you will rest sitting on the bike with both 
hands on the handle bars for 5 minutes. You will breathe through a mouthpiece and wear a nose clip 
during the test. Your breathing pattern, exercise energy needs, blood pressure, and arterial blood oxygen 
level will be monitored during the test. A cuff will be placed onto your arm, and a monitor will 
automatically display your blood pressure values. The amount of oxygen in the blood will be monitored 
using a sensor placed on the skin (e.g., forehead).  Throughout the test, you will be asked about your 
perceptual responses (e.g., ratings of perceived breathlessness, unpleasantness of breathlessness, and 
exertion) to the exercise. You will be asked to rate your responses by pointing with your finger to a 
number on a scale. The number will be repeated out loud in order to confirm your choice. During the 
exercise you may have an even stronger or greater intensity of breathlessness than you have previously 
experienced. If this occurs, you should point to the word “maximal” if the severity is greater than 10. 
After the mouthpiece is removed, you can tell us the number. You may stop exercise when you wish,  
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because of personal feelings of fatigue or discomfort, but you will be encouraged to cycle for as long 
as you can. Following completion of the test, you will perform a light intensity cool-down. 
 
 
 
Flow-Volume Loops 
During the maximal exercise test, the speed at which you breathe air in and out and the volume of air 
you breathe will be measured. Approximately once every 60 seconds during the exercise test, you will 
be prompted to breathe in completely, filling your lungs with air, and then return to normal breathing. 
Before and after the exercise test, while at rest, you will be prompted to perform 3 breathing maneuvers, 
where you complete a big breath in (filling your lungs completely with air) followed by a forceful 
breath out (breathe out all the air you can). The investigators will coach you through these maneuvers. 
These procedures are performed during the maximal exercise test, and add no additional time. 
 
 
Visit 2-3: 
 
________ initial      Supplementation Procedure: Following the first visit, you will be given beetroot 
juice or tomato juice. When taking beetroot juice, you will consume two 70 mL bottles of beetroot juice 
twice a day, once in the morning and once in the evening, for a total of 140 mL per day. When taking 
tomato juice, you will consume two 70 mL bottles twice a day, once in the morning and once in the 
evening, for a total of 140 mL per day. The order in which you consume the beverages will be randomly 
decided. 
 
________ initial    Nutrition Recall: You will be asked to record all foods, supplements, and 
medications you consume during the 10-day supplementation procedure. You will be asked to keep 
your diet as similar as possible during the two different supplementation procedures. 
 
________ initial      Food Avoidances: You will be given a list of foods not eat during the 10 day 
beetroot juice period or during the 10 day tomato juice period.   
 
 
________ initial      Cessation of Mouthwash Use: You may not use mouthwash during this study. 
 
________ initial    Resting Seated Hyperventilation: While seated, but not exercising, on a cycle 
ergometer, you will begin by quietly breathing for 6 minutes. Following this you will be asked to breath 
at ventilation rates corresponding to 50%, 70%, and 90% of your VO2peak for 5 minutes each. The order 
of ventilation rates will be randomly determined. You will be breathing in gas that contains the addition 
of CO2 in order to prevent you from feeling dizzy. Additionally, the air will be moistened to minimize 
throat dryness. You will be given live feedback on a computer screen on the amount of air that you 
need to breath in and a metronome will signal how often you need to breath. At the end of each 
ventilation rate, you will be asked to quantify your level of breathlessness. You will be given 5 minutes 
of rest between each ventilation rate. A small finger cuff will be placed on one of your fingers which 
will measure how much blood is pumped by your heart. The measurements will take place right before 
the test at rest, and during the last minute of each hyperventilation phase. This will take about an hour. 
 
________ initial      Moderate Intensity Cycling: You will begin by sitting quietly on the cycle 
ergometer for 5 minutes. Then you will warm up by cycling with the cycle ergometer unloaded (no  
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resistance) for 3 minutes. You will then be asked to cycle for 6-minutes at a predetermined work rate. 
Entering into the last minute, you will be asked to rate you perceived breathlessness, unpleasantness 
due to breathlessness, and exertion. A small finger cuff will be placed on one of your fingers which 
will measure how much blood is pumped by your heart. The measurements will be taken right before 
the test at rest, and during the last minute of cycling. This will take about 30 minutes.  
 
       Mouth Pressure 
A mouthpiece with a small air hole in it will be placed into your mouth before hyperventilation, 
immediately after your third round of hyperventilation, and immediately before the onset of the 
cycling protocol. You will be asked to inhale as much as air as possible. You will be asked to do this 
at least 3 times at each setting (at least nine times total on visits 2 and 3). Each attempt will be 
separated by 1 minute. You will also be asked to exhale as much air as possible. You will be asked to 
do this at least 3 times at each setting (at least nine times total on visits 2 and 3). Each attempt will be 
separated by 1 minute.  
 
       Resting Blood Pressure 
Upon arriving for visits 2 and 3, your resting blood pressure will once again be taken. If it is above 
140/90, you will not be allowed to exercise on that day. You will be asked to come back another day. 
 
       Duration of participation  
The shortest duration possible to complete all three visits is 31 days. Visit 1 will occur on day one. You 
will then consume one of the beverages for 10 days. On the tenth day, you will come for visit 2. You 
will then undergo at least a 10 day washout period in which you consume neither beverage. Finally, 
you will consume the other beverage for 10 days. On the tenth day, you will come for visit 3. The 
duration may be longer than 31 days if there are scheduling conflicts or if your resting blood pressure 
is above 140/90 on visits 2 and/or 3.  
 
3.  Discomforts and risks: 
The risks involved with measuring/monitoring/performing: questionnaires, physical characteristics, 
lung function testing, flow-volume loops, and breathlessness during exercise. 
 
Body Composition: The risks involved are experiencing slight discomfort due to the small space. 
 
Maximal Exercise Test: The risks involved are abnormal heart beats, abnormal blood pressure 
responses, muscle cramps, muscle strain and/or joint injury, delayed muscle soreness (1 to 2 days 
afterwards), light headedness, fatigue, and in rare instances, heart attack.  
 
Beetroot Juice Consumption: The risks involved with consuming beetroot juice may cause urine to be 
pink.  
 
Tomato Juice Supplementation: There are no known risks in consuming 140 mL/day of tomato juice. 
 
Resting Seated Hyperventilation: The risks involved are that you may become light headed or feel out 
of breath at higher ventilation rates. 
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Loss of Confidentiality: Any time information is collected; there is a potential risk for loss of 
confidentiality.  Every effort will be made to keep your information confidential; however, this 
cannot be guaranteed.  
 
Other Risks: There may possibly be other side effects that are unknown at this time. If you are 
concerned about other, unknown side effects, please discuss this with the researchers. 
 
How you can help reduce some of the risks:  During your participation in this research, the 
researchers will closely observe your testing to determine whether there are problems that need 
medical care.  It is your responsibility to do the following: 
•  Ask questions about anything you do not understand. 
•  Keep appointments. 
•  Follow the study researchers’ instructions. 
•  Let the researchers know if your telephone number changes. 
•  Tell the researchers before you take any new medication. 
•  Tell your regular doctor about your participation in this research. 
  
 
 
4.    a. Benefits to you: You can expect to receive information about your cardiovascular conditioning, 
and physical fitness. We are performing these tests for research purposes only. The information 
collected is not intended for diagnostic or therapeutic purposes. Under no circumstance will the 
investigator or research staff interpret results as normal or abnormal. We are unable to make any 
medical comments about your results. The results will not be looked at for medical diagnostic or 
medical treatment purposes.  
 b. Potential benefits to society: The knowledge gained from this study will determine if one of 
the beverages being tested has the potential to lower the oxygen cost of breathing in obese, young 
males.   
 
5.  Alternative procedures that could be utilized:  Not participating in the study. 
The procedures and drinks used in this study are frequently used in research and are the most 
appropriate methods to accomplish the goals of this research. 
 
 
6. Time duration of the procedures and study:   
 
You will need to visit the Leon Levine Hall of Health Sciences (1179 State Farm Road) for the 
following: 
________ initial  Visit 1 (about 1.5 - 2 hr) 
________ initial  Visit 2 (about 1.5 hr). 
________ initial  Visit 3 (about 1.5 hr). 
 
Approximately 5.0 hours 
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7. Statement of confidentiality: Study participants are coded by an identification number for 
statistical analyses. All records are kept in a secure location. All records associated with your 
participation in the study will be subject to the university confidentiality standards and in the event 
of any publication resulting from the research no personally identifiable information will be 
disclosed. The Office of Human Research Protections in the U.S. Department of Health and Human 
Services, the U.S. Food and Drug Administration (FDA), the Office for Research Protections at 
Appalachian State University and the Institutional Review Board may review records related to this 
project. 
 
8. Right to ask questions: Please contact Dalton Fletcher, B.S. (fletcherds@appstate.edu, c. 336 – 
247 -1887) or Jonathon Stickford, Ph.D. (stickfordjl@appstate.edu 828-262-7471), with 
questions, complaints, or concerns about this research. If you have any questions about your 
rights as a research subject, please contact the IRB Administrator at the Appalachian State 
University Institutional Review Board Office at (828) 262-2692, irb@appstate.edu.  This study 
has been approved on 2/23/2019 by the Institutional Review Board (IRB) at Appalachian State 
University.  This approval will expire on 10/11/2019 unless the IRB renews the approval of this 
research. 
 
9. Compensation: You will receive a total of $30 upon completion of this study:  
Compensation Breakdown: You will be compensated $10 for each visit completed to be 
received following you last visit. 
 
You may be asked to repeat a trial.  If you agree to repeat a trial, you will be paid for the repeated 
trial as stated above. 
  
10. Injury Clause: In the unlikely event you become injured as a result of your participation in this 
study, standard emergency procedures will be followed. If you get hurt or sick when you are not 
at the research site, you should call your doctor or call 911 in an emergency. If your illness or 
injury could be related to the research, tell the doctors or emergency room staff about the research 
study, the name of the Principal Investigator, and provide a copy of this consent form if possible. 
Please contact the PI as soon as possible (Dalton Fletcher B.S. fletcherds@appstate.edu, c. 336-
247-1887) or Jonathon Stickford, Ph.D. (stickfordjl@appstate.edu, 828-262-7471). It is the policy 
of this institution to provide neither financial compensation nor free medical treatment for 
research-related injury. You will be responsible for any costs for medical care not paid by your 
insurance company. No other compensation is offered by Appalachian State University.  By 
signing this document, you are not waiving any legal rights that you have against Appalachian 
State University for injury resulting from negligence of the University or its investigators. 
 
11. Voluntary participation: Your participation in this study is voluntary. You may withdraw from 
this study at any time by informing the research personnel. You may decline to answer certain 
questions and may decide not to comply with certain procedures. However, your being in the study 
may be contingent upon answering these questions or complying with the procedures. The 
researcher may end your role in the study without your consent if the researcher deems that your 
health or behavior adversely affects the study or increases risks to you beyond those approved by 
the Institutional Review Board and agreed upon by you in this document. You have been given an 
opportunity to ask any questions you may have, and all such questions or inquiries have been 
answered to your satisfaction. 
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Appendix C: Informed Consent Statement continued 
 
 
 
____________________________________________________ 
      Volunteer         Date 
 
 
I, the undersigned, have defined and explained the studies involved to the above volunteer. 
 
 
____________________________________________________ 
      Person Obtaining Consent   Date 
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Appendix D: Telephone Screening Form 
 
Initial Telephone Screening Form for Oxygen Cost of Breathing 
Study 
 
General Information: 
 
Name: 
________________________________________________________________  
Email: 
________________________________________________________________ 
Address (if no email): 
____________________________________________________ 
Age: _________  Sex: _________       Phone: 
____________________________   
Height: _______  Weight: _______         Allergies (latex?) 
_____________________ 
 
 
Exclusion Criteria: any question answered “yes” in this section will disqualify the 
potential subject. 
 
Yes     No 
 
1.            Age – outside the ages of 18 and 40 yr? 
 
2.            Do you currently smoke tobacco cigarettes? Any history 
of   smoking? If so, how much did you smoke and for 
how long?   (Must be less than 0.5 pack·yrs) 
 
3.            Have you ever been diagnosed with a sleep disorder or 
use   CPAP? 
 
4.            Do you have a history of asthma, COPD, or any lung 
issues? 
 
5.            Do you have a history of an irregular heartbeat or any 
heart    condition? (Have you had an EKG performed?) 
 
6.         Do you have any known metabolic or renal diseases? 
 
7.    Do you have any known health conditions?  
        High blood pressure?  
         Diabetes?  
        Thyroid issues? 
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Appendix D: Telephone Screening Form continued 
 
 
8.            Are you currently engaging in an organized exercise                          
                      program? (≥90 min/wk of organized activity) 
 
      
 
Inclusion Criteria:  any question answered “yes” in this section will qualify the 
potential subject 
 
  Yes     No 
 
1.          Do you have a body mass index ≥ 30 kg/m2, but ≤ 40 
kg/m2? 
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Appendix E: Medical History Form 
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Appendix E: Medical History Form continued 
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Appendix E: Medical History Form continued 
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Appendix F: 24-Hour Health History Form 
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Appendix G: Nutrition Log 
Food Recording Form 
 
 
Subject number______      Age _____    Date __________ 
          (mm/dd/yyyy) 
 
 
Directions for Using the Food Diary 
1. Please record ALL food, beverage, medications and supplements eaten/ingested for 
the three days that are assigned for you.  To reduce error, please follow these 
directions: 
 
a. Keep your food diary current (list foods immediately after they are eaten). 
 
b. Whenever possible, MEASURE the volume consumed by using cups and 
tablespoons.  Record amounts in household measures---ounces, tablespoons, 
cups, and slices. 
 
c. Be specific when describing the foot item eaten, and the method that was used 
to prepare the food.  Remember to include condiments, sugar, oils, butter, and 
other visible fats  For example: 
 Apple, raw, fresh, with peel     1 medium 
 Bread, whole wheat, fresh      2 slices 
 Margarine, soft from tub   1 tablespoon 
 Tylenol     300 milligrams  
 Sugar, white    1 teaspoon 
 Milk, non fat    2 cups 
 Fish, salmon, baked   10 ounces 
 
d. This food record will be analyzed with a computerized dietary analysis 
program, so please provide sufficient detail.  
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Appendix G: Nutrition Log continued 
 
Day One 
Time 
Food/Beverage/Medication 
Consumed 
Food Item and 
Method of 
Preparation 
Amount 
Consumed (in 
cups, tablespoons, 
ounces, milligrams, 
etc.) 
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Appendix H: Foods to Avoid 
 
Foods to Avoid Eating (High Nitrate Levels) 
 
• Celery  
• Chervil  
• Cress 
• Lamb’s Lettuce 
• Lettuce 
• Radish 
• Red beetroot 
• Rocket 
• Spinach 
• Swiss chard 
• Celeriac  
• Chinese Cabbage 
• Endive 
• Escarola 
• Fennel 
• Kohlrabi 
• Leaf chicory 
• Leek 
• Parsley  
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Appendix I: Ratings of Perceived Breathlessness Scale 
     Rate Your Breathing 
    
 0   Nothing at all 
 
0.5 Very, very weak (Just Noticeable) 
 
1 Very Weak 
  
2 Weak (Light) 
 
3 Moderate 
 
4 Somewhat Strong 
 
5 Strong (Heavy) 
 
6  
 
7 Very Strong 
 
8  
 
9  
 
10 Very, very strong (Almost max) 
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Appendix J: Ratings of Perceived Breathlessness Description 
 
This is a scale for rating: 
 
 
 
BREATHLESSNESS 
 
 
 
 
 The number 0 represents no breathlessness. The number 10 represents 
the strongest or greatest breathlessness that you have ever experienced. Each 
minute during the exercise test you will be asked to point to a number, with your 
finger, which represents your perceived level of breathlessness at the time. The 
number will be repeated out loud in order to confirm your choice. During the 
exercise test you may have an even stronger or greater intensity of 
breathlessness than you have previously experienced. You should then point to 
the word “maximal” if the severity is greater than 10. You can tell us this number 
after the mouthpiece has been removed. 
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Appendix K: Ratings of Perceived Unpleasantness Scale 
Rate Unpleasantness of your Breathing 
    
 0   Not Unpleasant 
 
0.5 Very, very weak (Just Noticeable) 
 
1 Very Weak Unpleasantness 
  
2 Weak (Light) Unpleasantness 
 
3 Moderate Unpleasantness 
 
4 Somewhat Strong Unpleasantness 
 
5 Strong (Heavy) Unpleasantness 
 
6  
 
7 Very Unpleasant 
 
8  
 
9  
 
10 Maximal Imaginable Unpleasantness 
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Appendix L: Ratings of Perceived Unpleasantness Description 
 
This is a scale for rating: 
 
UNPLEASANTNESS 
OF 
BREATHLESSNESS 
 
 
Unpleasantness expresses the affective evaluation of the sensation 
regardless of whether the intensity is high or low. Unpleasantness describes how 
much you affectively dislike something or feel terrified by it. A low 
unpleasantness indicates that the perceived breathlessness does not feel bad. A 
high unpleasantness signifies that the breathlessness feels very bad or terrifying 
regardless of whether the intensity of the sensation is high or low. 
During the exercise test you will be asked to point to a number, with your 
finger, which represents your perceived level of the unpleasantness of 
breathlessness at the time. The number will be repeated out loud in order to 
confirm your choice.  
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Appendix M: Ratings of Perceived Exertion Scale 
 Rate Your Exercise 
 
  6 
 
  7 Very, very light 
 
  8 
 
  9 Very light 
 
10 
 
11 Fairly light 
 
12 
 
13 Somewhat hard 
 
14 
 
15 Hard 
 
16 
 
17 Very hard 
 
18 
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Appendix M: Ratings of Perceived Exertion continued 
 
19 Very, very hard 
 
20    
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Appendix N: Ratings of Perceived Exertion Description 
This is a scale for rating: 
 
PERCIEVED EXERTION 
During the graded exercise test we want you to pay close attention to how hard 
the work rate is for you. The feeling should be your total amount of exertion and 
fatigue, combining all sensations and feelings of physical stress, effort and 
fatigue. Don’t concern yourself with any one factor such as leg pain, shortness of 
breath or exercise intensity, but try to concentrate on your total, inner feeling of 
exertion. Don’t underestimate or overestimate, just be as accurate as possible. 
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